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ABSTRACT 
 
Eliminating Oxygen Supply Limitations for Transplanted 
Microencapsulated Islets in the Treatment of Type I Diabetes 
 
 
by Amy Suzanne Lewis 
 
 
Submitted to the Department of Chemical Engineering 
on May 19, 2008 in partial fulfillment of 
the requirements for the degree of 
Doctor of Philosophy in Chemical Engineering 
 
Type I diabetes is a disease that results from a person's impaired ability to produce insulin, a 
protein that regulates the blood glucose concentration. Insulin is produced by β-cells in the Islets 
of Langerhans, which are aggregates of cells averaging about 150 μm in diameter and 
constituting about 1 to 2% of the pancreas volume. The efficacy of islet transplantation as a 
treatment for diabetes has been demonstrated in humans by the Edmonton Protocol, but obstacles 
remain for wide scale application. One major issue is that successful islet transplantation requires 
permanent use of multiple immunosuppressive agents.  These agents may have serious side 
effects as well as a substantial financial burden. Microencapsulation is used for full or partial 
protection of transplanted islets from immune rejection. However, the microcapsule prevents 
islet revascularization and creates an additional mass transfer resistance for oxygen transport to 
islets.  This reduced oxygen transfer can lead to a hypoxic core within the islet that results in 
tissue death and reduced function.  We have studied two approaches to enhance 
microencapsulated islet survival and function by reducing oxygen transport limitations.  The first 
method involves incorporating a perfluorocarbon emulsion into alginate microcapsules to 
enhance oxygen permeability in order to protect islets from hypoxia.  The second method 
involves dispersing the islets into single cells and allowing them to reaggregate into cell clusters 
smaller than the original islet.  The smaller aggregates are less prone to the development of a 
necrotic core and can function normally because of adequate oxygen supply and the presence of 
cell to cell contacts.   
A theoretical reaction-diffusion model was developed to predict the oxygen partial pressure 
profile, extent of cell death, and rate of insulin secretion in alginate microcapsules or planar 
diffusion chambers containing an islet, islet cell aggregates, and dispersed single cells exposed to 
specified external PO2 values, with or without PFC.  Results show that hypoxic conditions are 
reduced, therefore enhancing islet viability and substantially maintaining insulin secretion when 
PFC emulsion is incorporated in the encapsulation material or when smaller islet cell aggregates 
are used.  
Methods were developed to assess encapsulated tissue through nuclei counting, DNA 
quantification, and oxygen consumption rate measurements. Experiments with islets and islet 
cell aggregates were performed to assess whether the benefits predicted by the theoretical model 
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can be observed experimentally.  After two days of culture in a limited oxygen environment 
comparisons were made between islets and islet cell aggregates within normal alginate and islets 
within PFC alginate microcapsules in their viability by measurement of oxygen consumption 
rate, function by measuring glucose stimulated insulin secretion (only tissue in normal alginate 
capsules), and total tissue content by measuring DNA or performing nuclei counts.  The PFC 
emulsion formulation that was used was toxic to islets and we were not conclusively able to 
demonstrate that it enhances survival in low oxygen.  Islet cell aggregates survive and function 
better in low oxygen environments during in vitro experiments than intact islets.    Encapsulated 
rat islet cell aggregates are also found to more effectively cure diabetes in mice than 
encapsulated islets. 
Thesis Supervisor: Clark K. Colton 
Title: Professor of Chemical Engineering 
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Chapter 1 Introduction 
 
1.1 BACKGROUND 
1.1.1 Type 1 Diabetes 
Type 1 diabetes is a disease that results from a person’s impaired ability to produce 
insulin, a protein that regulates blood glucose concentration. Insulin is produced by β-cells in the 
Islets of Langerhans, which are aggregates of cells averaging about 150 μm in diameter and 
constituting about 1 to 2% of the pancreas volume. Type 1 diabetes is caused by autoimmune 
attack and destruction of the β-cells, which compose about 60% of the islet by volume. Diabetes 
has a serious impact on the health care system. In 2005, there were an estimated 14.6 million 
people diagnosed (and about 50% more undiagnosed) with diabetes in the U.S. This number is 
expected to double by 2050 [1, 2]. Type 1 (insulin-dependent) diabetes patients represent 5-10% 
of the total number of diabetes cases [1]. The increased blood sugar level puts diabetic patients at 
a greater risk for various complications, including blindness, gangrene, stroke, ketoacidosis, and 
heart, kidney, nervous system, and periodontal disease. Diabetes was the sixth leading cause of 
death in the United States in 2002, and the risk of death among people with diabetes is about 2 
times greater than that of people without diabetes[1]. The cost associated with diabetes in the 
U.S. was $174 billion dollars in 2007 and represented 1 out of every 5 dollars spent on health 
care [2]. 
Conventional treatment for type 1 diabetes involves one or two daily insulin injections 
and daily monitoring of blood glucose but without adjustments of insulin dosage.  Insulin 
injections under these conditions are not optimal because blood glucose levels fluctuate 
incorrectly when there is no feedback control like that provided by β-cells in healthy patients [3].  
In a recent clinical trial, intensive insulin therapy (three or more times daily by injection or 
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external pump, adjusted according to results of self-monitoring of glucose at least four times per 
day) improved blood glucose control and substantially decreased occurrences of long term 
complications in comparison to conventional therapy [4].  The chief adverse event associated 
with intensive therapy was a two- to three-fold increase in severe hypoglycemia, a major concern 
because hypoglycemic unawareness can be life threatening and tends to occur when 
hypoglycemic episodes are more frequent.    
Alternative methods of insulin delivery have been investigated to deliver insulin in a pain 
free manner, thereby increasing patient compliance and more effectively regulate blood glucose 
levels.   Externally worn pumps that continuously deliver insulin subcutaneously are safe and 
effective with fewer hypoglycemic episodes and lower levels of glycosylated hemoglobin [5].   
Methods are being developed to deliver insulin transdermally and through the pulmonary system 
and to measure blood glucose without the use of a needle, for example by permeabilizing the 
skin with ultrasound, extracting interstitial fluid, and correlating the glucose concentration to 
blood glucose concentration [6-8].  Implantable glucose sensors would be the best way to 
measure blood glucose, in real-time, but they have been limited by a need for frequent 
recalibration as a result of changes in transport properties of the tissue surrounding the sensor 
from fibrotic overgrowth [9-13]. Methods of administering insulin that do not provide feedback 
control do not usually produce normal glucose control, which make patients vulnerable to 
complications.    
More advanced insulin delivery systems under study would provide feedback-controlled 
insulin delivery without patient intervention.   One example is an implantable glucose sensor 
placed in a feedback control loop that controls the delivery of insulin from a reservoir with a 
pump [12, 13].  Another example is implantation of a polymer that changes permeability in 
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response to glucose.   For example, glucose oxidase is immobilized on pH-responsive 
polyacrylic acid, which is grafted onto a porous support.  When glucose concentration increases, 
its oxidation is accompanied by a decrease in pH that causes acrylic acid to assume a more 
compact conformation, thereby opening pores for insulin release [14]. 
 
1.1.2 Current State of Human Islet Transplantation 
Islet transplantation gives promise of normoglycemia. The islets provide physiological 
feedback controlled insulin release and are capable of continuously producing insulin. In 
humans, this procedure involves implanting islets isolated from a cadaver donor into the 
recipient’s liver via the portal vein. Islet transplantation would allow patients to be free of daily 
insulin injections and have tighter blood glucose control, thus eliminating many of the secondary 
complications of diabetes [3]. After several decades of frustration, a dramatic improvement in 
efficacy was reported in July of 2000 by a group from the University of Alberta, Edmonton that 
renewed interest throughout the medical community in islet transplantation research [15]. Seven 
consecutive patients with type 1 diabetes were freed from the need for exogenous insulin with 
excellent metabolic control for 1 year or more. There were three new features in the work: (1) 
Islet isolation from a human pancreas was followed by immediate (no more than 4 hr) 
implantation in the recipient to prevent islet damage that may occur during culture. (2) Patients 
received islets from two or more donors (until normoglycemia was achieved). (3) Patients were 
treated with a glucocorticoid-free immunosuppressive therapy, consisting of tacrolimus, 
sirolimus, and daclizumab, that protected the islets from autoimmune and alloimmune reactivity 
[15]. In further clinical studies with the Edmonton protocol, 87% of patients are insulin free one 
year after implantation [16].  Long term function of clinical islet transplantation has yet to be 
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achieved, after a five year follow-up of patients treated by the Edmonton protocol only 10% are 
insulin independent after receiving islets from up to three donor pancreases [17]. 
The efficacy of islet cell transplantations has been demonstrated in humans, but obstacles 
remain for wide scale application [18, 19].  This first obstacle is that there is a lack of available 
tissue for transplantation procedures.   In the U.S. there are 1 million people with type 1 diabetes, 
and about 30,000 new cases per year.  By contrast, there are currently about 5,000 cadaver 
pancreases available.   Even if all other problems were eliminated, islet transplantation would be 
limited to a small fraction of those who can benefit from it.  Expansion to a much larger patient 
population requires identification and development of new sources of islets or glucose responsive 
insulin-secreting tissue.   The second issue is that successful islet transplantation requires 
permanent use of multiple immunosuppressive agents that may have serious side effects as well 
as a substantial financial burden.  Protecting the islets from immune attack with a semipermeable 
membrane barrier is the basic notion behind a wide variety of immunoisolation device constructs 
that have been investigated.  
 
1.1.3 Immune Destruction of Islets 
Type 1 diabetes is an autoimmune disease, and islet transplantation will trigger an 
immune attack by the same mechanisms that caused the patient to become diabetic in the first 
place. Additionally, if the transplant is an allograft or a xenograft, the immune system will 
recognize it as non-self and mount an additional response. The reaction to the xenograft is 
generally more intense because the immune system will also recognize the transplant as being 
from another species [20]. The final component that can elicit an immune response is an 
immunobarrier material surrounding the islets. Successful islet transplantations require that the 
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immune system be blocked from attacking the transplant or responding deleteriously to the 
implanted material. The immune system can be blocked with drugs administered systemically or 
by encapsulation of the islets in a semipermeable material that will allow for glucose, insulin, 
and oxygen transport while blocking the transport of large immune reactive molecules. Other 
approaches, such as inducing immune tolerance, immunomodulation, and local 
immunosuppression are also under study. 
 
1.1.4 Encapsulation Device Types 
 Various approaches have been investigated to impose a semipermeable barrier to immune 
system components between islets and the blood stream or surrounding tissue.  These approaches 
can be usefully categorized into three approaches [21, 22].   
(1) Intravascular devices are shunts between an artery and a vein.  Blood flows through the 
lumen of a cylindrical membrane with islets surrounding the outer surface.   This type of 
device is beneficial because islets come into close proximity with arterial blood, which 
has high oxygen content, thereby somewhat ameliorating the problem of oxygen supply 
limitations.  This approach is the most successful to date in terms of long-term 
xenotransplantation (porcine islets transplanted into the dog), which have been successful 
for more than a year [22].  Human clinical trials were in the planning stages but were 
stopped by the FDA several years ago because a mechanical failure of the cannula 
leading from the device, and the studies never went forward for economic and safety 
reasons.   
(2) Extravascular devices contain many islets in a device that is implanted into a cavity of the 
body.  This type of device may be limited by the amount of oxygen that can be provided 
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to islets if diffusion distances for oxygen are large, thus preventing adequate oxygen 
transfer to maintain islets without vascularization of the device.   This problem can be 
enhanced by the fibrotic tissue that can grow around implanted devices [23], but 
developments in improved interfacing materials can improve vascularization. 
(3) Islet microcapsules are spheres of a biomaterial that contain usually one or sometimes 
more islets and have a diameter as low as 200-300 µm in the case of a conformal coating 
to as much as 1 to 2 mm (sometimes called macrobeads) with many islets encapsulated.  
The most common material used is alginate.   A large number of these small capsules 
containing islets are usually implanted into the peritoneal cavity.   This approach has 
been found effective in rodents even when there is only a minimal acute insulin secretory 
response to glucose stimulation [24].   
 
Among the characteristics of the ideal microcapsule for islets are the following: (1) non 
cytotoxic to encapsulated cells, (2) biocompatible in transplantation location, (3) adequate 
permeability for oxygen, glucose and insulin, (4) impermeable to antibodies and complement 
proteins, (5) creates a physical barrier to prevent contact of transplanted tissue an immune cells 
(6) chemically and mechanically stable, (7) high purity materials, and (8) minimal 
shrinking/swelling after transplantation [25, 26]. Various materials have been studied as potential 
encapsulating materials. The most common is alginate, derived from seaweed and considered 
safe for human use, which is used alone or in combination with other materials such as poly-L-
lysine, chitosan, cellulose sulfate, aminopropyl silicate, or polytheylene glycol [27-29]. 
 
Alginate and Poly L-Lysine 
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Alginate and poly L-lysine (PLL) microcapsules were first shown to provide 
immunoprotection in 1980 [30], and over twenty years later it is still the most widely used 
system. Alginate has remained the most common material used for microencapsulation because 
the encapsulation procedure is simple, and purified alginate is biocompatibile. Alginate is a 
polysaccharide made up of blocks of mannuronic (M) and guluronic (G) acid. Alginate beads are 
formed by dropwise addition of alginate into a solution of a bivalent cation, typically calcium 
chloride or barium chloride. The cation crosslinks the monomers of alginate and rapidly forms a 
gel bead. Beads crosslinked with barium ions have a greater mechanical stability than those 
crosslinked with calcium ions [31]. 
Alginate is a biocompatible material, but virtually all materials induce some foreign body 
response by the immune system. The foreign body response inhibits transport to the islets and 
causes an increase in central islet necrosis because the tissue attached to the outside of the 
capsule is consuming oxygen and creating a diffusion barrier [32]. Purification of alginate and 
smoother capsules greatly improve its biocompatibility, and, as a result, increases the survival of 
encapsulated islets [32-35].  In studies of purified alginate PLL microcapsules in vivo, the 
responses against intermediate-G alginate capsules are always less severe than against high-G 
alginate capsules [36].  Ninety percent of empty capsules, with intermediate-G content, 
implanted in the peritoneal cavity remain free of fibrotic overgrowth after 24 months, as 
compared to unpurified alginate capsules which are completely overgrown within a month [37].  
 
Alginate Alone 
Alginate has been used alone to encapsulate islets in order to maximize biocompatibility 
by eliminating the use of PLL or other polycations that produce a surface immunobarrier and 
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cause immune reactions. Highly purified barium alginate microcapsules protected islets against 
allorejection and autoimmunity in mice for up to 400 days [38]. Cytokines could still permeate 
the gel, but islet survival was not impaired because of the lack of a cellular response to the 
implant [38]. Barium alginate provided immune protection for porcine neonatal pancreatic cell 
clusters in streptozotocin induced diabetic mice against xenorejection for over 20 weeks [39, 40]. 
The neonatal pancreatic cell clusters were able to survive and mature within the microcapsule. 
 
1.1.5 Mass Transfer Limitations 
Islets contained within the pancreas are very well vascularized with blood at arterial PO2. 
When islets are removed from the pancreas and implanted elsewhere, they loose their blood 
supply and must rely on diffusion for nutrient delivery and oxygen transport. In the case of naked 
islet transplantations, over time the islets are revascularized and regain their blood supply. Even 
then, transplanted islets may be exposed to a lower PO2 than in the pancreas (5 mmHg compared 
to 40 mmHg) [41]. Islets contained within devices never become revascularized and must rely on 
diffusion through the device for nutrient supply, insulin removal, and waste removal. Fibrotic 
tissue formation around an implant increases the diffusion distance of nutrients to islets and 
consumes nutrients, which worsens the mass transfer problem and decreases the survival of 
transplanted islets [42].  Hypoxic conditions can have deleterious effects on islet function and 
viability. 
Hypoxic conditions in vitro allow for normal basal insulin secretion rates, but lower 
insulin secretion rates in response to glucose stimulation [43-46]. Viability of encapsulated islets 
in vitro is reduced as a result of necrosis associated with depletion of ATP and to some extent 
apoptosis caused by hypoxia [19, 47]. Hypoxia is associated with increased expression of 
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inducible iNOS (inducible nitric oxide synthase) mRNA in the islets, which likely leads to 
increased secretion of NO (nitric oxide) by the islets themselves and to increased expression of 
monocyte chemoattractant protein mRNA, suggesting that islets contribute to their own graft 
failure by attracting cytokine-producing macrophages [47]. 
Successful outcomes for islet transplantations will require prolonged survival of islets 
after implantation. If the islets can be adequately protected from the immune system, they will 
still have to be properly nourished in devices that have been engineered to provide the necessary 
amount of oxygen and nutrients.  In order for immunobarrier devices to be successful, the 
transplanted cells must remain viable and functional post-transplantation. 
1.1.6 Methods to enhance oxygen mass transfer 
Methods have been studied to enhance mass transfer to immunoisolated tissue, most 
specifically transport of oxygen, by using vascularizing membranes, in situ oxygen generation, 
thinner microcapsules, smaller islet cell aggregates, and enhancing the oxygen carrying capacity 
of immunoisolating materials.   Mass transfer of oxygen to an immunoisolated device can be 
enhanced if the vasculature is brought in very close contact with the device.  The vasculature can 
not come into direct contact with the tissue itself, which would be a breach of the immunobarrier 
but vessels in close proximity to the device are beneficial.   The Theracyte™ (Baxter Healthcare) 
planar diffusion chamber has two membranes: (1) an exterior vascularizing membrane that has 
an optimal pore size (5µm) so that cells can penetrate the layer and vascularization is induced, 
and (2) an immunoisolating membrane, pore size 0.45µm, both made from PTFE [48].    The 
Theracyte™ device can be preimplanted in order to induce vascularization of the device prior to 
transplantation which aids in islet survival post-transplantation [49]. 
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 An alternative approach to overcome oxygen limitations is to supply implanted tissue 
with oxygen generated in situ adjacent to or within the immunobarrier device [50, 51].  One 
method for in situ oxygen generation can occur by the electrolytic decomposition of water in an 
electrolyzer [51].  The electrolyzer is in the form of a thin, multilayer sheet, within which 
electrolysis reactions take place on the anode and the cathode to form oxygen and hydrogen 
respectively [51].  On one side of the device oxygen is generated and on the other side, the 
exterior of the device is exposed to either culture medium for in vitro studies or the host tissue 
for in vivo conditions.    In vitro studies with βTC3 cells in the electrolytic in situ oxygen 
generation device show that the thickness of viable tissue increases with oxygen generation [51].  
Another in situ oxygen generation system consists of photo-synthetic algae co-encapsulated with 
islets [50].  The algae require a light source in order to produce oxygen.  Under anoxic 
conditions islets secreted insulin normally only when there was a light source to induce oxygen 
generation by the algae demonstrating that the photosynthetic algae can produce oxygen to 
support islet function [50]. 
Oxygen transport to encapsulated islets can be enhanced by reducing the diffusion 
distance through the use of smaller capsules or thinner membranes.  There are drawbacks to 
reducing the diffusion distance because free radicals that are released from immune system 
effector cells may not become inactivated prior to reaching the encapsulated tissue and the 
amount of shed antigens from the encapsulated tissue can be increased, thereby enhancing the 
recipient’s immune response to the transplant.   Alginate capsules made using an electronic 
droplet generator as opposed to an air-driven droplet generator can be made to be <500 µm 
instead of ~800 µm.  There are also techniques in which only a thin coherent membrane is used 
to coat the islets.  Examples are the use of an emulsion procedure to form calcium alginate PLO 
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(poly L-ornithine) microcapsules [52] or by centrifuging an islet alginate cell suspension in a 
discontinuous gradient that contains a barium chloride layer [53]. 
Another way to enhance oxygen transport is that instead of using thin capsules is to use 
smaller islet cell aggregates.  Aggregates that are smaller in size will have a shorter internal 
diffusion distance and thus the tissue on average should experience higher oxygen levels than an 
intact islet.  Transplanted islet cell aggregates (50-150 µm) can reverse hyperglycemia as 
effectively as islets [54].  Normal insulin secretion was shown to be maintained at lower oxygen 
levels for perfused unencapsulated aggregates with a diameter of 37 µm (above bulk perfuasate 
PO2 of 20 mmHg) compared to intact islets (above bulk perfusate PO2 60 mmHg) [55].  Also 
recent studies with rat and human islets have shown that small islets survive better than large 
islets in transplantation [56, 57]. 
 A final approach that can be employed to enhance oxygen delivery to encapsulated tissue 
is to enhance the oxygen carrying capacity of the material and thus increase the rate at which 
oxygen can be delivered to the tissue.  Components that can be used for this purpose are organic 
compounds with high oxygen solubility such as perfluorocarbons or silicone or soybean oils.  
Perfluorocarbon emulsions have been developed as blood substitutes and could be incorporated 
into the encapsulation material to increase its oxygen permeability.  Perfluorocarbons and 
silicone oils have been used to enhance oxygen transfer in bioreactors [58, 59].   There are 
reports in the literature that including a perfluorocarbon emulsion in islet culture medium 
enhances islet function [60].   Perfluorocarbons have also been used in the storage of the 
pancreas prior to islet isolation to increase islet yield and storage time [61].  Culture of islets at 
the interface of a perfluorocarbon and cell culture media (two layer method) has been studied 
and was not shown to be beneficial in improving islet survival  [62].  There are two potential 
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reasons for the lack of improvement (1) the culture system probably did not have any oxygen 
limitations for the islets cultured without PFC and (2) the two layer method is beneficial for short 
periods of time when the PFC can act as a source of oxygen, but as it is not exposed to the air 
directly it does not have an effect after its oxygen store has been depleted.  Inclusion of 
hemoglobin in alginate microcapsules increases the length of islet survival after transplantation 
[63], but this enhancement likely results from trapping of nitric oxide by hemoglobin.    
 
1.2 OBJECTIVES 
The central hypothesis of this thesis is that a higher viability and better function of transplanted 
microencapsulated islets will be maintained when the local dissolved oxygen level is increased. I 
have studied two approaches to enhance microencapsulated islet survival and function by 
reducing oxygen transport limitations.  The first method incorporates a perfluorocarbon (PFC) 
emulsion into alginate microcapsules to enhance oxygen permeability.  The second method 
involves dispersing islets into single cells and allowing them to reaggregate into smaller cell 
clusters, which are then encapsulated instead of whole islets.  In order to evaluate the two oxygen 
enhancement strategies the following tasks needed to be accomplished and are described in the 
subsequent chapters. 
 
1.3 OVERVIEW 
 
Chapter 2: Quantitative Assessment of Encapsulated Islets.   
This chapter describes the quantitative methods that were adapted and developed for 
encapsulated tissue quality and quantity assessment similar to those used in the lab for 
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unencapsulated islet tissue.  Tissue quality is assessed by oxygen consumption rate (OCR) 
measurements.  Tissue quantity is determined by measuring DNA content or counting nuclei.  
Capsule quantity is measured by measuring alginate or PFC emulsion content.   
 
Chapter 3: Theoretical Analysis of Methods to Enhance Oxygen Transport to Encapsulated 
Tissue 
This chapter describes the calculations that were performed to predict oxygen profiles, fractional 
viability and fraction of normal insulin secretion for single cells, smaller aggregates, and islets.  
The three different types of tissue were analyzed in both microcapsules and planar diffusion 
chambers with and without a PFC emulsion in the alginate phase.  These calculations assess the 
oxygen diffusion limitations for islets in immunoisolation devices and evaluate the benefits of 
the two strategies to enhance oxygen transport: smaller islet cell aggregates and a PFC emulsion. 
 
Chapter 4: Encapsulated islet cell aggregates are superior to intact islets in terms of in vitro 
survival and function in low oxygen and ability to reverse diabetes in rodents 
This chapter will discuss the experimental work that was done in collaboration with Esther 
O’Sullivan from Joslin Diabetes Center at Harvard Medical School with encapsulated 
aggregates.  Theoretical predictions of encapsulated aggregate and islet survival and function in 
culture were calculated to determine oxygen levels for experiments.  In vitro culture experiments 
were carried out for 2 days in 0.5%, 2% or 20% oxygen.  OCR recovery, nuclei recovery, insulin 
to DNA ratios, and glucose stimulated insulin secretion were measured before and after culture.  
Two different types of transplantation experiments were also performed: (1) syngeneic 
transplants with non-diabetic recipients to assess tissue survival in vivo without the stresses of 
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immune reactions or diabetes and (2) xenogeneic transplants with diabetic recipients to assess 
effectiveness of encapsulated aggregates to treat diabetes. 
 
Chapter 5: Evaluation of a perfluorocarbon emulsion within alginate capsules 
This chapter will discuss the work that was done with PFC containing alginate capsules. 
Theoretical predictions of encapsulated islet survival and function in culture were calculated for 
microcapsules with and without PFC to determine oxygen levels for experiments.  OCR 
measurements were performed after two days of culture in low oxygen (0.5% or 1%) for islet 
capsules with and without PFC.  Histological sections were prepared to observe potential toxicity 
of the PFC emulsion and its components to islets.   Empty capsule transplantation experiments 
were performed to assess the biocompatibility of the PFC containing alginate microcapsules. 
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Chapter 2 Quantitative Assessment of Encapsulated Islets in Alginate 
 
2.1 INTRODUCTION 
Microcapsules can be used to transplant islets to treat type 1 diabetes without the use of 
immunosuppressive drugs.  Microcapsules are the most extensively studied encapsulation system 
and are the system that is under study in our lab.  Microcapsules are hydrogels, most commonly 
made of alginate, that contain one to two islets.  The tissue within a microcapsule relies on 
diffusion of nutrients through the hydrogel to the tissue and diffusion of waste products and 
secreted proteins away from the tissue.  The cells are protected from the immune system because 
the hydrogel keeps immune system effector cells, such as T cells and macrophages, from coming 
in contact with the transplanted tissue along with preventing or minimizing access of some large 
immune molecules such as antibodies and complement components. 
The most commonly used methods to characterize islet preparations have been reviewed 
previously [64, 65].  Most of the commonly used techniques to characterize islet preparations are 
found to be flawed because they are operator dependent, rely on the microscopic analysis in two 
dimensions of an irregularly shaped three dimensional spheroid, and tend to overestimate islet 
number and viability.  Islet numbers are typically assessed by counting islet equivalents (IE), the 
volume of tissue equal to one 150 µm diameter sphere, in which tissue diameters are estimated 
using a microscope; only islet tissue that is stained with dithizone is counted.  Dithizone is a zinc 
binding dye that specifically stains islet β cells.  Islet equivalent counts typically overestimate the 
amount of tissue in an islet preparation by a factor of two [65].  Islet viability is typically 
determined by membrane integrity measurements using live/dead stains containing two 
fluorescent dyes.  One commonly used dye is FDA (fluorescein diacetate) which stains live cells.  
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The second, propidium iodide (PI) will only stain cells with permeabilized membranes (a sign of 
cell death) and thus the fraction of cells stained with PI represent the dead cells in the tissue 
sample.  The relative fraction of dead cells is estimated visually and no systematic counting 
procedure is typically performed.  Thus this method of assessing cell viability is rather 
qualitative and very operator dependent.   
Improved methods for accurately determining the total number of cells in an islet 
preparation and by assessing tissue viability have been developed in our lab for use with 
unencapsulated islets [64, 65].   The total number of cells in an islet preparation can be 
accurately determined by nuclei counting or DNA measurements [64, 65].  The viability of islet 
tissue can be assessed by the mitochondrial function assay for oxygen consumption rate (OCR) 
measurements in a stirred chamber [66].  It is preferred to perform mitochondrial function assays 
as opposed to membrane integrity assays as mitochondrial function is disrupted earlier than loss 
of membrane integrity during the cell death process [65]. 
Assessment of encapsulated tissue quantity and quality are commonly performed using 
similar methods as those used for free islets.  Membrane integrity measurements are commonly 
performed to assess encapsulated cell and islet viability [47, 67, 68], but as these methods have 
limited value for unencapsulated islets they are also of limited value for encapsulated tissue.  A 
two dimensional representation of an even more complex three dimensional system is being used 
to estimate tissue viability with FDA and PI.  OCR measurements have been performed on 
encapsulated cells, but have been done so using a perfusion system which is complex to operate 
and time consuming to use [69].   
Due to the complicated nature of assessing encapsulated islets much of the literature in 
the field of islet microencapsulation has focused on the results of transplantation studies.  For the 
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purpose of my thesis I wanted to be able to carry out meaningful in vitro experiments and thus 
desired to adapt the nuclei counting, DNA measurements, and oxygen consumption rate 
measurements for use with encapsulated cells and islets.  In order to improve oxygen transport to 
encapsulated tissue in some experiments a perfluorocarbon (PFC) emulsion was incorporated 
into the capsule.  The PFC emulsion further complicated tissue assessment as the emulsion made 
the capsule opaque such that the tissue inside could not be visualized within the microcapsules 
using a standard microscope and the emulsion particles effected and interfered with certain 
measurements.  In this paper the methods developed for quantitative assessment of encapsulated 
cells and islets will be described in detail and data verifying that the techniques are accurate will 
be presented.     
2.2 METHODS 
 
2.2.1 Islets and Cells   
Rat islets were isolated from male Sprague-Dawley rats weighing 200-250 g using standard 
techniques [70].  Islets were cultured in tissue culture flasks at a density of up to 30 islets/cm2 
and a medium depth of 1.3 mm in RPMI 1640 supplemented with 10% fetal bovine serum 
(FBS), penicillin 100 units/ml and 100 μg/ml streptomycin (Mediatech, Herndon, VA).  Rat 
insulinoma INS-1 cells were cultured in tissue culture flasks in cell medium further 
supplemented with 2 mM L-glutamine, 1mM sodium pyruvate (Mediatech), and 50 µM 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO).  INS-1 cells were detached from flasks by 
incubation with 0.05% (w/v) trypsin in 0.52 mM EDTA (Mediatech) for 3 min at 37oC. 
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2.2.2 PFC Emulsion Preparation 
A PFC emulsion made from perfluorodecalin (Fluoromed, Round Rock, TX) and 20% (w/v) 
Intralipid® (Baxter, Deerfield, IL) (a soybean oil emulsion composed of 20% (w/v)  soybean oil, 
1.2% (w/v) egg yolk phospholipids, 2.3% (w/v) glycerin with balance water) was prepared as 
previously described [71].   A 40-ml volume of Intralipid was added to the inlet reservoir of an 
M110Y Microfluidizer (Microfluidics, Newton, MA) and recirculated for 2 min at an operating 
pressure of 14,500 psi through the interaction chamber and cooling coil and back to the reservoir.  
During recirculation, 11.25 ml of perfluorodecalin was added dropwise over 3 min to the 
reservoir.  The system sat without running for 5 min to cool, and the ice bath surrounding the coil 
was changed.  An additional 11.25 ml perfluorodecalin was added dropwise to the reservoir over 
3 min with recirculation, followed by additional recirculation for 5 min.  The final PFC content 
of the emulsion was 70% (w/v), equivalent to 36% (v/v). 
2.2.3 Microencapsulation 
Microcapsules were produced using highly purified alginate (FMC Polymer, Norway).  For 
normal alginate capsules, 2% (w/v) LVG alginate was used with INS-1 cells and 1.5% (w/v) 
SLG100 alginate with islets both in 0.9% (w/v) NaCl.   For PFC alginate, LVG alginate with 
INS-1 cells and SLG100 alginate with islets was dissolved into a 70% (w/v) PFC emulsion to a 
final concentration of 1.5% and 0.5% (w/v), respectively.  Cells or islets were washed with 
calcium-free Krebs buffer (135 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 
25 mM HEPES, pH 7.4), resuspended in alginate (or PFC alginate) to form a tissue-alginate 
suspension, and microencapsulated by extrusion through a needle using an electrostatic droplet 
generator (Pronova Polymer, Norway) or a needle using an air droplet generator into 20 mM 
BaCl2.  Microcapsules made with the electronic droplet generator ranged from 350 μm to 
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600 μm diameter with an average for each batch between 400 μm and 500 μm.  Microcapsules 
made with the air droplet generator ranged from 1000 μm to 2000 μm diameter.  After sequential 
washes in HEPES buffer (132 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 25 mM HEPES, pH 7.4) 
and Krebs buffer (133 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM 
HEPES, 2.5 mM CaCl2, pH 7.4) the microcapsules were analyzed for OCR, nuclei or DNA, and 
alginate or PFC content. 
2.2.4 Oxygen Consumption Rate (OCR) 
Microcapsules containing islets or cells resuspended in DMEM without phenol red (to avoid 
interference with absorbance in subsequent measurement of alginate content) containing 4.5 g/l 
glucose supplemented with 0.6 g/l L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin,  
and 10 mM HEPES (all from Mediatech Inc.) without serum (to avoid formation of bubbles) 
were placed in a 200-μl stirred titanium chamber (Micro Oxygen Uptake System FO/SYSZ-
P250, Instech Laboratories, Plymouth Meeting, PA) maintained at 37oC and equipped with a 
fluorescence-based oxygen sensor (Ocean Optics, Dunedin, FL),  as previously described [66].   
The time dependent O2P  within the chamber was recorded, and data yielding the highest slope of 
O2P  greater than 60 mm Hg of O2P  versus time were fit to a straight line.  The OCR was 
evaluated from 
 O2ch s
POCR=V α
t
Δ⎛ ⎞⎜ ⎟Δ⎝ ⎠  (2-1) 
 
where chV  is the chamber volume, and sα  is the volumetric average Bunsen solubility 
coefficient of oxygen in the entire sample evaluated from 
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 s w w c cα α φ α φ= +  (2-2) 
 
where ii   and  φα  are the volumetric average oxygen solubility and volume fraction of the ith 
component in the sample, w is water, and c is capsule.  For PEC alginate, cα  was evaluated from 
 c j jα α φ=  (2-3) 
 
where jφ  is the volume fraction of the jth component in the capsule, and the components are 
water, PFC, soybean oil and tissue (or cells).  Parameters used to calculate sα  are summarized in 
Table 2-1 and Table 2-2 and the calculations are presented in detail in Section 6.1.  For further 
assays, the capsule suspension was removed and stored in a tube together with three consecutive 
350-μl washes of the chamber.  The capsules were allowed to settle, and 1.0 ml supernatant was 
removed, leaving a 250-μl suspension. 
2.2.5 Capsule Dissolution 
Quantitative assays of nuclei counts, DNA content, alginate content, and PFC emulsion content 
required that the capsule first be completely dissolved by adding 800 μl of 100 mM tetrasodium 
EDTA (pH = 8) to the 250 μl capsule suspension.  Samples were incubated at 37oC for 1 hr and 
vortex mixed every 30 min.  Because dissolution of barium alginate was much more difficult 
than calcium alginate, tetrasodium EDTA was used instead of sodium citrate.   
2.2.6 Nuclei Counts 
Nuclei were prepared from naked islets or cells as previously described [65].  For encapsulated 
cell and islet suspensions with dissolved alginate, a 100-µl volume of sample was added to an 
equal volume of lysis solution (0.1 M citric acid and 1%, 2%, or 10% (v/v) Triton X-100 (Sigma 
Aldrich)) and incubated for 5 min (encapsulated cells) or 15 min (encapsulated islets) with 
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vortex mixing three times during incubation.  For encapsulated islets, the sample was 
resuspended in 100 µl PBS prior to adding lysis buffer to remove EDTA because it interfered 
with nuclei liberation.  Suspensions of encapsulated tissue were sheared through a 26G x 3/8-in 
needle (Becton Dickinson) after incubation in the lysis buffer to liberate all nuclei, and 100 µl of 
100 mM tetrasodium EDTA was then added to the encapsulated islet nuclei suspension to 
prevent any alginate gelling.  Liberated nuclei were stained with 0.8 µM LDS 751 and 0.2 µM 
Sytox Orange (Invitrogen,) in D-PBS and counted using a benchtop flow cytometer (Guava 
Personal Cell Analyzer, Guava Technologies, Hayward, CA) as previously described [65].  
Nuclear membrane permeabilization by 10% Triton X-100 led to much brighter nuclei, and flow 
cytometer settings were adjusted accordingly. 
2.2.7 DNA Analysis 
DNA concentration was quantified by fluorospectrophotometry using the CyQUANT® Cell 
Proliferation Assay Kit and λ DNA standard (Invitrogen), which is based on the strong 
fluorescence enhancement that the CyQUANT GR dye undergoes when bound to cellular nucleic 
acids, as previously described [65]. Pre-treating the samples with DNAse-free RNAse (Sigma) 
eliminated fluorescence resulting from CyQUANT dye binding to RNA.   Fluorescence intensity 
was measured with 480 nm excitation and 520 nm emission wavelengths in a plate 
reader (FLUOstar/POLARstar Galaxy, BMG Labtechnologies, Inc., Durham, NC) and was 
linearly related to DNA concentration.  The presence of EDTA and dissolved alginate had no 
effect, but light scattering by the PFC emulsion droplets prevented use of this assay. 
2.2.8 Alginate Content 
The assay for alginate content of samples was adapted from a previously-described method using 
dimethyl methylene blue (DMMB)  (Sigma Aldrich), a cationic dye that binds to polyanions 
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such as alginate [72].  Samples of SLG100 alginate were diluted to between 0. 5-3 mg/l with 
100mM tetrasodium EDTA.  A standard curve using samples created from the alginate solution 
originally used for preparation of the microcapsules diluted to different concentrations of 
alginate was prepared with each batch of unknown samples.  To individual wells of a 96 well 
plate in triplicate 100 μl of each sample and standard were added, and 100 μl of 120 μM aqueous 
dye solution.  After incubation for 15 min, the ratio of the absorbance of a sample at the 
wavelengths of 520 nm and 650 nm was measured using a plate reader (VERSAmax tunable 
microplate reader, Molecular Device, Sunnyvale, CA).  For LVG alginate a DMMB dye 
concentration of 40 µM and an alginate standard of 3 g/l were used. 
2.2.9 PFC Emulsion Content 
The PFC emulsion content in dissolved capsule samples was assessed by absorbance.  As 
prepared, the original 70% (w/v) PFC emulsion was opaque, but the absorbance of a sample at 
any wavelength increased linearly with increasing emulsion concentration at very high dilution, 
as determined by preparation of a standard curve from samples diluted 200- to 1000-fold.  Each 
unknown sample was diluted so as to fall into this range.  A series of standard samples and 
100 µl of each unknown sample were added to wells of a 96 well plate in triplicate.  We chose to 
measure the absorbance at 620 nm in a plate reader (FLUOstar/POLARstar Galaxy, BMG 
Labtechnologies, Inc., Durham, NC). 
2.2.10 Statistics 
Data are expressed as average ± standard deviation. Statistical significance (p < 0.05) was 
determined by a two-way Student t-test. 
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2.3 RESULTS 
2.3.1 OCR Measurements to Assess Encapsulated Tissue Viability 
 Nothing about the way that OCR measurements are typically performed with naked islets 
or cells needed to be changed in order to perform OCR measurements of encapsulated tissue.  
However several conditions needed to be met to ensure that the data that was collected 
accurately reflected the rate of oxygen consumption of tissue and not diffusion of oxygen 
through the microcapsule and are discussed further in Section 2.5.  Example OCR data for 
encapsulated INS-1 cells is shown in Figure 2-1.  Even though the slopes of the two data sets are 
quite different, when the OCR is calculated in units of nmol/min the oxygen consumption rate of 
the two samples are found to be equal.  The rate of decrease of PO2 with time is less in the sample 
that contained PFC because there was initially a greater concentration of oxygen in the chamber 
due to the higher sample solubility. 
 
2.3.2 Nuclei Counting of Encapsulated Islets or Cells 
 In our lab a method had previously been developed for nuclei counting of islets in order 
to accurately assess the number of cells in an islet preparation.  We desired to adapt this method 
for the measurement of nuclei from encapsulated cells or islets in barium alginate with and 
without PFC.  It was first necessary to assess whether the PFC emulsion particles interfered with 
nuclei measurements using a bench top flow cytometer (Figure 2-2).  Nuclei counts were 
performed with INS-1 cells that had not been encapsulated but had an emulsion volume fraction 
in the sample of 0, 4 or 10% (v/v).  The nuclei counts were the same with and without emulsion 
(p>0.05) and thus PFC emulsion particles do not interfere when counting nuclei using a bench 
top flow cytometer. 
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 In order to effectively dissolve the barium alginate capsules a new protocol had to be 
developed that required the use of 100 mM tetrasodium EDTA at a pH of 8.  Nuclei samples 
from unencapsulated single cells only require vortex mixing and incubation with a 1% Triton 
X-100 lysis buffer in order to effectively liberate all nuclei in the sample [65].  It was desired to 
evaluate whether the presence of EDTA interfered with the liberation of nuclei, if the 
concentration of Triton X-100 could be increased without loss of nuclei, and if passing the 
sample through a needle more efficiently liberate nuclei (Figure 2-3).   In the presence of EDTA 
at any concentration of Triton X-100 tested there were fewer nuclei detected than the control 
sample in PBS when only vortex mixing was used to liberate the nuclei.  When any of the 
samples containing EDTA were sheared through a needle after vortex mixing there was no 
difference in the number of nuclei counted to the sample that contained only PBS.  There were 
no differences in the nuclei concentration counted based on what concentration of Triton X-100 
was used.  Samples that contain EDTA should be sheared through a needle after vortex mixing to 
ensure all the nuclei are liberated and any concentration of Triton X-100 up to 10% (v/v) can be 
used in the lysis buffer. 
 To verify that the capsules were effectively dissolved and all nuclei were counted 
measurements of pg DNA per cell were performed after dissolution of INS-1 cells in calcium 
alginate or barium alginate (Figure 2-4).  Comparisons were made between calcium and barium 
alginate because calcium does not bind as strongly to alginate as barium [73]. Calcium alginate 
capsules are easier to dissolve and prior methods developed for capsule dissolution are for 
calcium alginate capsules.  Additionally, we compared the DNA content of the sample to the 
number of nuclei in the sample to ensure all of the nuclei were counted.  DNA measurements can 
be performed on capsules without first dissolving the capsules since sonication alone breaks up 
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the alginate microcapsule [40].  Measurements of pg DNA per cell were the same for INS-1 cells 
liberated from calcium alginate with a lysis buffer of 1% or 10% Triton X-100 and for INS-1 
cells in barium alginate capsules using a lysis buffer with 10% Triton X-100.  The DNA content 
per cell was slightly higher (although not statistically significant p=0.36) for INS-1 cells in 
barium alginate capsules using a lysis buffer with 1% Triton X-100 indicating that all nuclei in 
the sample were not counted.  Based on these observations we chose to use a lysis buffer with 
10% Triton X-100 to liberate the nuclei from barium alginate capsules that contain INS-1 cells. 
 In order to liberate nuclei from naked islet samples the extra step of shearing the sample 
through a needle is required which is not necessary for an unencapsulated single cell suspension 
[65].  When it came to measuring the number of nuclei in an islet sample after the tissue was 
removed from a capsule it was found that a few extra steps were required in order to obtain 
accurate nuclei measurements.  Prior to incubation with the lysis buffer the sample was 
resuspended in PBS because EDTA interferes with nuclei liberation, the sample was incubated in 
lysis buffer for 15 instead of 5 minutes, and after the sample was sheared through a needle and 
the nuclei were liberated 100 µl of EDTA was added to the sample to keep any trace amounts of 
alginate from gelling.  Following the methods described we have been able to demonstrate that 
nuclei measurements are accurate for INS-1 cells, rat islets and human islets in barium alginate 
capsules as there is no difference in the measured pg DNA per cell compared to each 
unencapsulated tissue type (Table 2-5).   
DNA measurements can not be performed in the presence of PFC emulsion as the 
emulsion particles interfere with the fluorescence reading that is used to quantify DNA.  
Measurements of pg DNA per cell could not be performed to verify that nuclei counting is 
accurate in PFC containing microcapsules.  However, lower alginate concentrations are used to 
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make the PFC capsules and PFC capsules were always observed to more easily dissolve than 
normal alginate capsules.  We thus assume that since the method is accurate for normal alginate 
capsules and the PFC emulsion particles do not interfere with nuclei counts the nuclei counting 
method is accurate for islets or cells in PFC capsules. 
 
2.3.3 Capsule Quantification 
 The methods that were developed to assess either alginate content of a sample in grams 
or PFC emulsion volume fraction were determined to effectively measure the quantity of 
capsules in a sample.  Standard curves for either assay were generated and they were both found 
to linearly increase with increases in alginate (Figure 2-5) or PFC emulsion content (Figure 2-6).  
The volume of alginate capsules can be calculated by dividing the number of grams of alginate in 
a sample by the concentration of the alginate solution used to make the capsules.  Depending on 
the type of alginate that was used, different dye and alginate concentrations were required to 
generate a standard curve that is a straight line.  PFC emulsion particles interfere with the 
alginate assay and thus measurements of alginate content could only be performed on dissolved 
normal alginate samples.  Either assay method can be used to normalize a sample by the capsule 
content in order to reduce errors due to differences in capsule sampling.  This is critical to 
measurements performed with PFC containing capsules.  The density of PFC is approximately 
twice the density of water and thus the high density of PFC containing capsules make it 
impossible to sample from a uniform suspension. 
2.4 DISCUSSION 
 The quantitative measurements for the assessment of islet quantity and quality that have 
been developed in our lab for use with naked islets have been effectively adapted to be used with 
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encapsulated cells or islets.  OCR measurements of small capsules can be performed to assess 
mitochondrial function.  Nuclei measurements can be performed to assess tissue quantity in 
normal alginate or PFC alginate capsules.  DNA measurements can be performed to quantify 
tissue in normal alginate capsules.   
 It was determined by scaling approximations that OCR measurements can effectively 
measure the kinetics of oxygen consumption in small capsules (~500 µm).  OCR measurements 
are also an effective means of measuring the mitochondrial function of tissue encapsulated in 
PFC containing alginate capsules.  However, the PFC emulsion content of the chamber must be 
measured and the effective solubility of the contents of the chamber must be used in the 
calculation of oxygen consumption rate.   
 Nuclei measurements can be performed on tissue in alginate or PFC alginate capsules 
after the capsules have been dissolved with 100 mM tetrasodium EDTA.  PFC emulsion particles 
do not interfere with nuclei measurements quantified with the Guava PCA bench top flow 
cytometer.  In the presence of EDTA, shearing of a cell suspension through a needle is required 
to effectively liberate all nuclei.  Higher concentrations of Triton X-100 in the lysis buffer result 
in more effective liberation of nuclei from INS-1 cells in barium alginate.  Nuclei measurements 
of encapsulated islets require removal of EDTA prior to incubation in the lysis buffer in order to 
effectively liberate all nuclei in a sample.  The final verification that the nuclei counting method 
is effective is that the measurement of pg DNA per cell for naked cells or islets to cells or islets 
in barium alginate capsules were the same. 
 The use of OCR, nuclei, DNA, alginate content, and PFC emulsion content 
measurements for the assessment of encapsulated islet tissue quantity and quality will allow for 
quantitative measurements of results from in vitro experiments.  These methods will allow for 
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accurate determinations of tissue quality that should allow for one to observe the effects of 
culture under low oxygen and evaluation of methods to enhance oxygen transport to increase 
tissue survival in low oxygen. 
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2.5 Supplementary Material: Validity of Equation (2-1) for Measuring OCR 
The oxygen consumption rate N within the chamber is assumed to be related to PO2 changes 
within the medium (measured Pm) and capsule (Pcap) by 
 cap mcap cap m m
dP dPN = v α  + v α
dt dt
 (2-4) 
where vcap and vm are the volumes of capsules and medium, respectively, and αcap and αm are the 
volume averaged oxygen solubility in capsules and medium, respectively.  At high PO2 where 
OCR is constant and independent of PO2, N is related to volumetric consumption rate expressed 
in different forms by 
 cap max,cap t max,t cell cell max,cellN = v V = v V = n v V  (2-5) 
where Vmax,cap, Vmax,t, and Vmax,cell are the maximal consumption rates expressed per unit volume 
of capsule, islet tissue, or cell, vt and vcell are the volume of total tissue in the chamber and of an 
individual cell, respectively, and ncell is the number of cells in the chamber. 
 If Pcap and Pm are equal, Equation (2-4) reduces to Equation (2-1) and (2-2).  These 
assumptions are reasonable if (1) quasi-steady conditions exist within the capsules, and (2) PO2 
differences within the capsule and across the boundary layer around the capsule are small 
compared to Pm.  Following the development for a similar problem [74], the species conservation 
equations for oxygen diffusion in a capsule with a constant, uniformly distributed oxygen sink 
(e.g. encapsulated cells) is 
 ( )cap cap2cap max,capcap 2P P1α = αD r -Vt r rr
∂ ∂⎛ ⎞∂ ⎜ ⎟∂ ∂ ∂⎝ ⎠
 (2-6) 
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By equating the transient term to the diffusion term, the time scale for relaxation of diffusion 
gradients within the sphere is 
 
2
cap
D
cap
R
~
D
τ  (2-7) 
Assuming that Pm=Pcap, Equations (2-2), (2-4), and (2-5) may be combined to yield 
 mch s cap max,cap
dPv α  = v V
dt
 (2-8) 
from which the time scale of the experiment may be estimated as 
 ( )ch s mE
cap max,cap
v α P 0
~
v V
τ  (2-9) 
The transient term in Equation (2-6) may be neglected if D Eτ τ , which leads to 
 ( )
2
cap cap max,cap
s cap m ch
R v V
1
α D P 0 v
  (2-10) 
This may be rewritten using Equation (2-5) as  
 ( )
2
cap max,ch
s cap m
R V
1
α D P 0
  (2-11) 
where max,ch chV = N v is the measured OCR per unit chamber volume. 
 Gradients within the capsule are small enough to be neglected if the rate of oxygen 
consumption is small relative to its rate of diffusion.  Comparing the two terms on the right hand 
side of Equation (2-6) leads to 
 ( )
2
cap max,cap
cap cap m
R V
1
α D P 0
  (2-12) 
which has the same form as Equation (2-11) but is slightly more restrictive. 
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 The PO2 drop across the boundary layer surrounding the capsule can be obtained directly 
from the boundary conditions at the surface of the capsules: 
 ( ) 2 3m m cap cap max,cap cap4kα P -P R 4πR  = V πR3⎡ ⎤⎣ ⎦  (2-13) 
The most conservative estimate for the mass transfer coefficient k corresponds to the case of a 
sphere in a stagnant medium, 
 ( )k 2R = 2
D
 (2-14) 
so that  
 m capk= D R  (2-15) 
and the resulting limit on the boundary layer PO2 difference ( )m m capΔP =P -P R  becomes 
 ( ) ( )
2
cap max,capm
m m m m
R VΔP =  1
P 0 3α D P 0
  (2-16) 
which is slightly less restrictive than Equation (2-12). 
 For the case of an islet at the center of the capsule, Equation (2-16) remains the same, 
since the right side of Equation (2-13) remains the same when it is replaced by N.  Additionally, 
the condition that diffusion through the capsule to the islet is not limiting, the PO2 drop within the 
capsule can be estimated from the boundary conditions written at the islet surface (r = RI): 
 
( ) ( ) ( ) 3c cap cap cap I max,t I
I cap
4π αD 4P R -P R =V πR =N1 1 3-
R R
⎛ ⎞⎡ ⎤ ⎜ ⎟⎣ ⎦ ⎝ ⎠  (2-17) 
where αc and Dc apply to the continuous phase of the capsule without tissue, leading to 
 
( ) ( )
( ) ( ) ( )
cap2
cap max,cap
cap cap cap I I
m mc
R
R V -1P R -P R R
= 1
P 0 3 αD P 0
⎡ ⎤⎢ ⎥⎣ ⎦   (2-18) 
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 To evaluate these dimensionless groups, solubilities were taken from Table 2-1 and Table 
2-2.  Effective diffusivities of heterogeneous phases were evaluated by successive application of 
Maxwell’s equation [75]. 
 
( )
( ) d dd d
αD 2-2 +ρ(1+2 )eff  = 
αD 2+ +ρ(1- )c
φ φ
φ φ  (2-19) 
Where ( ) ( )d cρ= αD αD , c is the continuous phase, d is the dispersed phase, and φd is the 
volume fraction of the dispersed phase.  Additional details of the calculation are described 
elsewhere (Chapter 6.1).  Effective diffusivities of various combinations of materials are given in 
Table 2-2.  Additional parameters for calculations are in Table 2-3. 
 Estimates of dimensionless parameters for typical conditions of interest in this study are 
summarized in Table 2-4.  The condition that the diffusion rates are faster than reaction rates 
within the capsules (Equation (2-12)) and diffusion through the capsules to the islet does not 
limit reaction (Equation (2-18)) are more restrictive for normal alginate capsules than PFC 
containing capsules and are the most stringent conditions that need to be satisfied.  The condition 
that quasi-steady state exists within the capsule (Equation (2-11))  is more restrictive for PFC 
containing capsules than normal alginate capsules.  The condition of the external boundary layer 
being negligible (Equation (2-18)) is unaffected by capsule type.  In general, validity criteria for 
validity of Equation (2-1) were satisfied with 500-µm diameter capsules but not with 2000-µm 
diameter capsules.      
Contributions:  Rat islet isolations were performed with the assistance of Jennifer Hollister-
Lock, Vaja Tchipasvilli, and Vassileios Kostaras from Joslin Diabetes Center.  Human islets 
were received from the Islet Cell Resource Consortium. 
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Figure 2-1: Example OCR data for INS-1 cells in normal alginate or PFC alginate microcapsules. 
The slopes of the data from the two samples are quite different, but after calculating OCR in 
units of nmol/min and thus correcting for differences in the solubility of the chamber contents of 
the two measurements, the OCRs of the two samples were determined to be equal. 
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Figure 2-2: Nuclei counts of INS-1 cells performed without or with PFC emulsion. 
PFC emulsion volume fraction (4 or 10% (v/v)) in the sample.  Each bar represents the average 
of triplicate samples from the same experiment.  Nuclei counts were not affected by the presence 
of PFC emulsion particles (p>0.05). 
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Figure 2-3: Nuclei counts of INS-1 cells in either PBS or 100mM tetrasodium EDTA (pH = 8). 
The lysis buffer that was used to liberate the nuclei contained 1% (v/v), 2% (v/v), or 10% (v/v) 
Triton X-100.  Nuclei were liberated by vortex mixing only or vortex mixing followed by 
shearing through a needle.   In the presence of EDTA shearing through a needle was required to 
effectively liberate nuclei (p<0.05 by Student t-test).  There were no differences between any of 
the samples that were sheared through a needle (p>0.05). Each bar represents the average of 
triplicate samples from the same experiment.   
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Figure 2-4: Nuclei counts and DNA content measurements were performed for encapsulated 
INS-1 cells. 
INS-1 cells in calcium alginate or barium alginate capsules after capsule dissolution with 
100mM tetrasodium EDTA (pH = 8).   The lysis buffer that was used to liberate the nuclei 
contained 1% (v/v) or 10% (v/v) Triton X-100. Each bar represents the average of triplicate 
samples from the same experiment.  There was no difference in pg DNA per cell for cells in 
calcium alginate with nuclei liberated with 1% or 10% Triton X-100 (p=0.80).  There was no 
difference in DNA per cell for cells in calcium or barium alginate with nuclei liberated with 10% 
Triton X-100 (p=0.59).  There appears to be a difference in the lysis buffer used for barium 
alginate capsules but this is not statistically significant (p=0.36). 
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Figure 2-5:  Example standard curve for alginate assay.   
Ratio of Absorbance at 520 nm to 650 nm was plotted versus alginate concentration for a 
standard curve of 8 samples with known alginate concentrations.  
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Figure 2-6: Example standard curve for PFC emulsion content assay.   
Absorbance at 620 nm was plotted versus emulsion volume fraction for a standard curve of 9 
samples with known emulsion volume fractions.  
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Table 2-1: Volume fraction (φ) of phases in capsules. 
Capsules contained 2.4x107 cells/ml or the pure PFC emulsion contained 70% (w/v) PFC. 
 
Component Cells + Alginate PFC Emulsion
Cells + Alginate 
+ PFC 
Tissue 0.023 0 0.023 
Alginate 0.02 0 0.02 
PFC 0 0.36 0.36 
Soybean Oil 0 0.12 0.12 
Water 0.957 0.52 0.477 
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Table 2-2:  Diffusion coefficient (D), Bunsen solubility coefficient (α) or permeability 
coefficient (αD) for oxygen in all pure components and composite phases in OCR 
measurements. 
Parameters are from the literature or calculated.  The cell concentration in the microcapsules is 
2.4x107 cells/ml. 
 
  D (cm2/s) 
α  
(mol/mmHg/ml) 
αD 
(mol/cm/mmHg/s) Source
Water 2.78x10-5 1.27x10-9 3.53x10-14 [23] 
PFC 5.61x10-5 2.54x10-8 1.42x10-12 [76] 
Soybean Oil 2.13x10-5 6.84x10-9 1.46x10-13 [77, 78]
Tissue 1.24x10-5 1.00x10-9 1.24x10-14 [23] 
Alginate 0 0 0 [23] 
2% (v/v) Alginate 2.77x10-6 1.24x10-9 3.43x10-14 Ch. 6.1
Cells Normal Alginate 2.73x10-5 1.23x10-9 3.36x10-14 Ch. 6.1
70% (w/v) PFC Emulsion 9.36x10-6 1.06x10-8 9.92x10-14 Ch. 6.1
70% (w/v) PFC Emulsion in 2% (v/v) Alginate 9.08x10-6 1.06x10-8 9.63x10-14 Ch. 6.1
Cells 70% (w/v) PFC Alginate 8.83x10-6 1.06x10-8 9.36x10-14 Ch. 6.1
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 Table 2-3: Other parameters used for OCR feasibility calculations 
 
Description Variable Equation Value Units 
Experimentally measured 
OCR per cell  
(4 fmol/min/cell) 
OCR  6.67x10-17 mol/s/cell
Volume of an islet with a 
diameter of 150 µm vI  1.77x10
-6 cm3 
Volume of a capsule with a 
diameter of 500 µm v500capsule  6.54x10
-5 cm3 
Maximum oxygen 
consumption rate for solid 
tissue 
Vmax_tissue 
I
1560cells IEOCR
v
 5.89x10-8 mol/(cm3*s)
Maximum oxygen 
consumption rate for 
capsules containing cells 
Vmax_capsule 
I
500cap
max_tissue
vV *
v
 1.59x10-9 mol/(cm3*s)
Initial partial pressure of 
oxygen in chamber Po  160 mmHg 
Volume fraction capsules 
in chamber φcaps  0.1  
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Table 2-4: Calculation of conditions that need to be met in order for OCR measurements to be 
valid. 
Calculations were performed for alginate and PFC capsules of either 500-µm or 2000-µm in 
diameter.  The volume fraction of capsules in the chamber was assumed to be 0.1. 
  
Equation 
(2-11) 
Equation 
(2-12) 
Equation 
(2-16) 
Equation 
(2-18) 
2% (v/v) Alginate 500µm 0.02 0.18 0.06 0.14 
2% (v/v) Alginate 2000µm 0.29 2.96 0.94 11.91 
70% (w/v) PFC 2% (v/v) Alginate 500µm 0.03 0.07 0.06 0.05 
70% (w/v) PFC 2% (v/v) Alginate 2000µm 0.51 1.06 0.94 4.24 
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Table 2-5: Summary of measurements of pg DNA per cell for naked cells or islets or cells or 
islets in barium alginate 
 Unencapsulated Barium Alginate 
INS-1 Cells 6.0 ± 0.8 (n=25) 
6.5 ± 0.8 
(n=5) 
Rat Islets (n=7) 6.5 ± 0.8 6.1 ± 1.1 
Human Islets (n=6) 6.2 ± 0.8 7.3 ± 3.0 
 
 
 
 
 
 
 57
Chapter 3 Theoretical Analysis of Methods to Enhance Oxygen Transport to 
Encapsulated Tissue  
 
3.1 INTRODUCTION  
Immunoisolation devices can be used to transplant cells to treat a variety of human 
diseases without the use of immunosuppressive drugs.  An immunoisolation device consists of 
cells that are entrapped within a perrmselective membrane.  The tissue relies on diffusion of 
nutrients through the device membrane to the tissue and diffusion of waste products and secreted 
proteins of interest away from the tissue.  The cells are protected from the immune system by a 
membrane that keeps immune system effector cells, such as T cells and macrophages, from 
coming in contact with the transplanted tissue along with preventing or minimizing access of 
some large immune molecules such as antibodies and complement components.  
Immunoisolation devices could possibly be used to treat a large variety of human diseases that 
result from the body’s inability to produce a required protein.  Some diseases that might be 
treated by immunoisolation include diabetes [79], hemophilia [80], anemia [81], parathyroid 
disease [82], chronic pain [83], Parkinson’s disease [84], Huntington’s disease [85], and 
amyotrophic lateral sclerosis [86].  The work in our lab is focused on the use of immunoisolation 
devices for the treatment of diabetes.   For all of the diseases listed above diabetes is probably 
the hardest to treat by the transplantation of immunoisolated cells as it requires more cells to be 
transplanted - about 109 cells to be transplanted into a patient compared to 106-107 for diseases of 
the central nervous system [22].  Also when the number of cells needed to be transplanted is 
large, the size of an immune device that can support efficient oxygen transport can in some cases 
becomes infeasible [87]. 
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There are three main types of immunoisolation devices: (1) intravascular devices, (2) 
extravascular devices, and (3) microcapsules [21, 22].  Intravascular devices are inserted as a 
vascular shunt between an artery and a vein.   Theses devices are typically hollow fibers in which 
blood flows through the lumen of the device.  This type of device was extensively studied and is 
probably the best design for effective oxygen delivery since oxygenated blood flows through the 
device lumen, but due to the threat of thrombosis within the device lumen it is no longer being 
evaluated for the transplantation of immunoisolated tissue.  The second type of device is an 
extravascular macrocapsule which is most commonly a planar diffusion chamber or a hollow 
fiber.  Both types of macrocapsules have encapsulated cells within their interior surrounded by 
an immunoisolating membrane.  One advantage of this type of device is that due to its large size 
it can, depending on the circumstances, be retrieved after transplantation.  Many researchers 
working in the field of islet encapsulation have been working with planar diffusion chambers.  
Planar diffusion chambers are typically implanted into the subcutaneous tissue or the peritoneal 
cavity.  Recent work by Gianello and Dufrane where encapsulated pig islets were transplanted 
into non-immunosuppressed monkeys has even further invigorated research in this area [88].  
The final type of immunoisolation device is a microcapsule.  Microcapsules are small spherical 
gels that range in size from 200 µm to 2 mm.  Microcapsules are the most extensively studied 
encapsulation system and are under study in our lab.  Microcapsules are hydrogels that contain 
one to two islets.  The most common implantation site is the peritoneal cavity. 
Islets within the native pancreas are heavily vascularized, and during islet isolation 
procedures the vascular network of the islet is destroyed, collapses during culture and does not 
regenerate when the islets are transplanted within an immunoisolating device [89-91].  Tissue 
within an immunoisolation device must rely on delivery of oxygen and other nutrients by 
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diffusion from the exterior of the device.  Oxygen diffusion is much more limited than glucose 
diffusion because glucose concentrations in vivo are much higher than oxygen [92].  The oxygen 
level will be studied as the critical nutrient that determines encapsulated tissue survival and 
function.  For oxygen to reach the encapsulated tissue it must diffuse from the vasculature to the 
device exterior, through the device to the tissue and through the islet while being consumed to 
reach the cells at the center.  Oxygen delivery is even further hampered when an immune 
reaction to the transplanted cells or immunoisolating material results in cells adhering to the 
outside of the device consuming oxygen before it is able to reach the cell in the device interior 
[23].   
Reduced oxygen levels have been shown to reduce islet insulin secretion below what was 
observed under normoxic conditions [44, 47].  In the work by Dionne et al. [44] islets were 
perfused with media that was equilibrated with air at various oxygen levels, at gas phase PO2 
values below 60 mmHg there was a reduction in insulin secretion.  The ability of an islet to 
effectively secrete insulin following transplantation is essential for transplantation success.  
Thus, since reduced oxygen levels have been shown to decrease islet survival and function, 
effective oxygen delivery is critical for successful transplantation of immunoisolated islets to 
treat type 1 diabetes.  Previous theoretical analysis of oxygen limitations to immunoisolated 
tissue have been studied and have shown that depending on the transplantation conditions these 
problems can be quite serious [23, 93].   
In this work we expand on previous models to evaluate what the oxygen limitations are 
for islets in either microcapsules or planar diffusion chambers over a range of external oxygen 
levels.  We chose to look at these two types of devices because they are the two most commonly 
studied in the field of islet immunoisolation.  We will also evaluate the use of two different 
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methods to reduce oxygen transport limitations to encapsulated tissue: (1) increasing the 
permeability of the immunoisolating material through the use of a perfluorocarbon emulsion and 
(2) dispersing the islets into single cells and allowing them to reaggregate into aggregates with a 
smaller diameter than an intact islet.  Perfluorocarbons are highly desirable materials for 
enhancing oxygen transport, due to their very high oxygen solubility, approximately 25 times 
that of water, on a volumetric basis.  Enhanced solubility will lead to enhanced permeability 
because the permeability is a product of the solubility and diffusivity.  Perfluorocarbon 
emulsions have been developed as a blood substitute and can be incorporated into encapsulation 
materials.  There are reports in the literature that including a perfluorocarbon emulsion in islet 
culture enhances function [60].    Perfluorocarbons are also used during pancreas storage prior to 
islet isolation [61].  Culture of islets at the interface of a perfluorocarbon and cell culture media 
(two layer method) has been studied and was not shown to be beneficial in improving islet 
survival  [62].  There are two potential reasons for the lack of improvement (1) the culture 
system probably did not have any oxygen limitations for the islets cultured without PFC and (2) 
the two layer method is beneficial for short periods of time when the PFC can act as a source of 
oxygen, but as it is not exposed to the air directly it does not have an effect after its oxygen store 
has been depleted.  All of these facts taken together indicate that the incorporation of 
perfluorocarbons into an encapsulating material is likely to be beneficial, and in this work we 
evaluate the theoretical benefits perfluorocarbons can have on increasing oxygen levels 
experienced by encapsulated tissue along with improving fractional viability and fraction of 
normal insulin secretion after transplantation.    We are interested in studying aggregates because 
it is likely that for an intact islet with a diameter of 150-µm all oxygen is consumed prior to 
reaching the cells at the center of the islet.  However, with aggregates, by reducing the internal 
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diffusion distance within the tissue there are potential benefits to tissue survival and function.  
Normal insulin secretion was shown to be maintained at lower oxygen levels for perfused 
unencapsulated aggregates with a diameter of 37 µm (above bulk perfuasate PO2 of 20 mmHg) 
compared to intact islets (above bulk perfusate PO2 60 mmHg) [55].  Also recent publications 
have suggested that smaller islets are superior to larger islets in terms of survival in low oxygen 
and transplantation outcome [56, 57].   
In this work a theoretical model was developed to assess the oxygen level, fractional 
viability, and fraction of normal insulin secretion for islets, single cells and aggregates ranging in 
size from 37.5 to 125 µm.  The different tissue sizes were analyzed in two types of 
immunoisolation devices – microcapsules and planar diffusion chambers with and without a 
perfluorocarbon emulsion at varying tissue loadings and over a range of external oxygen 
environments.  The theoretical analysis in this paper can be used to determine which oxygen 
enhancement strategy is most beneficial under a particular transplantation situation and is worth 
further investigation. 
3.2 MODELING 
To assess the benefits of aggregate and PFC-containing immunoisolation devices, a 
theoretical model has been developed to predict the local partial pressure of oxygen, which, in 
turn, is used to assess tissue viability and fraction of normal insulin secretion for encapsulated 
islets, aggregates, and single cells in microcapsules and planar diffusion chambers.  For most 
calculations the microcapsules have a diameter of 500 µm and the planar diffusion chambers 
have a thickness of 500 µm.  A few calculations were performed for device sizes of 250, 1000 
and 2000-µm for microcapsules and diffusion chambers.  For both device types the 
immunoisolating material will be 2% (v/v) alginate as this is the most commonly used material 
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for microcapsules and is sometimes used in planar diffusion chambers.  We chose to use the 
same immunoisolating material for both types of devices so that any differences observed in the 
calculations are due to differences in device geometry and not to the selection of different 
immunoisolating materials. 
 
3.2.1 Model Geometry 
 Sketches of example geometries that were analyzed are presented in Figure 3-1A for 
microcapsules and Figure 3-1B for planar diffusion chambers.  All aggregate and islet tissue are 
assumed to be spheres.  Tissue in a microcapsule was arranged four different ways: (A1) a single 
tissue sphere which is a centrally located 150-µm diameter islet or smaller aggregate, (A2) 
aggregates or islets arranged in a cubic array where the tissue lies throughout the capsule 
diameter and the length of the side of the cube is equal to the capsule diameter, (A3) aggregates 
in a cubic array where the cube fits entirely within the capsule, and (A4) homogenously 
distributed tissue which is meant to approximate single cells.  Comparisons between capsule and 
device loadings will be made using islet equivalents.  An islet equivalent (IE) is a volume of 
tissue equal to that of a 150-µm sphere.  For the aggregate case, calculations were performed for 
five different sizes of aggregates – 37.5, 50, 75, 100 and 125-µm diameter at many different 
capsule loadings starting with one single centrally located aggregate to about 2-10 IE of 
encapsulated tissue.  Calculations were only performed for arrangement model geometry (A2) 
with an odd number of aggregates across the capsule diameter such that an aggregate was always 
placed at the center of the capsule, and calculations were performed with increased capsule tissue 
loading up to the point where the aggregates filled the capsule diameter.  For each capsule, with 
the origin placed at the center of the capsule, there are three planes of symmetry perpendicular to 
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each axis through the origin, thus the model can be solved for only one eighth of the capsule in 
order to reduce the number of degrees of freedom. 
 Calculations were performed for three different types of tissue in a planar diffusion 
chamber – islets, aggregates and single cells.  Sketches of the geometries studied are presented in 
Figure 3-1B.  (B1) For a single layer of islets or any size aggregate, the tissue spheres were 
placed at the central plane of the device arranged in a cubic array.  The unit cell that was 
analyzed for a monolayer of tissue is sketched in Figure 3-1B for the monolayer planar device 
that contains islets and represents one quarter of an islet.  (B2) When multiple layers of tissue 
were modeled the bottom and top tissue layers were nearly touching the device membrane.    The 
positions of the alternating layers are offset to create a body centered cubic configuration.   An 
example unit cell that was analyzed for many tissue layers is shown in Figure 3-1B2 for a 
multilayer planar device where one quarter of an aggregate from each layer is modeled.  (B3) In 
the homogenously distributed tissue planar device cells were modeled as a homogenous phase of 
tissue equally distributed throughout the device. 
 
3.2.2 Material and Tissue Properties    
 The effective permeability in subdomains containing several components was determined 
from theoretical relationships.  The ratio of the effective permeability (αD)eff,i for layer i 
consisting of a dispersed (d) phase and a continuous (c) phase (as occurs in the alginate 
subdomains of the model system) to the permeability of the continuous phase (αD)c was 
calculated from Maxwell’s relationship [75] 
 
( )
( )
eff,i
c
αD 2-2 +ρ(1+2 ) = 
αD 2+ +ρ(1- )
φ φ
φ φ  (3-1) 
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where αD is the effective permeability of the material (mol/cm/mmHg/s), ( ) ( )d cρ= αD αD  is 
the ratio of the permeability of the dispersed phase to the permeability of the continuous phase, 
and φ  is the volume fraction of the dispersed phase.  For the multiple dispersed phases employed 
in our model system, Maxwell’s relationship was used sequentially, starting with the phase with 
the smallest particle size and ending with the phase with the largest particle size.  For particle 
types of the same size, Maxwell’s relationship was used for one particle, then the other (and in 
the reverse order), and the two results were averaged. 
The perfluorocarbon emulsion that we have been studying in the lab consists of 70% 
(w/v) perfluorodecalin and 20% (w/v) Intralipid® (Baxter), a soybean oil emulsion, and a PFC 
emulsion of this composition is used in all model simulations that contain PFC alginate [71].  In 
the final PFC alginate composite phase, there were perfluorodecalin and soybean oil droplets of 
approximately the same size (0.4 µm); the alginate polymer itself was treated as an impermeable 
dispersed in water.  The pure component material transport properties are given in Table 3-1 and 
the effective properties for different alginate types are given in Table 3-2.  A detailed description 
of the calculation of effective solubility, permeability and diffusivity for the different composite 
materials used in the model can be found in Section 6.1.   
 
3.2.3 Model Equations 
The three-dimensional species conservation equation for reaction and diffusion at steady 
state was used to predict the oxygen profile within the different tissue and material subdomains 
in the immunoisolation device: 
 2i i iD C = V∇  (3-2) 
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where Di (cm2/s) is the effective diffusivity of oxygen in subdomain i, Ci (mol/cm3) is the 
concentration of oxygen in subdomain i, and Vi (mol/cm3/s) is the local oxygen consumption rate 
per unit volume in subdomain i.  For convenience, since partial pressures are equal across 
interfaces of different materials, we make use of oxygen partial pressure instead of 
concentration, which are related by 
 C = αP  (3-3) 
where α (mol/cm3/mmHg) is the effective Bunsen solubility coefficient in subdomain i and P is 
the partial pressure of oxygen.  Combining  Eq. (1) and Eq. (2) gives   
 ( ) 2i i iαD P = V∇  (3-4) 
The oxygen consumption rate is assumed to follow Michaelis-Menten kinetics for all tissue, 
 max i ii
m i
V ε P
V  = 
K +P
 (3-5) 
where Vmax is the maximum oxygen consumption rate for the tissue, εi is the tissue volume 
fraction in subdomain i, and Km is the Michaelis-Menten constant.  For the immunoisolation 
devices that contain an islet or aggregates, no oxygen is consumed in the alginate subdomain; 
therefore Vi is equal to zero, and the tissue volume fraction in the islet or aggregate subdomains 
is equal to one.  For the case of an immunoisolation device containing dispersed single cells, the 
model consists of only one subdomain and the tissue volume fraction (ε) is less than one and is 
calculated based on the particular tissue density used.  The equations for each subdomain are 
written out in detail in Section 6.2. 
The boundary conditions for these problems are as follows.  For the microcapsule there 
are planes of symmetry where the capsule was cut to create the unit cells and thus zero flux of 
oxygen across these surfaces for both the alginate and tissue subdomains 
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at x=0, y=0 or z=0 
 ( )in• -Dα P =0∇  (3-6) 
 
At the boundary between a tissue subdomain (t) and the alginate subdomain (a) there is 
continuity and thus the partial pressure of oxygen and the flux of oxygen across the boundary are 
both equal. 
At r=Rtissue 
 atP =P  (3-7) 
 ( ) ( )t an• -Dα P - -Dα P =0⎡ ⎤∇ ∇⎣ ⎦  (3-8) 
The final boundary condition that is required to solve the problem is the assumption that the 
external partial pressure of oxygen is specified at the capsule surface (s), 
at r=Rcapsule 
 a sP =P  (3-9) 
We chose to assume a value of the exterior surface PO2 rather than model external oxygen 
diffusion because within the peritoneal cavity oxygen levels vary greatly and have been 
measured to be anywhere between near 0 and 38 mmHg [94].  Therefore, as microcapsules in the 
peritoneal cavity are likely to move and thus likely to experience wide ranges of oxygen levels it 
is important to know how tissue survival and function will be affected over the range of oxygen 
levels likely to be experienced.  
For the planar device there are planes of symmetry where the device was cut to create the 
unit cells and thus zero flux of oxygen across these surfaces for both the tissue and alginate 
subdomains  
 ( )in• -Dα P =0∇  (3-10) 
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At the boundary between a tissue subdomain (t) and the alginate subdomain (a) there is 
continuity and thus the partial pressure of oxygen and the flux of oxygen across the boundary are 
both equal. 
At r=Rtissue 
 atP =P  (3-11) 
 ( ) ( )t an• -Dα P - -Dα P =0⎡ ⎤∇ ∇⎣ ⎦  (3-12) 
 
The final boundary condition that is required to solve the problem is the assumption that the 
external partial pressure of oxygen is specified at the device surface (s), 
at z= ± h/2 where h is the device thickness 
 a sP =P  (3-13) 
The model was solved by the finite element method using the commercially available 
software package COMSOL Multiphysics in combination with MATLAB and using the model 
parameters in Table 3-1, Table 3-2, and Table 3-3.  Equation (3-4) was solved simultaneously for 
all subdomains of the immunoisolation devices subject to the boundary conditions stated above.  
The mesh size that was chosen for each calculation was verified to be fine enough when on 
further decreases in mesh size the solution did not change.   
The fractional viability of the encapsulated tissue was estimated by determining the 
volume fraction of tissue where P>PC.  PC is the critical oxygen partial pressure below which 
tissue dies and the value of PC is assumed to be 0.1 mmHg.  The fractional viability was 
calculated using the following equation: 
 Viable
Tissue
V
Fractional Viability=
V
 (3-14) 
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where VViable is the volume of tissue where P is greater that 0.1 mmHg and VTissue is the total 
encapsulated tissue volume. 
 The relationship used to predict the local fraction (FI) of normal insulin secretion rate as a 
function of local oxygen partial pressure within the islet was developed from data on the effect of 
hypoxia on islet insulin secretion, estimating the oxygen partial pressure profile within the islet 
in the experimental system, and then determining the simplest model type and parameters(s) that 
best predict the insulin secretion level [44, 93].  The result for a value of Vmax = 4x10-8 mol/cm3/s 
is  
 I
I
PP <  5.1 mmHg     F  = 
5.1
P  5.1 mmHg     F  =  1.0≥
 (3-15) 
 
The fraction of normal insulin secretion averaged over all tissue within the microcapsule or 
planar device was determined by evaluating the volume integral of FI in all tissue containing 
subdomains 
 
I
S
Viable
Tissue
FdV
F =
V
∫
 (3-16) 
where FS is the fraction of normal insulin secretion averaged over all of the encapsulate tissue. 
    
3.3 RESULTS 
3.3.1 Estimation of Oxygen Diffusion Limitations in Microcapsules and Planar Diffusion 
Chambers 
To begin our analysis of the benefits of using smaller islet cell aggregates or a permeability 
enhancer we first performed a scaling analysis to determine if and under what circumstances 
either strategy would be beneficial to enhancing oxygen transport.  The first scaling 
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approximation that was studied was to compare the rate of reaction to the rate of diffusion for 
solid spheres of tissue also known as the Damkohler number. 
 ( )( )
2
max,t t
m s,t t
V R
Da=
K +P αD
 (3-17) 
where Da is the Damkohler number and Ps,t is the given partial pressure of oxygen at the tissue 
surface.  The calculation of the Damkohler number is only an approximation of relative rates of 
oxygen diffusion and reaction because oxygen gradients do exist within the islet and as a result 
not all tissue is respiring at the same rate. In many cases the oxygen consumption rate by the 
tissue is being over estimated as the oxygen level decreases.   
One would want the Damkohler number to be small for a given tissue size and oxygen 
level such that oxygen consumption would not be limited by diffusion. The Damkohler number 
was calculated for tissue that has a diameter of 37.5, 50, 75, 100, 125, and 150 μm over a range 
of 1-40 mmHg (Figure 3-2).  Only for the smallest tissue sizes (37.5 and 50 μm) is the 
Damkohler less that 1 and then only when the surface oxygen level is greater than 20 mmHg.  
COMSOL models were also solved for the six different tissue sizes over a range of specified 
tissue surface oxygen levels.  Lines are drawn across the family of curves to show at which point 
the tissue no longer remains functional or viable.  The Damkohler number at which these cutoffs 
occur is greater than one as some gradients within the tissue can be tolerated as long as the 
oxygen level at the tissue center does not get below 0.1 or 5.09 mmHg for either maintenance of 
tissue viability or insulin secretion respectively.  The value of the Damkohler number for the 
fraction of normal insulin secretion cutoff increases with increasing tissue diameter and occurs at 
higher oxygen levels for the larger tissue sizes.  The value of the Damkohler number for the 
fractional viability cutoff has some dependence on tissue size and the external oxygen level for 
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which it occurs increases with tissue size and always occurs for lower oxygen levels than the 
fraction of normal insulin secretion cutoff.   From the simple analysis of the Damkohler we were 
able to show that oxygen gradients within smaller aggregates can be greatly reduced compared to 
intact islets over the entire range of oxygen levels likely to be experienced by transplanted tissue.   
Aggregates should be beneficial in allowing tissue to maintain function and viability in lower 
oxygen environments.  Since the Damkohler number is only ever less than one for 37.5 or 50-μm 
aggregates these size aggregates should be the most beneficial in reducing oxygen transport 
limitations to encapsulated tissue. 
 The next scaling approximation that was performed was to estimate the pressure drop 
through the alginate phase of a microcapsule that contains a centrally located tissue of diameter 
37.5 to 150-μm or through the alginate phase of a planar device to a layer of tissue located in the 
central plane of the device.  For the case of a centrally located sphere of tissue at the center of a 
microcapsule the pressure drop within the capsules can be estimated from the boundary 
conditions written at the tissue surface: 
 
( ) ( )cap max,t s 3s,cap cap t t
m s
t cap
4π αD V P 4πP -P R = R1 1 K +P 3-
R R
⎛ ⎞⎡ ⎤ ⎜ ⎟⎣ ⎦ ⎝ ⎠  (3-18) 
where Rt is the radius of the tissue sphere and Rcap is the radius of the capsule.  Rearranging to 
determine the scaled capsule pressure drop: 
 ( ) ( )
2 t
max,t t
capcap
s m scap
RV R 1- RΔP
=
P 3 αD K +P
⎛ ⎞⎜ ⎟⎝ ⎠  (3-19) 
To determine a similar expression for the pressure drop through the encapsulating material to a 
layer of tissue at the center of the device a few assumptions needed to be made.  First, the tissue 
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within the device could not be approximated as discrete spheres and therefore was assumed to be 
a slab with a tissue volume fraction of π/6 and thus Vmax,t was multiplied by this value.  Second, 
this assumed tissue volume fraction is therefore approximating the case where the monolayer of 
tissue within the device consists of spheres that are touching and therefore does not represent the 
case where lower tissue loadings are used.  The pressure drop within the device can be estimated 
from the boundary conditions written at the tissue surface: 
 
( ) ( ) ( )max,t sdev s,dev dev t t
dev t m s
V PA αD 6P -P R = A*z
z -z K +P
π
⎡ ⎤⎣ ⎦  (3-20) 
where A is the device surface area, zcap is the device half thickness, zt is the tissue half thickness, 
dev refers to the device.  Rearranging to determine the scaled device pressure drop: 
 
( )
( ) ( )
max,t t dev t
dev
s m sdev
V z z -zΔP 6=
P αD K +P
π
 (3-21) 
It is desirable that the expression on the right hand side of both equation (3-19) for microcapsules 
and (3-21) for planar devices is small such that the encapsulating material does not impose a 
large mass transfer resistance.  Comparing the two equations a couple of interesting observations 
can be made.  First by examining Equation (3-19) 
 cap 2 tt
caps
ΔP RR 1- RP
⎛ ⎞∝ ⎜ ⎟⎝ ⎠  (3-22) 
when Rt<<Rcap  equation (3-22) becomes 
 cap 2t
s
ΔP
R
P
∝  (3-23) 
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the pressure drop through the microcapsule loses any sort of dependence on capsule size and thus 
after a certain point there is no further detriment to the tissue of using a larger capsule.  By 
examinging Equation (3-21) 
 ( )dev t dev t
s
ΔP z z -z
P
∝  (3-24) 
when zt<<zdev Equation (3-24) becomes 
 dev t dev
s
ΔP z z
P
∝  (3-25) 
The pressure drop through the device always gets worse with increasing device thickness.  The 
fact that the pressure drop is proportional to the square of the tissue size for microcapsules and is 
only linearly proportional to pressure drop for a planar device indicates that tissue size is going 
to have a greater impact in microcapsules.  For either type of device the scaled pressure drop is 
inversely proportional to the effective permeability of the encapsulating material.  Thus the 
benefits that will be observed by incorporating a permeability enhancer such as the 70% (w/v) 
PFC emulsion which has 2.8 times the permeability of normal alginate is to decrease the pressure 
drop by approximately one third.  The spherical geometry should also be better for oxygen 
transport compared to planar device because the expressions for the pressure drop are quite 
similar except the microcapsule expression has a factor of three in the denominator.   
 The scaled pressure drop for capsules and planar diffusion devices was calculated for 
tissue sizes of 37.5 to 150-µm over a range of capsule or device surface PO2 for a device or 
capsule diameter of 500 µm (Figure 3-3) with the encapsulating material being normal alginate 
or 70% (w/v) PFC alginate.  The predicted pressure drop is always less for the microcapsules 
(Figure 3-3A,B) compared to the planar device (Figure 3-3C,D) at all oxygen levels and for the 
smaller tissue at the higher oxygen levels the pressure drop through the microcapsule is 
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negligible.  The curves for the planar device are much close together for the various tissue sizes 
compared to the microcapsules indicating that the aggregates have a greater effect in the 
microcapsules. 
 The scaled pressure drop for capsule and planar diffusion devices was calculations for a 
tissue sizes of 37.5 to 150-µm over a range of capsule or device sizes at a surface PO2 of 40 
mmHg (Figure 3-4).  The predictions for the microcapsule suggest that above a capsule diameter 
of 500 µm there will be a minimal effect of increasing the capsule diameter (Figure 3-4A,B).  
The degree of the pressure drop varies greatly with tissue size and the presence of PFC in the 
encapsulating material reduces the pressure drop.  The predictions for the planar device are that 
the pressure drop always increases with increasing device size there are less differences between 
different tissue sizes and the magnitude of the pressure drop is several order of magnitude higher 
in the planar device (Figure 3-4C,D).  The spherical geometry of the microcapsule is much more 
favorable to oxygen transport than the planar slab geometry of the planar diffusion chamber.   
In some of the scaling calculations for pressure drop through the encapsulating material 
the predictions are greater than one which is not actually feasible unless negative partial pressure 
of oxygen can be obtained.  The pressure drop being greater than one is a result of the fact that 
the oxygen levels within the tissue are low enough that the oxygen consumption rate is less than 
the value that we approximate by using the oxygen level at the tissue surface due to entrance into 
the first order regime of Michaelis-Menten kinetics where oxygen consumption is dependent on 
oxygen level and decreases with decreasing oxygen level. 
Although in this section very simple expressions were used to represent a very complex 
problem many very useful insights were gained.  The microcapsule is the more ideal geometry 
for oxygen delivery.  Aggregates have a greater impact in a microcapsule than in a planar 
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diffusion chamber.  Increasing device size is always detrimental but increasing microcapsule size 
is not.  Incorporation of a permeability enhancer is always going to decrease the pressure drop 
through the encapsulating material and the overall benefits of the permeability enhancer will 
depend on if you are within a regime where decreasing the pressure drop through the 
encapsulating material is going to impact viability or insulin secretion. 
 
  
3.3.2 Microcapsules 
Oxygen profiles were calculated for a centrally located 150-μm diameter islet with and 
without PFC emulsion in a 500-µm microcapsule at a capsule surface PO2 of 40 mmHg.  
Comparing the oxygen profiles for the capsules containing a single centrally located intact islet 
with (Figure 3-5B) and without PFC emulsion (Figure 3-5A), the oxygen level at the outer 
surface of the islet is higher when PFC emulsion is incorporated into the alginate phase of the 
microcapsule (PO2 = 25 versus 35 mmHg at r = Rtissue).  The oxygen gradient in the capsule 
subdomain is greater for a normal alginate capsule compared to a 70% (w/v) PFC alginate 
capsule.  The minimum oxygen level at the islet center is greater for an islet within PFC alginate 
(5.5 versus 0.15 mmHg at r=0).     
Oxygen profiles were also calculated for a 500-µm capsule containing many 50-μm 
diameter aggregates with a total tissue volume of 1.2, 4.6 or 9.5 islet equivalents at a capsule 
surface PO2 of 40 mmHg (Figure 3-6).  The aggregates were arranged in a cubic array that 
extended over the entire capsule diameter (model geometry A2).   Comparing the oxygen profile 
in a normal alginate capsule that contains an islet (Figure 3-5A) or aggregates (Figure 3-6A) of 
approximately the same total tissue volume, the minimum oxygen level that the tissue 
experiences in the microcapsule is significantly increased for the aggregates (Pmin = 30 mmHg) 
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compared to the islet where the minimum oxygen level is low enough to cause reduced function 
and almost low enough to cause tissue death (Pmin = 0.15 mmHg).  The oxygen gradients within 
the alginate subdomain are also greatly reduced for the a capsule with 1.2 islet equivalents of 
tissue.  The minimum oxygen level experienced by tissue in capsules containing aggregates that 
also contain PFC emulsion (Figure 3-6B) is even further increased (Pmin = 34 mmHg).  
Increasing the tissue loading for 50-µm aggregates in a 500-µm normal alginate capsule to 4.6 IE 
(Figure 3-6C) and then 9.5 IE (Figure 3-6E) results in increased gradients within the capsule and 
lower oxygen levels within the tissue at the center of the capsule (16 mmHg and <0.1 mmHg, 
respectively).  The same capsule loadings of 4.6 IE (Figure 3-6D) and 9.5 IE (Figure 3-6F) in 
PFC alginate have less oxygen gradients and higher oxygen levels are maintained for tissue at 
the center of the capsule (29 and 13 mmHg respectively).  The minimum oxygen levels 
experienced in the PFC containing capsules are similar to those in normal alginate at the tissue 
loading that is one step lower (Figure 3-6A and D are similar and Figure 3-6F and C are similar).  
The permeability enhancement of the PFC is beneficial because it reduces the oxygen gradients 
within the alginate subdomain allowing for a greater oxygen level at the tissue surface and thus 
greater oxygen delivery to the encapsulated tissue. 
Oxygen profiles were also calculated for a 1000-µm capsule containing many 50-μm 
diameter aggregates with a total tissue volume of 1.2 or 9.5 islet equivalents at a capsule surface 
PO2 of 40 mmHg (Figure 3-7).  The oxygen gradients within all four oxygen profiles are less in 
Figure 3-7 for 1000-µm capsules compared to the oxygen profiles in Figure 3-6 for the exact 
same total encapsulated tissue volume and encapsulating material.  In fact the tissue actually 
does better in the larger capsules because there is greater spacing between individual aggregates.    
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 Oxygen profiles were calculated for a variety of tissue sizes, tissue configurations, and 
capsule surface oxygen levels.  The oxygen profiles were then used to make predictions of 
fractional viability and fraction of normal insulin secretion.  The predictions allow one to assess 
the benefits of both methods of enhancing oxygen delivery to microencapsulated tissue: smaller 
islet cell aggregates and incorporating PFC emulsion into the microcapsule.   The first 
comparisons of tissue viability and insulin secretion were for a centrally located intact islet and 
one islet equivalent of tissue homogenously distributed throughout the entire capsule to 
approximate the case of encapsulated single cells (Figure 3-8).  The homogenous case represents 
the limit of the best case for uniform tissue distribution in a microcapsule; both tissue viability 
and insulin secretion are maintained in lower oxygen environments in capsules containing a 
homogenously distributed islet compared to intact islets.  Adding 70% (w/v) PFC emulsion to 
the capsules containing homogeneously distributed tissue has essentially no benefit.  Adding 
PFC emulsion to microcapsules containing an intact islet results in a modest improvement in the 
oxygen environments where islets maintain viability and insulin secretion.  For the rest of the 
calculations for microencapsulated tissue only the predictions for fraction of normal insulin 
secretion will be presented since oxygen effects on insulin secretion are seen at higher oxygen 
levels than reductions in tissue viability, but the predictions of fractional viability can be found in 
Section 6.4 of the Appendix. 
 The next comparison was to examine the effect of breaking up a 150-μm islet into 37.5, 
50, or 75-μm diameter aggregates and comparing microcapsules that all contain a total tissue 
volume equal to one islet equivalent (Figure 3-9).  The aggregate tissue for these calculations 
was arranged in a cube that fit entirely within the capsule (Model Geometry A3).   The 
predictions for normal insulin secretion show that the use of aggregates allows for the tissue to 
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secrete insulin normally in much lower external oxygen environments than an islet and are quite 
similar to the homogeneous case.  It is very beneficial to use smaller aggregates in order to have 
the tissue function in lower oxygen environments while keeping the total tissue volume within 
the capsule constant.  Decreasing the tissue diameter to at least half of an intact islet significantly 
improves tissue function in low oxygen environments.  
 The predictions for fraction of normal insulin secretion for homogeneously distributed 
tissue (total encapsulated tissue volume of 1 islet equivalent) and an intact islet (1 islet 
equivalent (IE)) were compared to 50-μm aggregates with a total capsule tissue loading of 1.2 or 
9.5 islet equivalents all in a 500-μm capsule (Figure 3-10A).  The tissue for these calculations 
and all subsequent calculations was arranged in a cube that was the same size as the capsule 
(model geometry A2).  This type of cubic arrangement was more desirable than model geometry 
A3 because it allowed for greater capsule tissue loadings but does result in numbers of islet 
equivalents that were not whole numbers.  For the case of 1.2 islet equivalents of aggregate 
tissue, function was maintained at lower oxygen than an intact islet and the effects of reduced 
oxygen were similar to those seen for single cells.  Increasing the capsule tissue loading to 9.5 
islet equivalents of aggregates, the predicted fraction of normal insulin secretion was similar to 
one intact islet over the range of oxygen levels examined.  Much higher capsule tissue loadings 
can be achieved for 50-µm aggregates with similar losses in function as an intact islet which 
could lead to a reduction in total transplant volume assuming the current effectiveness of intact 
islets is considered satisfactory. It is advantageous to reduce the total transplant volume as the 
large volume of microcapsules required to treat diabetic patients is a drawback for the use of 
microcapsules [87]. 
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 Predictions for fraction of normal insulin secretion were also made for microcapsules 
containing 50-μm aggregates with a total tissue volume of 1.2 or 9.5 islet equivalents with 70% 
(w/v) PFC emulsion incorporated into the alginate phase of the microcapsule (Figure 3-10B).  
Marginal improvements in insulin secretion were predicted for capsules containing 70% (w/v) 
PFC emulsion with an aggregate loading of 1.2 islet equivalents.  However, incorporating PFC 
into capsules at high tissue loadings (9.5 islet equivalents) offers a significant improvement in 
the ability for the tissue to function in lower oxygen environments.  Increased permeability of the 
alginate phase of the microcapsules is beneficial in improving insulin secretion of 50-µm 
aggregate containing capsules at high tissue loadings. 
 The minimum capsule surface PO2 at which all of the encapsulated tissue remained fully 
functional can be used to compare the oxygen effects for all microencapsulated tissue 
calculations that were performed for 500-µm capsules.  Calculations were performed at various 
capsule loadings for single cells; 37.5-µm, 50-µm, 75-µm, 100-µm, and 125-µm aggregates; and 
150-µm islets with (Figure 3-11B) and without PFC emulsion (Figure 3-11A).   The minimum 
surface PO2 for fully functional tissue is always the lowest in either capsule type for capsules that 
contain single cells at all capsule loadings studied.  As the size of the aggregate increases, the 
minimum surface PO2 for fully functional tissue increases at a specified capsule tissue loading.  
For any size tissue in normal alginate the minimum surface PO2 increases as the capsule tissue 
loading increases.  The results for capsules that contain 70% (w/v) PFC emulsion in the alginate 
phase (Figure 3-11B) are shifted down slightly compared to the results for the same tissue size in 
normal alginate in Figure 3-11A.  The increase in minimum surface PO2 for fully functional 
tissue, as tissue loadings increase, is not as steep for the capsules that contain PFC as compared 
to those without.  In both types of capsules the smaller aggregates (37.5 and 50-µm) come 
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closest to the theoretical homogenous limit represented by the single cells, 75-µm aggregates are 
quite beneficial in maintaining tissue function in low oxygen environments compared to normal 
intact islets, and even aggregates of 100 and 125-µm aggregates provide some assistance in 
reducing oxygen limitations compared to the predictions for a 150-µm islet. 
 Predictions for fraction of normal insulin secretion for a centrally located islet in different 
size microcapsules (250, 500, 1000 and 2000-µm) were made in order to determine the effects 
that decreasing or increasing the capsule size has on oxygen transport (Figure 3-12).  Increasing 
the capsule size above 500-µm had small effects in normal alginate capsules and nearly no effect 
in PFC alginate capsules.  Decreasing the capsule size in normal alginate capsules had almost the 
same benefit as incorporating a PFC emulsion into a 500-µm microcapsule.  There was a slight 
benefit of decreasing the size of a PFC containing microcapsule.  All of these predictions are in 
keeping with the analysis of scaled pressure drop in section 3.3.1; there would be some benefit in 
lowering the capsule size below 500-µm but there would be nearly no effect of increasing the 
capsule size above 500-µm. 
 The effects of increasing the capsule size from 500-µm to 1000-µm for 50-µm aggregates 
in alginate capsules and a total tissue loading of 1.2 or 9.5 IE (Figure 3-13A) were assessed by 
calculating the fraction of normal insulin secretion for capsules with a specified capsule surface 
PO2 of 0-40mmHg.  The same amount of total encapsulated tissue can maintain normal levels of 
insulin secretion in lower oxygen environments in the larger capsule, due to the increased 
spacing between aggregates.  1.2 IE in a 500-µm capsule and 9.5 IE in a 1000-µm capsule have 
the same tissue density in the capsule on a volumetric basis.  The tissue at the same density does 
better in the smaller capsule since oxygen has to travel a shorter distance and through less tissue 
to reach the aggregates located at the center of the capsule.  Predictions of fraction of normal 
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insulin secretion were also made for 500 and 1000-µm capsules containing 50-µm aggregates in 
which PFC emulsion was incorporated into the alginate phase of the microcapsule (Figure 
3-13B).   For all three tissue configurations presented, the incorporation of PFC into the alginate 
microcapsule is beneficial to promoting tissue function in lower oxygen environments.  The 
predicted fraction of normal insulin secretion was identical for 1.2 IE in 500-µm normal alginate 
(solid red curve) and 9.5 IE in 1000-µm (dashed blue curve).  These two cases have the same 
tissue density and the negative effects that are observed for increasing the capsule size while the 
spacing between the aggregates is kept constant is negated by the incorporation of a permeability 
enhancer into the alginate phase of the microcapsule.      
 In summary we have calculated oxygen profiles in microcapsules containing 
homogeneously distributed tissue, aggregates, and islets.  The oxygen profiles are then used to 
predict tissue fractional viability and fraction of normal insulin secretion.  The model predictions 
demonstrate that using smaller aggregates as opposed to intact islets greatly improves the ability 
of encapsulated tissue to function in lower oxygen environments.  Incorporating a PFC emulsion 
into the microcapsule, to increase the material’s permeability to oxygen, allows for intact islets to 
function in lower oxygen environments and is most beneficial to capsules containing aggregates 
at high tissue loadings. 
 
3.3.3 Planar Device 
 
Oxygen profiles and predictions of fractional viability and fraction of normal insulin 
secretion were made for single cells, aggregates, and islets in planar devices.  For most 
calculations device thickness was 500-µm.  These calculations were performed because we also 
wanted to investigate the effectiveness of both methods, the use of aggregates and incorporation 
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of a PFC emulsion into an immunoisolating device, to enhance oxygen transport to encapsulated 
islets in the other commonly used immunoisolation system – an extravascular planar device.  It is 
important to assess that the benefits of each method to enhance oxygen transport that were 
observed in microcapsules also translate to different geometries, and to assess under what 
circumstances in a planar diffusion chamber each type of oxygen enhancement strategy is the 
most beneficial.  A planar device is typically implanted in a location (such as the subcutaneous 
space) in which the exterior of the device will be in close contact with the vasculature.  There are 
even some planar diffusion chambers that have been developed in which the external membrane 
of the device becomes vascularized [48].  The close proximity to the vasculature results in a 
partial pressure of oxygen at the device surface similar to that of venous blood as long as no 
foreign body reaction occurs.  The first set of calculations performed assumed that the device 
surface PO2 was 40 mmHg, the oxygen level in venous blood.   
Oxygen profiles were calculated for a range of tissue sizes – 37.5, 50, 75, 100 and 
125-µm aggregates and 150-µm islets in one centrally located monolayer of tissue with a device 
surface oxygen level of 40 mmHg at either a tissue surface density of 500 (Figure 3-14) or 2000 
IE per cm2 (Figure 3-15).  At 500 IE per cm2 the portion of the tissue that is blue and is thus 
severely oxygen limited increases with increasing tissue size in normal alginate devices (Figure 
3-14A) and PFC alginate devices (Figure 3-14B).  The oxygen gradient within the alginate 
subdomain is greater in the normal alginate devices showing that PFC alginate is an effective 
permeability enhancer in a planar device by reducing oxygen gradients within the encapsulating 
material.  At 2000 IE per cm2 (Figure 3-15A) for the smallest tissue presented, 75-µm 
aggregates, in normal alginate it is observed that because the tissue spheres are so close together 
the oxygen profile begins to approximate that of a slab.  Even though the overall tissue densities 
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are the same, the fractional surface coverage is higher (0.7) for the 75-µm aggregates compared 
to the fractional surface coverage of a 150-µm islet (0.35) and thus neighboring tissue spheres 
have a greater influence over each others oxygen profile.  At this higher tissue surface density 
the oxygen gradients outside the tissue are significant with and without PFC present but they are 
reduced in the presence of PFC alginate.  The minimum oxygen level experienced by the tissue 
is always lower in normal alginate devices. Observing these oxygen profiles it becomes apparent 
that there are different length scales that are important in different regimes – the tissue diameter, 
spacing between capsules and the distance the tissue is from the capsule surface. 
The predictions of fractional viability and fraction of normal insulin secretion as a 
function of tissue surface density in islet equivalents per centimeter squared, center to center 
tissue spacing, and fractional surface coverage for a range of tissue sizes – 37.5, 50, 75, 100 and 
125-µm aggregates and 150-µm islets in one centrally located monolayer of tissue with a device 
surface oxygen level of 40 mmHg are shown in Figure 3-16.  The maximum tissue surface 
density that can be achieved depends on the tissue diameter.  The maximum tissue surface 
density is lower for 50-µm aggregates (1400 IE/cm2) in a cubic array where the spheres are 
touching compared to 4400 IE/cm2 for 150-µm islets.  37.5 and 50-µm aggregates are fully 
viable and functional at all tissue loadings achievable with a monolayer of tissue.  Tissue with a 
diameter of 150-µm arranged in a monolayer is not fully functional even at very low densities 
but it is fully viable.  The predicted fractional viability is always better for the smaller aggregates 
at any loading density.   As the tissue diameter decreases from 125 to 100 to 75-µm the tissue 
remains fully functional up to a surface density of 500, 1000, and 1200 IE/cm2 respectively.  
However, with decreasing tissue diameter, at the surface density where oxygen limitations begin 
to effect insulin secretion the decrease in function is steeper with increased tissue loading.   The 
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steeper decrease in predicted fraction of normal insulin secretion is because the smaller the tissue 
is, the closer the tissue spheres are together and thus they have more interaction and greater 
decreases in the oxygen profile.  Aggregates arranged in a monolayer within a planar diffusion 
chamber are able to maintain function at higher tissue surface densities than a 150-µm islet, but 
the predictions show that one should be cautious to not enter the regime where oxygen 
limitations do occur for the smaller aggregates as the aggregates could secrete insulin less 
effectively than an intact islet.  Instead of plotting the predictions of fractional viability and 
fraction of normal insulin secretion versus tissue density in IE/cm2 the results were plotted as a 
function of the center to center spacing in number of tissue diameters (Figure 3-16C,D) and 
fractional surface coverage (Figure 3-16E,F).  The results plotted in this fashion demonstrate that 
the smaller the tissue diameter is the closer the tissue spheres can be brought to each other before 
there are detrimental effects on viability and insulin secretion (Figure 3-16C,D).  Additionally 
the smaller tissue can cover a greater fraction of the device surface before there is loss of 
viability or function (Figure 3-16E,F). 
Figure 3-17 is a plot of the predicted fraction of normal insulin secretion versus the 
device tissue surface density in islet equivalents per square centimeter for 50-µm aggregates, 
75-µm aggregates, or 150-µm islets in a planar device of alginate with or without 70% (w/v) 
PFC emulsion at a device surface PO2 of 40 mmHg.  The calculations were performed for three to 
ten layers of 50-µm aggregates, 1,3-6 layers of 75-µm aggregates, and 1 or 3 layers of 150-µm 
islets arranged in a body centered cubic array.  Devices made from normal alginate maintained 
100% insulin secretion for tissue densities up to 2,500-3,000 IE/cm2 for 50-µm or 75-µm 
aggregates (3-6 layers) depending on the number of tissue layers within the device.  Full insulin 
secretion capacity is maintained in PFC alginate devices that contain 50-µm or 75-µm aggregates 
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at surface densities up to 6,000 IE/cm2.  At a particular tissue surface density the results are quite 
similar for all numbers of tissue layers for 50-µm aggregates in normal alginate devices as all the 
results fall within one serpentine band.  The reason that the serpentine behavior is observed is 
that the aggregates are discrete entities throughout the device thickness and the undulations occur 
as an additional aggregate is effected by experiencing reduced insulin secretion.  For the 
maximum number of layers that can be observed for 50-µm aggregates the serpentine behavior is 
not observed as the tissue layers are close enough together that they behave as a continuous 
phase.  The results for different numbers of layers are indistinguishable from each other for 
devices that contain 50 or 75-µm aggregates in 70% (w/v) PFC emulsion.  At a device surface 
PO2 of 40 mmHg it is very beneficial to incorporate PFC emulsion into the alginate phase of a 
device that contains 50 or 75-µm aggregates in order to maintain tissue function at higher tissue 
densities.  Although the tissue surface densities at which function is lost are similar for 75-µm 
aggregates there appears to be a transition in the normal alginate devices that above this level the 
results are not the same for the different number of layers.  The serpentine behavior is not 
observed most likely because the oxygen transport within the aggregate has become more 
limiting.  The predictions of fraction of normal insulin secretion are quite different for an islet 
containing planar device than they are for the aggregates (Figure 3-17C).  There is a larger 
difference between having 1 and 3 layers of tissue within the device and there are still large 
differences in the number of layers when PFC emulsion is used.  The incorporation of PFC 
emulsion into a planar device with any size tissue or number of layers is very beneficial in order 
to improve tissue function at higher loading densities. 
Prediction of fractional viability and fraction of normal insulin secretion were made for 
the homogeneously distributed tissue in a planar device with increasing tissue loading and 
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compared to the predicted results for 13 layers of 37.5-µm aggregates and 3 layers of 150-µm 
islets (Figure 3-18).  For predictions of fractional viability and insulin secretion there are 
conditions under which the homogeneously distributed tissue does worse than either 37.5-µm 
aggregates or islets in either normal alginate or PFC alginate planar devices.  This indicates that 
Maxwell’s Equation and the homogenous assumption are not an accurate approximation to 
model single cells at high tissue loadings especially in the presence of PFC alginate.  The 
inaccuracies are greater in the PFC containing devices because there is a greater difference 
between the permeability of PFC alginate and tissue compared to normal alginate and tissue.  
When the tissue is modeled as discrete elements within PFC alginate a greater permeability 
enhancement can be obtained and increasing the tissue density does not decrease the effective 
permeability of the alginate phase.       
The predictions of fraction of normal insulin secretion as a function of device tissue 
surface density for an external device oxygen level of 40 mmHg over a range of tissue sizes and 
for a device with and without PFC that containing the maximum number of layers that would fit 
within in a 500-µm thick device are shown in Figure 3-19.  This corresponds to 13, 10, 6, 5, 4, 
and 3 layers of tissue for 37.5, 50, 75, 100, 125 and 150-µm diameter tissue respectively.  It is 
predicted that the smallest aggregate sizes (37.5 and 50-µm) behave nearly identical when the 
tissue surface density is increased.  As the tissue diameter increases above 50-µm the tissue 
begins to have slightly worse function at similar tissue densities.  The tissue is no longer fully 
functional at loadings of 2000, 1500, and 750 IE/cm2 for 75, 100, and 125-µm aggregates 
respectively compared to being fully functional at up to 2500 IE/cm2 for 37.5 and 50-µm 
aggregates.  As the tissue surface density gets higher, above 4000 IE/cm2, the results for all 
tissue sizes become quite similar in normal alginate devices.  There is a shift of all curves for all 
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tissue sizes for devices that contain 70% (w/v) PFC emulsion such that the incorporation of PFC 
into the device allows for function at much higher tissue densities. 
Following the analysis of oxygen effects on tissue function at different surface densities 
at a given device surface oxygen level of 40 mmHg, the effects of lowering the device surface 
oxygen level below 40 mmHg were examined.  Theses calculations were performed for a tissue 
surface density of 150, 1000, 2000, and 7272  IE/cm2 for all tissue sizes (37.5, 50, 75, 100, 
125-µm aggregates and 150-µm islets) using the maximum number of tissue layers for each 
tissue size as used for the predictions in Figure 3-19.  Plots of the predictions of insulin secretion 
as a function of device surface PO2 for all tissue sizes are shown in Figure 3-20.  At the lowest 
device loading (150 IE/cm2 Figure 3-20A) the use of smaller aggregates had the largest effect on 
improving insulin secretion in low oxygen environments.  As the tissue density increased to 1000 
and 2000 IE/cm2 (Figure 3-20B,C) there were still benefits of using smaller aggregates but they 
were not as great.  At the very high tissue density of 7272 IE/cm2 (Figure 3-20D) there were 
nearly no benefits of using aggregates as the predictions of fractional viability were low even at 
40 mmHg and there were nearly no differences in the predictions for different tissue sizes.  
Aggregates can be beneficial to increasing tissue function in low oxygen environments, but 
within normal alginate devices they have the greatest impact at low tissue densities. 
The same calculations as shown in Figure 3-20 were repeated with the addition of PFC 
emulsion into the alginate phase of the device.  The predictions of insulin secretion for select 
tissue sizes (37.5, 75, and 150-µm) with and without PFC are shown in Figure 3-21 as a function 
of device surface PO2 for device with a tissue surface density of 150, 1000, 2000, and 
7272 IE/cm2.  At all tissue densities there are similar benefits to incorporating PFC emulsion into 
planar devices that contain 150-µm islets.  It is predicted for the smaller tissue sizes (37.5 and 
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75-µm) there are always benefits to adding PFC emulsion to the device in order to maintain 
function in low oxygen environments.  As the loading density increases for 37.5 or 75-µm 
aggregates the curves for predicted levels of insulin secretion shift to the right indicating the 
function is not maintained in as low of oxygen environments.  PFC emulsion has the biggest 
impact in improving insulin secretion at low oxygen at the intermediately high tissue density of 
2000 IE/cm2 by shifting the curves to the greatest extent.   PFC has the biggest impact at 
intermediate loadings where the tissue is relatively close together such that reduction in external 
gradients is very beneficial but when the gradients are too severe, there is only so much that a 
permeability enhancer can do. 
Up until this point only a planar device that has a thickness of 500-µm has been 
examined, it also desirable to see what effects decreasing and increasing the device thickness can 
have on predictions of fraction of normal insulin secretion.  Predictions for fraction of normal 
insulin secretion were made for 50-µm aggregates in a 250, 500, and 1000-µm device consisting 
of 5, 10 and 20 layers of tissue respectively (Figure 3-22).   Predictions for fraction of normal 
insulin secretion were made for the three different device sizes as a function of increasing tissue 
density at a device surface PO2 of 40 mmHg (Figure 3-22A) or over a range of device surface PO2 
at a tissue surface density of 1000 IE/cm2 (Figure 3-22B).  The smaller the device thickness the 
higher the tissue density that can be achieved before tissue function begins to be lost and there 
are always benefits to incorporating PFC emulsion into the device.  Similarly the thinner device 
is able to maintain tissue function in lower oxygen environments than the larger device when 
normal alginate is the encapsulating material.  There are benefits to incorporation of a PFC 
emulsion into the planar device for all thicknesses but it has the largest impact for the 1000-µm 
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device.  It is always detrimental to increase the device thickness of a planar device but PFC 
emulsion can help to improve oxygen transport when the use of thicker device is necessary. 
3.3.4 Comparison of Microcapsules and Planar Devices 
Thus far the analysis has focused on microcapsules and planar devices individually and it 
has been demonstrated that aggregates and PFC emulsion are beneficial in promoting tissue 
survival and function at higher densities and in lower oxygen environments.  It also desirable to 
compare the results for microcapsules and planar devices at similar tissue loadings in order to 
assess under what situations aggregates and increased encapsulating material permeability are 
going to have the biggest impact on improving tissue function.  Predictions of fraction of normal 
insulin secretion were made for one centrally located 150-µm islet in a 500-µm microcapsule and 
1.2 and 9.5 IE of 50-µm aggregates which corresponds to a tissue volume fraction (φt) in the 
device of 0.03, 0.03, and 0.3 respectively (Figure 3-23A).  Similar calculations were also 
performed for 150-µm islets arranged in 3 layers and 50-µm aggregates arranged in 10 layers in 
a 500-µm thick planar device (Figure 3-23B) at a tissue loading of 764 IE/cm2 which 
corresponds to a tissue volume fraction of 0.03.  Additionally calculations were performed with 
10 layers of 50-µm aggregates at a loading of 2000 and 7272 IE/cm2 which corresponds to a 
tissue volume fraction of 0.07 and 0.3 respectively.  The predictions for the fraction of normal 
insulin secretion for the islet cases are very similar in Figure 3-23A and B.  Aggregates at a 
tissue volume fraction of 0.03 or 0.3 in normal alginate do better in a microcapsule and the 
predictions for fraction of normal insulin secretion are much lower in a planar device at tissue 
volume fraction of 0.3 than the islet predictions compared to being quite similar in a 
microcapsule.  The planar device does not allow for the achievement of such high tissue loadings 
through the use of aggregates.  Predicted fraction of normal insulin secretion for the aggregate 
 89
cases with PFC incorporated into the encapsulating material are shown in Figure 3-23C and D 
respectively.  PFC is always beneficial to improving aggregate function, but the benefits at the a 
tissue volume fraction of 0.3 are greatest in a microcapsule.  The greatest benefit of PFC for the 
planar device is at an intermediate tissue volume fraction of 0.07. 
3.4  DISCUSSION 
This chapter has studied the effects of oxygen diffusion limitations to immunoisolated 
islets and the benefits that two methods: (1) incorporation of a perfluorocarbon emulsion into an 
immunoisolation device to enhance encapsulation material permeability to oxygen and (2) use of 
aggregates that have a smaller tissue diameter than an intact islet have on eliminating oxygen 
diffusion limitations.  Severe oxygen limitations can occur for islets encapsulated in 
microcapsules and planar diffusion chambers.  The use of either strategy to enhance oxygen 
transport, a perfluorocarbon emulsion or smaller aggregates, has beneficial effects in either type 
of device geometry, but there are certain configurations or conditions in which one oxygen 
enhancing strategy is the most beneficial.   
Following the transplantation of microcapsules into the peritoneal cavity many of the 
capsules are likely to experience surface oxygen levels below that of the vasculature due to the 
likelihood of capsules being located large distances away from the vasculature.  Islets within the 
microcapsule will likely experience oxygen levels low enough to result in tissue death and loss 
of insulin secretion capabilities.  When single cells (the homogenous case) are encapsulated in 
microcapsules the cells are able to maintain function and viability in much lower oxygen 
environments than intact 150-µm islets.  The use of smaller islet cell aggregates (37.5-75 µm) 
with one islet equivalent of total encapsulated tissue volume are predicted to maintain tissue 
function in lower oxygen environments than an intact 150-µm islet and are quite similar to those 
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for the homogenous single cell case.  If the oxygen effects on insulin secretion are considered to 
be satisfactory for an intact 150-µm islet then one is able to obtain similar results with aggregates 
at much higher capsule loadings.  The incorporation of 70% (w/v) PFC emulsion into alginate 
microcapsules has modest effects on enhancing 150-µm islet survival and function over a range 
of oxygen levels.  The benefits of incorporating a permeability enhancer for single cells or 
aggregates (37.5-75 µm) at tissue loadings around 1 IE are negligible in order to better maintain 
tissue function in lower oxygen environments.  It is beneficial to incorporate a permeability 
enhancer into aggregate containing capsules at high capsule loadings (6-10 islet equivalents) in 
order to have tissue function in lower oxygen environments.   
Calculations have been performed for 37.5, 50, 75, 100, and 125-µm aggregates and 
150-µm islets in a planar device for various numbers of layers at a device surface PO2 of 
40 mmHg over a range of surface densities and for a tissue surface density of 150, 1000, 2000 
and 7272 IE/cm2 at a device surface PO2 of 0-40 mmHg.   The number of layers of tissue did not 
greatly affect the predicted tissue function for smaller tissue sizes at a given surface density.  The 
smaller an aggregates is, the higher the surface density that can be achieved in which the tissue 
will remain fully functional.  In all results shown, the addition of a permeability enhancer was 
very beneficial to maintaining function either at higher surface densities or in lower oxygen 
environments especially at intermediate loading densities.   
The use of smaller islet cell aggregates and a permeability enhancer in the encapsulation 
matrix have both been shown to be beneficial in reducing oxygen limitations to immunoisolated 
islets in microcapsules and planar diffusion chambers based on theoretical calculations.  The 
effects of the two methods on enhancing oxygen transport are greatest when used in 
combination. For microcapsules this is at high density, for example 9.5IE of 50-µm aggregates 
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microencapsulated in PFC alginate.   For planar diffusion chambers this is a medium density 
where 50-µm aggregates are using in a planar device containing PFC alginate at 2000 IE/cm2.   
In the calculations that were performed, aggregates were most beneficial for eliminating oxygen 
transport limitations and maintaining encapsulated tissue viability and function in the 
microcapsule geometry.  When the device surface PO2 was 40 mmHg in a planar diffusion 
chamber twice the amount of tissue could be kept fully functional when 70% (w/v) 
perfluorocarbon is incorporated into the alginate matrix.   When direct comparisons were made 
between microcapsules and planar diffusion chambers it was seen that the highest tissue densities 
could be achieved in microcapsules as they are a more ideal geometry for oxygen transport.  
However, this conclusion could be slightly misleading because the microcapsules were modeled 
individually and thus the potential effects of capsules stacking on top of each other during 
transplantation were not taken into account.  Capsule stacking is likely to occur as large number 
of capsules would be transplanted into the peritoneal cavity, ~500,000 for human islet 
transplantation diabetes using current transplant doses and assuming 1 islet per capsule. Capsule 
stacking may actually make microcapsules less favorable under the transplant setting compared 
to a planar device where likely only one or a handful devices would be transplanted and 
interactions between devices would not be important. 
It is critical that the necessary amount of oxygen be delivered to immunoisolated tissue 
after transplantation in order to maintain normal levels of insulin secretion.  Without a solution 
that allows for effective oxygen delivery transplantation of immunoisolated tissue will never be 
successful as the tissue will not be capable of effectively delivering its protein of interest.  Based 
on theoretical predictions it seems that both strategies hold the potential to improve oxygen 
delivery to immunoisolated tissue and improve the success rate of cell therapies with 
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immunoisolation devices.  Both methods – incorporation of PFC emulsion and the use of islet 
cell aggregates should be further evaluated experimentally for their ability to enhance 
encapsulated tissue survival and function both in vitro and in vivo. 
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Figure 3-1: Sketches of example model geometries studied. 
 (A) for microcapsules and (B) for planar devices.  In both A and B the geometries are sketched 
for an islet, many aggregates or islets, or for single cells. The dashed lines represent the unit cell 
that was analyzed for each geometry. 
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Figure 3-2: Predictions of the Damkohler number for different size tissue with a given PO2 at the 
tissue surface. 
(A) predictions of the Damkohler number plotted on a semilog plot and (B) prediction of the 
Damkohler number plotted on a linear plot.  The solid grey curve cutting across the family of 
curves represents the maximum value of the Damkolher number where all levels of PO2 are 
greater than Pc (0.1 mmHg) at all positions within the tissue. The dashed grey curve represents 
the cutoff for the Damkohler number above which all tissue is not fully functional. 
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Figure 3-3: The scaled pressure drop within a capsule (A&B) or a planar device (C&D) to 
centrally located tissue was estimated for a range of surface PO2. 
A&C are the predictions for tissue in normal alginate, B&D are the predictions for tissue in PFC 
alginate.  The predictions were made for tissue that has a diameter of 37.5, 50, 75, 100, 125, and 
150-µm in a capsule or planar device of 500-µm.   
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Figure 3-4: The sclaed pressure drop within a capsule (A&B) or a planar device (C&D) to 
centrally located tissue was estimated for a range capsule and device sizes. 
A&C are the predictions for tissue in normal alginate, B&D are the predictions for tissue in PFC 
alginate.  The predictions were made for tissue that has a diameter of 37.5, 50, 75, 100, 125, and 
150-µm at a capsule or device surface PO2 of 40 mmHg.   
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Figure 3-5: Plot of predicted oxygen profiles for a centrally located 150-μm diameter islet in 
500-μm diameter microcapsules with a capsule surface PO2 equal to 40 mmHg.   
(A) 150-µm islet in normal alginate (B) 150-µm islet in 70% (w/v) PFC alginate.  Contours are 
drawn at 1-40 mmHg at 1 mmHg increments and at 0.1 mmHg. 
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Figure 3-6: Plot of predicted oxygen profiles for 50-μm aggregates in 500-μm diameter 
microcapsules with a capsule surface PO2 equal to 40 mmHg.   
 99
(A) 1.2 IE in normal alginate (B) 1.2 IE in 70% (w/v) PFC alginate (C) 4.6 IE in normal alginate 
(D) 4.6 IE in 70% (w/v) PFC alginate (E) 9.5 IE in normal alginate (F) 9.5 IE in 70% (w/v) PFC 
alginate.  IE (islet equivalents) is a volume of tissue equal to that of a 150-μm sphere.  Contours 
are drawn at 1-40 mmHg at 1 mmHg increments and at 0.1 mmHg. 
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Figure 3-7: Plot of predicted oxygen profiles for 50-μm aggregates in 1000-μm diameter 
microcapsules with a capsule surface PO2 equal to 40 mmHg.   
(A) 1.2 IE in normal alginate (B) 1.2 IE in 70% (w/v) PFC alginate (C) 9.5 IE in normal alginate 
(D) 9.5 IE in 70% (w/v) PFC alginate.  IE (islet equivalents) is a volume of tissue equal to that of 
a 150-μm sphere.  Contours are drawn at 1-40 mmHg at 1 mmHg increments and at 0.1 mmHg. 
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Figure 3-8: The predicted fractional viability (A) and insulin secretion (B) for an encapsulated 
islet or homogenously distributed tissue (H) in a 500-µm capsule. 
Total encapsulated volume is one islet equivalent with and without 70% (w/v) PFC emulsion.  
The homogenous case is meant to be an approximation of the case for single cells distributed 
throughout the entire capsule. 
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Figure 3-9: Predicted fraction of normal insulin secretion as a function of capsule surface PO2 for 
a 500-μm capsule that contains one islet equivalent - homogeneously distributed throughout the 
capsule (H), as 64 37.5-μm aggregates , 27 50-μm aggregates, 8 75-μm aggregates, or 1 150-μm 
islet. 
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Figure 3-10: Predicted fraction of normal insulin secretion for single cells (H), an islet, and 
50-μm aggregates at various loadings in a 500-µm capsule.  
(A) Alginate capsules (B) 50-μm aggregates at various loadings in a capsule containing 70% 
(w/v) PFC emulsion. IE = islet equivalent 
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Figure 3-11: Predictions of the minimum capsule surface oxygen level that results in all 
encapsulated tissue being fully functional for a 500-µm capsule.   
(A) Results for a variety of tissue sizes and capsule loadings for normal alginate capsules (B) 
results for a variety of tissue sizes and capsule loadings for 70% (w/v) PFC alginate capsules. 
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Figure 3-12: Predictions of fraction of normal insulin secretion for one centrally located islet in a 
250, 500, 1000, or 2000-µm capsule with (dashed lines) and without (solid lines) 70% (w/v) PFC 
emulsion. 
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Figure 3-13: Predictions of fraction of normal insulin secretion for 50-µm aggregates in either a 
500-µm or 1000-µm diameter capsule.   
(A) Normal alginate capsule (B) normal alginate (solid curves) and 70% (w/v) PFC alginate 
(dashed curves). 
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Figure 3-14:  Predicted oxygen profiles in 500-μm planar devices with tissue of different sizes 
(37.5, 50, 75, 100, 125, 150 µm) arranged in a monolayer at the center of the device.   
The tissue surface density is 500 IE per cm2, the device surface PO2 is 40 mmHg (A) normal 
alginate device and (B) 70% (w/v) PFC alginate device.  Contours are drawn at 1-40 mmHg at 1 
mmHg increments and at 0.1 mmHg. 
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Figure 3-15:  Predicted oxygen profiles in 500-μm planar devices with tissue of different sizes 
(75, 100, 125, 150 µm) arranged in a monolayer at the center of the device.   
The tissue surface density is 2000 IE per cm2, the device surface PO2 is 40 mmHg (A) normal 
alginate device and (B) 70% (w/v) PFC alginate device.  Contours are drawn at 1-40 mmHg at 1 
mmHg increments and at 0.1 mmHg. 
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Figure 3-16: Predictions of fractional viability (A,C,E) and fraction of normal insulin secretion 
(B,D,F) for tissue arrange in a monolayer in the central plane of a 500-μm device at varying 
densities. 
Device surface oxygen level equals 40 mmHg.  Encapsulation material is normal alginate. (A,B) 
device loading measured in IE/cm2 (C,D) device loading measured in center to center tissue 
spacing in number of tissue diameters (E,F) device loading measured by fractional surface 
coverage. 
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Figure 3-17: Predictions of the fraction of normal insulin secretion for 50-µm aggregates, 75-µm 
aggregates, and 150-µm islets in a 500-μm planar device.   
The device surface oxygen level is 40 mmHg and the tissue within the device is arranged in 
multiple layers. (A) 50-µm aggregates in 3-10 layers  (B) 75-µm aggregates in 1,3-6 layers (C) 
150-µm islets in 1 and 3 layers The solid lines are for the predictions in normal alginate devices 
and the dashed lines are the predictions for 70% (w/v) PFC alginate devices.
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Figure 3-18: Predictions of fractional viability (A) and fraction of normal insulin secretion (B) 
for homogenously distributed tissue (H), 13 layers of 37.5-µm aggregates, and 3 layers of 
150-µm islets in a 500-µm device made of normal alginate (solid curves) and 70% (w/v) PFC 
alginate (dashed curves) with a device surface PO2 of 40 mmHg. 
 113
 
 
Figure 3-19: Fraction of normal insulin secretion as a function of tissue surface density for tissue 
of a variety of sizes with tissue arranged in multiple layers throughout the device thickness. 
The number of which being the maximum number that will fit for a particular size - 37.5-µm 13 
layers, 50-µm 10 layers, 75-µm 6 layers, 100-µm 5 layers, 125-µm 4 layers, and 150-µm 3 
layers.  Device surface PO2 equals 40 mmHg and device thickness equals 500-µm.  The solid 
lines are the predictions for normal alginate the dashed lines are the predictions for 70% (w/v) 
PFC alginate. 
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Figure 3-20: Predictions of fraction of normal insulin secretion over a range of device surface 
PO2 for tissue of a variety of sizes arranged in multiple layers within a planar diffusion chamber. 
The number of layers used is the maximum that would fit for a particular tissue size – 
37.5-µm 13 layers, 50-µm 10 layers, 75-µm 6 layers, 100-µm 5 layers, 125-µm 4 layers, and 
150-µm 3 layers.   The device is 500-µm thick and made of normal alginate. The tissue device 
surface density was equal to (A) 150 IE/cm2, (B) 1000 IE/cm2, (C) 2000 IE/cm2, and (D) 7272 
IE/cm2.   
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Figure 3-21: Predictions of fraction of normal insulin secretion over a range of device surface 
PO2 for tissue of a variety of sizes arranged in multiple layers within a planar diffusion chamber. 
The number of layers used is the maximum that would fit for a particular tissue size – 
37.5-µm 13 layers, 75-µm 6 layers, and 150-µm 3 layers.   The device is 500-µm thick and made 
of normal alginate (solid curves) and 70% (w/v) PFC alginate (dashed curves). The tissue device 
surface density was equal to (A) 150 IE/cm2, (B) 1000 IE/cm2, (C) 2000 IE/cm2, and (D) 7272 
IE/cm2.  
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Figure 3-22:  Effects of increasing device thickness on predictions of fraction of normal insulin 
secretion for 50-µm aggregates arranged in multiple layers. 
250-µm device 5 layers, 500-µm device 10 layers, and 1000-µm device 20 layers made from 
normal alginate (solid curves) or 70% (w/v) PFC alginate (dashed curves).  (A) The effects of 
varying surface density for a device surface PO2 of 40mmHg were investigates and (B) the effects 
of reducing the device surface PO2 at a tissue loading of 1000 IE/cm2.  
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Figure 3-23: Comparison of the predictions of fraction of normal insulin secretion for 500-µm  
microcapsules (A,C) and 500-µm planar devices (B,D) that have similar loading of 50-µm 
aggregates and 150-µm based on the encapsulated tissue volume fraction (φt). 
Comparisons between predictions in A & B examine the benefits of using aggregates in 
microcapsules and planar devices.  Comparisons between predictions in C & D examine the 
benefits of using 70% (w/v) PFC emulsion (dashed lines) compared to normal alginate (solid 
lines) at different loadings in both types of encapsulation devices.  
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Table 3-1:  Oxygen transport properties of materials in system 
 
  D (cm^2/s) 
α  
(mol/mmHg/ml) 
αD  
(mol/cm/mmHg/s) Source 
H20 2.78x10-5 1.27x10-9 3.53x10-14 [23] 
PFC 5.61x10-5 2.54x10-8 1.42x10-12 [76] 
Soybean  
Oil 2.13x10
-5 6.84x10-9 1.46x10-13 [77, 78] 
Tissue 1.24x10-5 1.00x10-9 1.24x10-14 [23] 
Alginate 0 0 0 [23] 
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Table 3-2: Effective permeability of oxygen calculated using Maxwell's relationship. 
All capsules are composed of 2 vol% Alginate. 
 
  
αD  
(mol/cm/mmHg/s)
70%  (w/v) PFC Emulsion 9.92x10-14 
70% (w/v) PFC Alginate 9.63x10-14 
Dispersed Cells 70% (w/v) PFC Alginate 9.31x10-14 
Pure Alginate 3.43x10-14 
Dispersed Cells Pure Alginate 3.35x10-14 
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Table 3-3:  Other Model parameters 
 
 Parameter Symbol Value Units Source
Maximum  oxygen consumption rate Vmax 4x10-8 mol/cm3/s [23] 
Michaelis-Menten Constant Km 0.44 mmHg [23] 
Insulin Secretion Model Parameter P* 5.1 mmHg [93] 
Critical PO2 for cell death Pc 0.1 mmHg [23] 
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Chapter 4 Encapsulated islet cell aggregates are superior to intact islets in 
terms of in vitro survival and function in low oxygen and ability to reverse 
diabetes in rodents 
 
 
This chapter was written in collaboration with Esther O’Sullivan from Joslin Diabetes Center.  
The experiments were performed together using tissue from the same isolations.  Due to the 
number of assessment methods that were performed on the tissue this effort was divided between 
the two of us.  I performed the modeling portions of the work and the OCR and nuclei 
measurements.  Esther performed the Insulin to DNA measurements, glucose stimulated insulin 
secretion measurements, and the transplantation experiments. 
 
4.1 INTRODUCTION 
Microencapsulation has been shown to effectively confer immunoprotection on 
transplanted islets, thereby potentially making the use of immunosuppressive therapy in clinical 
islet transplantation unnecessary [38, 79, 95]. Immunosuppressive drugs have undesirable side 
effects and have even been shown to have harmful effects on transplanted islet tissue [96]. If a 
clinically useful new in vitro source of beta cells can be found – either derived from adult or 
embryonic stem cells or otherwise [97-103] – it is likely that their immunogenicity will remain 
an obstacle to be overcome for their success in transplantation, and microencapsulation is an 
attractive means of protecting these beta cells from the host immune response. A further obstacle 
to successful islet cell transplantation is loss of the islets’ normal vascularity and rich blood 
supply [104]. This limits the supply of oxygen and nutrients to the islet cells, leading to cell 
death and necrosis. In human islet transplant 50% or more of the islet tissue is lost in the 10 week 
period immediately following transplantation [105]. This is likely to be due in large part to 
hypoxia in the period prior to engraftment and delay in development of a vascular network [106]. 
Oxygen supply to encapsulated islets is limited in the long-term as they never become 
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revascularized, and the islet cells are completely dependant on diffusion of oxygen from their 
surroundings. It has been shown that small islets survive better than large islets in transplantation 
[56, 57]. This is because for larger islets oxygen must diffuse over a greater distance and cell 
number to reach cells at the core. Oxygen supplied in this way is not sufficient to keep up with 
demand, resulting in hypoxic beta cells and central necrosis. Furthermore hypoxic and necrotic 
islet cells are pro-inflammatory [47, 107], and the capsules containing them are permeable to the 
debris and pro-inflammatory factors produced. Once released it is likely that these act to elicit a 
host immune response. We hypothesize that well oxygenated healthy islet cells are better 
equipped to evade immune surveillance resulting in a more successful longer-lasting 
transplantation.  
When islets are dispersed into single cell they tend to reaggregate to clusters [108] and if 
left long enough to islet-like structures.  We know that transplanted islet cell aggregates (50-
150 µm) can reverse hyperglycemia as effectively as islets [54]. It is clear that aggregates that 
are smaller than whole islets act as less of a barrier to oxygen diffusion, as there is a shorter 
distance, and fewer cells between the tissue surface and tissue core (Chapter 3). A further 
advantage to the use of islet cell aggregates is the potential for higher capsule packing density, 
which up to now has been limited by the problem of increasing oxygen demands. Higher capsule 
packing density is advantageous because a curative volume of beta cells could be provided in a 
lower capsule volume which is more amenable to transplantation to sites where space is limited, 
such as the intraportal site, subcutaneous site, and under the kidney capsule. Furthermore islet 
tissue that remains healthy even when densely packed is of use not only in microcapsules but in 
all encapsulation devices.  
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In this study we first showed that encapsulated islet cell aggregates survive and function 
better than encapsulated islets when cultured in low oxygen tensions to simulate the transplant 
setting. We then used diabetic and non-diabetic transplant models to show that encapsulated islet 
cell aggregates also prove to be superior to encapsulated islets on transplantation. 
4.2 MODELING 
To determine the culture conditions where the benefits of aggregate containing 
microcapsules will be observed in terms of enhanced tissue survival and function compared to 
intact islets, a theoretical model has been developed to predict the local partial pressure of 
oxygen, which, in turn, is used to assess tissue viability and fraction of normal insulin secretion 
for encapsulated islets and aggregates in culture.  This model was adapted from the model for 
microcapsules containing islets and aggregates discussed in Chapter 3.  For all calculations the 
microcapsules have a diameter of 500 µm and the microcapsule material will be 2% (v/v) 
alginate.   
 
4.2.1 Model Geometry 
 Sketches of example geometries that were analyzed are presented in Figure 4-1A for 
microcapsules cultured on polystyrene which is assumed to have an oxygen impermeable bottom 
and Figure 4-1B for microcapsules cultured in silicone rubber bottom plates which are highly 
oxygen permeable.  Two tissue configurations in microcapsules were analyzed: (1) one centrally 
located 150-µm diameter islet or (2) 1.2 islet equivalents of 50-µm aggregates arranged in a 
cubic array of spheres where the tissue lies throughout the capsule diameter.  An islet equivalent 
(IE) is a volume of tissue equal to that of a 150-µm sphere.  The capsules are arranged in a 
monolayer on the bottom of the culture dish in a cubic array.  For each capsule, with the origin 
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placed at the center of the capsule, there are planes of symmetry perpendicular to the bottom of 
the culture dish, thus the model can be solved for only one quarter of the capsule in order to 
reduce the number of degrees of freedom. 
 
4.2.2 Material and Tissue Properties    
 The effective permeability of the alginate microcapsule was determined from theoretical 
relationships assuming that alginate is the dispersed phase and has a permeability of zero.  The 
ratio of the effective permeability (αD)eff,i for layer i consisting of a dispersed (d) phase and a 
continuous (c) phase (as occurs in the alginate subdomains of the model system) to the 
permeability of the continuous phase (αD)c was calculated from Maxwell’s relationship [75] 
 
( )
( )
eff,i
c
αD 2-2 +ρ(1+2 ) = 
αD 2+ +ρ(1- )
φ φ
φ φ  (4-1) 
where αD is the effective permeability of the material (mol/cm/mmHg/s), ( ) ( )d cρ= αD αD  is 
the ratio of the permeability of the dispersed phase to the permeability of the continuous phase, 
and φ  is the volume fraction of the dispersed phase.  The parameters used in the model are in 
Table 3-1.   
 
4.2.3 Model Equations 
The three-dimensional species conservation equation for reaction and diffusion at steady 
state was used to predict the oxygen profile within the different tissue, alginate, cell culture 
media, and silicone rubber membrane subdomains of the culture system: 
 2i i iD C = V∇  (4-2) 
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where Di (cm2/s) is the effective diffusivity of oxygen in subdomain i, Ci (mol/cm3) is the 
concentration of oxygen in subdomain i, and Vi (mol/cm3/s) is the local oxygen consumption rate 
per unit volume in subdomain i.  For convenience, since partial pressures are equal across 
interfaces of different materials, we make use of oxygen partial pressure instead of 
concentration, which are related by 
 C = αP  (4-3) 
where α (mol/cm3/mmHg) is the effective Bunsen solubility coefficient in subdomain i and P is 
the partial pressure of oxygen.  Combining  Eq. (1) and Eq. (2) gives   
 ( ) 2i i iαD P = V∇  (4-4) 
The oxygen consumption rate is assumed to follow Michaelis-Menten kinetics for all tissue, 
 max i ii
m i
V ε P
V  = 
K +P
 (4-5) 
where Vmax is the maximum oxygen consumption rate for the tissue, εi is the tissue volume 
fraction in subdomain i, and Km is the Michaelis-Menten constant.  No oxygen is consumed in 
the alginate, cell culture media, or silicone rubber subdomains; therefore Vi is equal to zero in 
those subdomains, and the tissue volume fraction in the islet or aggregate subdomains is equal to 
one. 
The model was solved by the finite element method using the commercially available 
software package COMSOL Multiphysics in combination with MATLAB and using the model 
parameters in Table 4-1.  (4-4) was solved simultaneously for all subdomains of the culture 
system subject to the following conditions.  There are planes of symmetry on the sides of the unit 
cell where the media or capsule was cut and thus zero flux of oxygen across these boundaries.  
At the boundary between a tissue subdomain and the alginate subdomain or the alginate 
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subdomain and culture media the partial pressure of oxygen and the flux of oxygen across the 
boundary are both equal.  For the case of capsules cultured on polystyrene the bottom of the 
culture dish is assumed to be impermeable to oxygen and the flux across that boundary is zero.   
For the silicone rubber bottom culture condition, at the culture media and silicone rubber 
boundary the oxygen partial pressure and flux of oxygen across the boundary are equal.  The 
bottom boundary of the silicone rubber membrane is at the partial pressure of oxygen in the gas 
phase.  The external partial pressure of oxygen in the gas phase is specified and it is assumed that 
the top surface of the culture media is at the gas phase partial pressure of oxygen.   
The fractional viability of the encapsulated tissue was estimated by determining the 
volume fraction of tissue where P>PC.  PC is the critical oxygen partial pressure below which 
tissue dies and the value of PC is assumed to be 0.1 mmHg [23].  The fractional viability was 
calculated using the following equation: 
 Viable
Tissue
V
Fractional Viability=
V
 (4-6) 
where VViable is the volume of tissue where P is greater than 0.1 mmHg and VTissue is the total 
encapsulated tissue volume. 
 The relationship used to predict the local fraction (FI) of normal insulin secretion rate as a 
function of local oxygen partial pressure within the islet was developed from data on the effect of 
hypoxia on islet insulin secretion, estimating the oxygen partial pressure profile within the islet 
in the experimental system, and then determining the simplest model type and parameter(s) that 
best predict the insulin secretion level [44, 93].   
 I
I
PP <  P* mmHg     F  = 
P*
P  P* mmHg     F  =  1.0≥
 (4-7) 
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When Vmax is equal to 4x10-8 mol/cm3/s, P* equals 5.1 mmHg and when Vmax equals 6x10-8 
mol/cm3/s, P* equals 1.1 mmHg [93].   A value of Vmax of 6x10-8 mol/cm3/s was used for the 
predictions of encapsulated tissue viability and function in culture because it corresponds to an 
OCR per cell of 4 fmol/min/cell, within the range that was measured for the rat islets used in 
these experiments.  The fraction of normal insulin secretion averaged over all tissue within the 
microcapsule was determined by evaluating the volume integral of FI in all tissue containing 
subdomains 
 
I
S
Viable
Tissue
FdV
F =
V
∫
 (4-8) 
where FS is the fraction of normal insulin secretion averaged over all of the encapsulate tissue. 
    
4.3 MODELING RESULTS 
Traditional cell culture is carried out in polystyrene dishes which have a bottom that can 
be assumed to be impermeable to oxygen.  We performed calculations to predict the fractional 
viability for islet and aggregate capsules cultured on polystyrene dishes over a range of oxygen 
levels.  We performed these calculations in order to determine what gas phase oxygen level 
should be used for in vitro culture experiments in order to show that aggregate survival is 
enhanced compared to islet survival.  The predictions for differences in fractional viability were 
not as great between the aggregate and islet conditions as we would have hoped based on 
previous theoretical predictions with a specified capsule surface PO2 (Chapter 3) and the 
predictions were very dependent on tissue surface density (Figure 4-2A-C).  We also performed 
calculations in which the capsules were cultured in oxygen permeable silicone rubber bottom 
dishes (Figure 4-2D-F) which have been previously used to enhance oxygen transport to islets 
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cultured at PO2 of 142 mmHg and for better oxygen control during embryonic stem cell 
differentiation in low oxygen [109, 110]. Calculations predicted greater differences in 
encapsulated islet and aggregate survival, tissue could survive at lower gas phase oxygen levels 
for both tissue types, and the predicted viabilities had less of a dependence on surface density.  
The silicone rubber membranes allow for better oxygen control to the encapsulated tissue and 
maximize the predicted differences in tissue survival.  Silicone rubber membranes were therefore 
used for in vitro experiments to demonstrate that aggregates will survive better than intact islets 
in low oxygen. 
Calculations were performed to predict the fraction of normal insulin secretion and 
fractional viability of encapsulated islets and aggregates cultured on silicone rubber over a range 
of gas phase oxygen levels.  These calculations were used to determine what gas phase oxygen 
level should be used during in vitro experiments to observe that aggregates function and survive 
better in low oxygen than intact islets.  At a gas phase oxygen level of 3.5 mmHg (0.5%) 
aggregate survival is predicted to be greater than islet survival (60% versus 20% at low surface 
densities) (Figure 4-3A).  Insulin secretion is significantly impaired for both tissue types (<20%) 
(Figure 4-3B).  We chose to culture tissue at a gas phase PO2 of 3.5 mmHg in order to ensure that 
there would be loss of tissue in the islet capsules, but still greater survival rates in the aggregate 
capsules.  We also wanted to show experimentally that at intermediately low oxygen levels the 
aggregates function and secrete insulin normally while function is impaired for intact islets.  The 
intermediate oxygen level that we chose to study these effects at was a gas phase PO2 of 
14 mmHg or 2% oxygen.  In 2% oxygen when the aggregates and islets are cultured at a 
relatively low surface density all aggregate tissue is predicted to survive and nearly normal levels 
of insulin secretion (93%) are expected (Figure 4-3C & D).  In comparison only 55% of 
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encapsulated islets are predicted to survive 2% O2 culture and the fraction of normal insulin 
secretion will only be 40%. 
 
  
4.4 METHODS 
4.4.1 Animals 
Male Lewis or Sprague-Dawley rats weighing 200-250 g (Harlan Sprague-Dawley) were 
used as islet donors. Lewis rats were used as recipients for syngeneic transplants. Hyperglycemic 
BALB/c mice (Taconic) were used as diabetic recipients. Diabetes was induced with an 
intraperitoneal injection of streptozotocin (Sigma Aldrich) at 250 mg/kg 10 to 14 days prior to 
transplantation. Mice having fed glucose levels higher than 350 mg/dl on two separate occasions 
were used as recipients. Normoglycemia was defined as two consecutive measurements on 
different days with non-fasting blood glucose levels below 200 mg/dl. All animal experiments 
were approved by the Joslin Animal Care Committee.  
4.4.2 Islet Isolation 
Rat islets were isolated according to standard techniques [70]. Briefly a laparotomy was 
performed under anesthesia with Ketamine/Xylazine. The common bile duct was cannulated and 
8-10 ml of rodent Liberase RI ((Roche) 0.33 mg/ml) in M199 media was injected. Pancreas was 
then removed and incubated in a circulating water bath at 37oC for 24.5 minutes. The digested 
pancreatic tissue was washed with M199 containing 10% newborn calf serum (Mediatech) and 
then strained through 400 μm wire mesh (Thomas Scientific). Islets were purified by 
centrifugation at 1750xg for 17 minutes through a discontinuous Hisotpaque 1077 gradient 
(Sigma Aldrich). Islets were handpicked under a dissecting microscope, counted, and then 
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cultured overnight at a density of up to 30 islets/cm2 and a media height of 1.3 mm. Islet culture 
media was RPMI 1640 supplemented with 10% fetal bovine serum, penicillin 100 units/ml and 
100 μg/ml streptomycin (Mediatech). 
4.4.3 Islet Dispersion and Reaggregation 
Islets were washed twice in PBS. A solution of bovine pancreas trypsin (Sigma Aldrich) 
1 mg/ml and bovine pancreas DNAse 1 (Roche) 30 µg/ml in PBS was added. The islet 
suspension was incubated at 37oC for 13.5 minutes with mixing by vortexing every 4.5 minutes. 
Cold islet culture media was added to stop the digestion. Cells were counted using a 
haemocytometer and then put in ultra low attachment dishes (Corning) at 500,000 cells per 
60 mm dish. They were cultured overnight prior to encapsulation to allow for the cells to 
reaggregate.  The size of the resulting aggregates were 39±25 µm. 
4.4.4 Microencapsulation 
Microcapsules were produced using purified alginate with high guluronic acid content 
(SLG 100, FMC Polymer, Norway) at a concentration of 1.5% (w/v) in 0.9% (w/v) NaCl. Whole 
islets or islet cell aggregates were washed with calcium free Krebs buffer (135 mM NaCl, 
4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, pH 7.4) and then resuspended 
in alginate to form a tissue-alginate suspension.  Microcapsules were produced by extrusion of 
the tissue-alginate suspension through a needle using an electrostatic droplet generator (Pronova 
Polymer, Norway) into 20 mM BaCl2 solution. Microcapsules ranged in size from 350 μm to 
600 μm in diameter with an average for each batch between 400 μm and 500 μm. After 
sequential washes in HEPES buffer (132 mM NaCl, 4.7 mM KCl, 1.2mM MgCl2, 25 mM 
HEPES, pH 7.4) and Krebs buffer (133 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
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MgSO4, 25 mM HEPES, 2.5 mM CaCl2, pH 7.4) the encapsulated islet tissue was cultured in 
islet culture media.  
4.4.5 Encapsulated Tissue Culture 
Capsules that were cultured in 20% oxygen were placed in 100 cm2 silicone rubber flasks 
(PR-AY-5-0017-5 from Wilson Wolf Manufacturing Inc., New Brighton, MN) in islet culture 
media at a depth of 2.5 mm, at a density of less than 30 IE/cm2 where there should be no oxygen 
limitations, and placed in a standard humidified air incubator with 5% CO2 at 37oC.   Capsules to 
be cultured at 0.5% or 2% oxygen were placed in 24 well plates that were custom made to 
contain silicone rubber bottoms (PR-AY-7-0004, from Wilson Wolf Manufacturing Inc., New 
Brighton, MN) in islet culture media at a depth of 10 mm at a density of 50-200 IE/cm2 and then 
placed into a humidified incubator (Xvivo from Biospherix Ltd., Redfield, NY) where the gas 
levels were controlled to be at 5% CO2, 0.5% O2 or 2% O2, and balance N2.  Capsules were 
cultured for two days under these conditions for the in vitro experiments.  
4.4.6 Oxygen Consumption Rate (OCR) 
The oxygen consumption rate measurements were performed as previously described 
(Chapter 2 and [66]). Islet or aggregate containing microcapsules were resuspended in DMEM 
without phenol red containing 4.5 g/l glucose supplemented with 0.6 g/l L-glutamine, 
100 units/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES (Mediatech) without serum for 
OCR measurements.  Phenol red free media was required such that the media would be colorless 
as to not interfere with the absorbance measurements associated with the alginate assay.  The 
tissue microcapsule samples were added to a 200 μl stirred titanium chamber maintained (Micro 
Oxygen Uptake System FO/SYSZ-P250, Instech Laboratories, Plymouth Meeting, PA) at 37oC 
[66].  After the samples equilibrated with air at 37oC the chambers were sealed.  The time 
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dependent PO2 within the chamber was recorded with a fluorescence-based oxygen sensor 
(Ocean Optics, Dunedin, FL), and the data at high PO2 was fit to a straight line. The maximal 
OCR was evaluated from OCR=Vchα(ΔPO2/Δt), where Vch is the chamber volume and α is the 
effective Bunsen solubility coefficient for the contents of the OCR chamber. 
 
4.4.7 Capsule Dissolution 
Many of the quantitative measures of encapsulated tissue - nuclei counts, DNA content, 
alginate content, or insulin content require that the capsule first be dissolved.  After OCR 
measurements were complete the tissue was collected from the chamber and the tissue and 
capsule quantity were determined.  Tissue was removed from microcapsules by adding 800 μl of 
100 mM tetrasodium EDTA (pH=8) to approximately 300 μl of a capsule suspension.  The 
samples were placed in an incubator at 37oC for 1 hour and were vortex mixed every 30 minutes 
to dissolve the capsules.  
4.4.8 Nuclei Counts 
Nuclei suspensions were prepared and quantified as described in Chapter 2. 200 µl 
aliquot of islet tissue from dissolved capsules (~ 2.5 x 106 cells/ml or 125 IEQ/ml) was 
resuspended in 100 µl of PBS and then incubated in a lysis solution (0.1 M citric acid and 10% 
(v/v) Triton X-100 (Sigma Aldrich)) for 15 min with vortex mixing every 5 minutes.  Next the 
nuclei samples was sheared through a needle to liberate all nuclei.  100 µl of 100 mM 
tetrasodium EDTA was added to the nuclei suspension to prevent alginate gelling prior to the 
nuclei counting. The liberated nuclei were stained with 0.8 µM LDS 751 and 0.2 µM Sytox 
Orange (Invitrogen,) in D-PBS and counted using a benchtop flow cytometer (Guava Personal 
Cell Analyzer, Guava Technologies, Hayward, CA).  
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4.4.9 DNA Analysis 
DNA concentration was quantified by fluorospectrophotometry using the CyQUANT® 
Cell Proliferation Assay Kit (Invitrogen), which is based on the strong fluorescence enhancement 
that the CyQUANT GR dye undergoes when bound to cellular nucleic acids. Pre-treating the 
samples with DNAse-free RNAse eliminated fluorescence resulting from CyQUANT dye 
binding to RNA. The fluorescence intensity was linearly related to the concentration of nucleic 
acids in the sample. 
 
4.4.10 Insulin and DNA content 
An aliquot of the islet or islet cell aggregate suspension in EDTA was frozen, then 
thawed and diluted to a known volume with PBS. The samples were sonicated on ice. An aliquot 
was taken for insulin, immediately adding 2X high salt buffer (NaCl 2.15M, NaH2PO4 0.01M, 
Na2HPO4 0.04M, EDTA 0.002M), and then transferring to 4oC for overnight insulin extraction. 
Thereafter the sample was stored at 20oC until assayed using a rat insulin ELISA kit (ALPCO 
Diagnostics, Salem, NH) after appropriate dilution. 
 
4.4.11 Alginate Content 
The alginate content of samples were assayed by a method adapted from the literature 
using dimethyl methylene blue (DMMB)  (Sigma Aldrich) dye which is a cation that binds to 
polyanions such as alginate (Chapter 2 and [72]).  The ratio of the absorbance of a sample at the 
wavelengths of 520 nm and 650 nm increased linearly with increases in alginate concentration. 
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4.4.12 Glucose stimulated insulin secretion 
Encapsulated islets or islet cell aggregates were suspended in Krebs Ringer buffer Hepes 
(KRBH) (NaCl 137 mM, KCl 4.8 mM, KH2PO4 1.2 mM, MgSO4.7H20 1.2 mM, CaCl2.2H20 
2.5 mM, NaHCO3 5 mM, HEPES 16 mM, BSA 0.1% (w/v), pH 7.4) containing 2.8 mM glucose.  
The pre-culture and 20% O2 culture samples were kept at 37oC in humidified air and 5% CO2 for 
the duration of the measurement.  The low oxygen samples were kept in a controlled oxygen 
environment (Xvivo from Biospherix Ltd., Redfield, NY) throughout the duration of the 
measurement at 37oC in humidified 2% or 0.5% oxygen, 5% CO2, and balance N2.  The use of 
the Xvivo was critical to these measurements as they allowed for tissue collection, washes, and 
media changes without exposing the tissue to atmospheric oxygen allowing for static glucose 
stimulated insulin secretion measurements in low oxygen. Five 1-ml aliquots with approximately 
equal numbers of microcapsules containing islets or islet cell aggregates were pre-incubated for 
one hour. The in vitro insulin secretion was then assessed by consecutive incubations of one hour 
in KRBH containing 2.8mM glucose and 16.8mM glucose. At the end of each incubation 800 μl 
of the KRBH was removed and frozen for insulin assay.  The tissue was collected and the DNA 
content was measured to normalize insulin secretion results. 
4.4.13 Histology 
Encapsulated islets or islet cell aggregates were fixed in 2.5% (w/v) glutaraldehyde in 
0.1M phosphate buffer pH 7.4. Plastic 1-μm thick sections were generated and stained with 
toluidene blue (Thermo Fisher Scientific). 
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4.4.14 Immunohistochemistry 
Encapsulated islet tissue was fixed in 4% paraformaldehyde for 2 hours then centrifuged 
in 2% agar before embedding in paraffin. 2 step sections from each block were stained in insulin 
and glucagon. Briefly sections were hydrated and guinea-pig anti-bovine insulin antibody 
(1:200) was added for 1 hr followed by washing in lamb serum before Texas red–conjugated 
anti–guinea pig antibody (1:200) was added for 1 hr After washing unconjugated Streptavidin 
was added for 1hr followed by biotin for 30 min. Then rabbit anti-goat glucagon antibody 
(1:3000) was added and sections were left in a humidity chamber overnight at 40C. After 
washing biotinylated anti-rabbit antibody (1:200) was added for one hour and finally 
Streptavidin-conjugated DTAF (dichlorotriazinyl amino fluorescein)(1:200). Coverslips were 
applied with DAPI (4',6-diamidino-2-phenylindole) containing mounting media (Vector 
laboratories). Stained sections were photographed in confocal mode of a LSM410 microscope. 
Insulin-positive (red) and glucagon-positive (green) cells were counted on one or two sections 
from each preparation to a total number 300 to 800 cells per preparation. Sections were prepared 
for encapsulated islets and islet cell aggregates from 3 separate experiments. 
4.4.15 Syngeneic normoglycemic transplants 
Encapsulated islets or islet cell aggregates were transplanted intraperitoneally to 
syngeneic (Lewis rat) recipients. Microcapsules were injected into the peritoneal cavity through 
a central midline 5-10 mm incision using a sterile plastic transfer pipette (Fisher Scientific). The 
incision was closed using 5/0 silk, the outer layers were stapled. The animals were anesthetized 
with Ketamine/Xylazine. Capsules were retrieved 2 weeks after transplantation by laparotomy 
and peritoneal lavage.  Capsules were washed in PBS and prepared for Histology sections. 
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4.4.16 Xenogeneic hyperglycemic transplants 
On day 2 post-isolation and shortly after encapsulation, islets and islet cell aggregate 
containing capsules were sampled in triplicate and total tissue volume was quantified by nuclei 
counting. The remaining tissue was cultured overnight in Ultraculture media (Cambrex 
Bioscience, Walkersville, MD) supplemented with glutamine (300mg/L) penicillin (100units/ml) 
and streptomycin (100ug/ml). On day 3 aliquots of 85 islet equivalents (IE) were prepared for 
each encapsulated tissue type, washed in KREBS buffer and transplanted intraperitoneally to 
diabetic BALB/c mice.  
 
4.4.17 Intraperitoneal Glucose Tolerance Tests and blood glucose measurement 
Transplant recipients were fasted overnight for 15 hours. They received 2g/kg of glucose 
by intraperitoneal injection using a 10% (w/v) glucose solution. Blood glucose was measured 
immediately prior to the injection (time 0) and at 15, 30, 60, 90 and 120 minutes thereafter. For 
determination of blood glucose concentrations blood was obtained from the tail vein and applied 
to a glucometer (One Touch). 
 
4.4.18 Statistics 
Data are expressed as average ± standard error of measurement (SEM). Statistical 
significance was determined by a two-way Student t-test or Fisher exact test as indicated for each 
data set.  
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4.5 RESULTS – IN VITRO EXPERIMENTS 
4.5.1 Histology 
 Plastic sections (1-µm) were prepared for histological examination of encapsulated islets 
or aggregates following culture in 2% oxygen.  Figure 4-4A is section of a microcapsule 
containing islets after 2 days of culture in 2% oxygen.  The cells in the center or the islet are only 
stained lightly by toluidene blue indicating that the cells at the center of the islet are necrotic 
most likely due to a lack of oxygen.  Figure 4-4B is a section of a microcapsule containing 
aggregates after 2 days of culture in 2% oxygen where the tissue looks healthy and there are not 
signs of necrosis.  Qualitative observations of encapsulated tissue histological sections indicate 
that encapsulated aggregates survive better than encapsulated islets in low oxygen.  Sections 
shown are representative of sections prepared from 3 separate experiments. 
 
4.5.2 Oxygen Consumption Rate 
 Oxygen consumption rate (OCR) measurements of encapsulated tissue were performed 
on the day of encapsulation and again after two days of culture under normal (20%) or low (0.5% 
or 2%) oxygen conditions.  The OCR is measured for a sample of capsules, and then the capsules 
are removed from the chamber and dissolved.  The dissolved capsule tissue and alginate 
suspension can be analyzed to determine the insulin content, nuclei count, DNA content, or 
alginate content of the sample within the OCR chamber.  The alginate content is measured in 
order to normalize the OCR results by the volume of capsules in the chamber.  The capsule 
volume normalization is necessary due to the high variability of capsule sampling.  In Figure 4-5 
the results for OCR per ml capsule are shown for one experiment in which the encapsulated islets 
and aggregates are cultured in 20% and 2% oxygen. For all conditions in this experiment, the day 
of encapsulation or after two days of culture in 20% or 2% oxygen, the OCR per ml capsule is 
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higher for the aggregate containing capsules, indicating that the viable tissue density is higher in 
the aggregate capsules for all conditions.  Even though the viable tissue density was higher for 
the aggregate capsules initially, there was less of a change in viable tissue density in capsules 
after culture in low oxygen for aggregate containing capsules (p=0.54) compared to islet 
containing capsules (p=0.062).  The p-values compare OCR per ml capsules for either capsule 
type pre-culture to 2 days of culture in 2% oxygen. 
OCR recovery, a measure of the fractional recovery of viability tissue from culture, is 
calculated from the measured values of OCR per ml capsule using the following equation: 
 
( )
( )
After 2 Day Culture
Pre-Culture
OCR per ml capsule
Fractional OCR Recovery = 
OCR per ml capsule
 (4-9) 
The fractional OCR recovery results are presented in Figure 4-6.  Under normal culture 
conditions (20% O2), all of the viable tissue was recovered for both aggregate and islet capsules 
because the measured fractional OCR recovery was greater than one.  Culture in very low 
oxygen (0.5%) resulted in recovery of almost all viable tissue in aggregate capsules (fractional 
OCR Recovery = 0.94) but significantly less viable tissue from the islet capsules (fractional OCR 
Recovery = 0.59). Culture in low oxygen (2%) resulted in the recovery of all viable aggregate 
tissue (fractional OCR Recovery = 1.14) but only 61% of viable encapsulated islet tissue.  
Significantly less islet tissue was recovered after culture in low (0.5% or 2%) oxygen than after 
culture in 20% oxygen.   There was only a small but significant loss of viable aggregate tissue 
after culture at 0.5% oxygen compared to the normal oxygen condition (20%), but the amount of 
aggregate tissue recovered after 0.5% oxygen culture was significantly higher than for 
encapsulated islets cultured at 0.5% oxygen.   The measured fractional OCR recoveries 
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demonstrate that encapsulated aggregate survival is better than encapsulated islet survival in low 
oxygen.  
 
4.5.3 Tissue Recovery 
 The tissue recovery from culture in normal (20%) and low (0.5% or 2%) oxygen is 
calculated by the following equation:   
 
( )
( )
After 2 Day Culture
Pre-Culture
Nuclei per ml capsule
Fractional Nuclei Recovery = 
Nuclei per ml capsule
 (4-10) 
The alginate content of the sample is measured to normalize the nuclei count by the total volume 
of capsules in the sample due to the high variability of capsule sampling.  The fractional nuclei 
recoveries after two days of culture in normal and low oxygen are presented in Figure 4-7.  After 
culture in 20% or 2% oxygen there is no difference in tissue recovery between islet and 
aggregate capsules.  There is also no difference in the tissue recovery for aggregate capsules 
between any of the culture conditions.  There is a trend towards less tissue recovery in the islet 
capsules compare to the aggregate capsules cultured at 0.5% oxygen (p=0.08).  The tissue 
recovery is significantly lower for islet capsules cultured at 0.5% oxygen compared to the islet 
capsules cultured at 20% oxygen.  The measured losses in total tissue (nuclei recovery) are not as 
dramatic as those for viable tissue (OCR recovery) after culture in low oxygen.  This is most 
likely due to the fact that although viable tissue has been lost the tissue has not yet been cleared 
from the capsules and is being detected by nuclei counts.     
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4.5.4 Insulin to DNA Ratio 
The ratio of insulin to DNA is considered an index of beta cell viability because viable 
beta cells store insulin. This ratio decreased markedly in encapsulated islets cultured in 0.5% 
oxygen for 2 days, in contrast to no decline in encapsulated islet cell aggregates (Figure 4-8). 
This indicates an improved ability of islet tissue to withstand low oxygen tensions when islets 
are dispersed and reaggregated prior to encapsulation. The insulin to DNA ratio does not decline 
in either tissue type, and even increases in the encapsulated islets when cultured in 20% oxygen 
or 2% oxygen (p<0.05) indicating that these conditions are compatible with beta cell viability in 
both islets and islet cell aggregates.  The improvement in insulin to DNA ratio in the 
encapsulated islets is in keeping with recovery of insulin stores and or loss of DNA through cell 
death in the islets following the encapsulation procedure [111].  
 
4.5.5 Quantification of beta-cells versus non-beta cells 
The increase in insulin to DNA ratio in the islets after culture in 20% oxygen may be 
somewhat explained by the beta cell counts which show a significant rise in the proportion of 
islet cells that are beta cells after culture in 20% oxygen (74±2% to 83±0%, p<0.05), indicating 
preferential survival of beta cells compared to non-beta cells in the islets (Table 4-2). This was 
not the case for islet cell aggregates in which the proportion of beta cells remained constant after 
normoxic culture (73±2%). Conversely after culture in 2% oxygen the proportion of beta cells in 
islets remained constant – presumably due to equal rates of death of beta and non-beta cells, 
whereas the proportion of beta-cells in the islet cell aggregates increased (73±2% to 84±5%, 
p<0.05) indicating preferential survival of beta cells compared to non-beta cells. It has 
previously  been shown that on transplantation of non-encapsulated islets, over time there is 
preferential loss of non-beta cells [54]. It may be the case that when encapsulated, the normally 
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outermost non-beta cells are protected from the local stresses of handling (shearing forces for 
example), thereby preserving the normal beta to non-beta cell ratio. The rise in the ratio of beta 
to non-beta cells in the islet cell aggregates could be accounted for by a reduction in the rate of 
beta cell death compared to that which occurs due to central necrosis in the normal islet 
structure. The non-significant difference in cell composition after culture in 2% oxygen cannot 
however account for the marked difference in insulin to DNA ratio between the two tissue types 
– indicating that this difference truly indicates a greater islet tissue viability in the islet cell 
aggregates.  
 
4.5.6 Glucose stimulated insulin secretion 
Insulin secretion at basal glucose levels (2.8mmol/l) was appropriately low in both 
encapsulated tissue types on the day of encapsulation and a good response to high glucose 
concentration (16.8mmol/l) was demonstrated (Figure 4-9). Our results show that this normal 
pattern of insulin secretion was preserved in both tissue types after 2 days culture in 20% oxygen 
but became abnormal after 2 days culture in 2% or 0.5% oxygen. Basal insulin secretion was 
inappropriately high in both encapsulated islets and islet cell aggregates cultured in 2% or 0.5% 
oxygen. However in contrast to the islets, the islet cell aggregates continued to show a significant 
rise in insulin secretion in response to high glucose (p<0.05) after culture in 2% oxygen 
indicating a degree of preservation of regulated insulin secretion.  Insulin secretion was 
significantly impaired for islets or aggregates cultured at 0.5% oxygen as the basal insulin 
secretion level was actually higher than the stimulated insulin secretion.  The high basal insulin 
secretion rate that was observed could also have been from β cell degranulation or release of 
insulin from dead cells. 
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4.6 RESULTS – IN VIVO EXPERIMENTS  
4.6.1 Histology 
Encapsulated islets and islet cell aggregates were transplanted intraperitoneally to 
syngeneic (Lewis rat) recipients. Toluidene blue stained sections of the encapsulated tissue 
retrieved two weeks later were prepared (Figure 4-10).  Large areas of central necrosis were 
apparent in many of the islets, and were especially prominent in the larger islets as demonstrated 
by pale stained cells, loss of nuclear staining and in some cases complete absence of tissue in the 
core. In contrast encapsulated aggregates remained healthy in appearance.  
 
4.6.2 Hyperglycemic xenogeneic transplants 
A volume of encapsulated rat islet tissue that would cure some but not all diabetic mouse 
recipients was determined in preliminary transplant experiments (data not shown).  A marginal 
mass of 85IE (determined by nuclei counting) was chosen and this volume of encapsulated islets 
or islet cell aggregates was transplanted to diabetic BALB/c mice (n=10,12 respectively). Fed 
blood glucose concentrations were measured on day 1,3,7,10,and 13 post-transplantation (Figure 
4-11). Transplanted encapsulated islet cell aggregates cured a greater proportion of recipients 
(83%) compared to encapsulated islets (30%) (p<0.03 Fisher exact test). IPGTTs performed on 
the cured transplant recipients showed a trend towards a better glucose clearance for the islet cell 
aggregate recipients than the islet recipients – a trend that was not significantly different due to 
the small number in the cured islet transplant recipient group (n=3) and comparable glucose 
clearance to the normoglycemic controls (Figure 4-12). This once again shows that the islet cell 
aggregates function effectively in response to glucose challenges, and indeed are more effective 
than islets in encapsulated intraperitoneal transplants at maintaining euglyemia in the fed state.  
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4.7 DISCUSSION 
 In this study we found that islet cell aggregates, as compared to intact islets, were 
superior in their ability to survive and function in a low oxygen culture and in the transplantation 
setting.  Histological sections of capsules after culture in 2% oxygen or syngeneic transplantation 
showed signs of central necrosis in the islet tissue, but not for the aggregate tissue.  OCR 
recovery, tissue recovery, the ratio of insulin to DNA content, and glucose stimulated insulin 
secretion measurements, the parameters that were measured to assess the ability of tissue to 
survive and function under low oxygen conditions, were all favorable towards the aggregates 
under at least one low oxygen condition.  Since each of these measurements is an assessment of a 
slightly different but important parameter of islet tissue health it is to be expected that all of the 
results will not have the same degree of effect at a particular oxygen culture condition or all be 
effected at the same oxygen level.  Results of OCR recovery are more dramatic than those for 
nuclei recovery because viable tissue is lost and then the nuclei are cleared from the capsule.  
Glucose stimulated insulin secretion is dysfunctional at 0.5% oxygen in both tissue types and for 
islets in microcapsules at 2% oxygen, but stimulation is observed for aggregates in capsules at 
2% oxygen.  It has been observed in previous work [44, 93] and is also consistent with the 
modeling results that insulin secretion is impaired at higher oxygen levels than is the case for 
tissue viability.  The insulin to DNA ratio is considered to be a measure of tissue viability 
because a major function of healthy beta cells is to store insulin.  However the ability of an islet 
to store insulin and normal mitochondrial function as measured by OCR are two very different 
parameters; exact agreement and response to low oxygen are not expected.  The important 
conclusion from all of the measured viability parameters is that after culture in low oxygen, 
when oxygen causes detrimental effects on any of these parameters, it is always more severe for 
the intact islets as compared to the aggregates. 
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The modeling predictions proved to be a useful tool in guiding selection of oxygen levels 
at which to carry out experiments such that differences in aggregate and islet survival and 
function could be observed experimentally.  The modeling predictions did not exactly agree with 
the experimental results, but the measured trends for OCR recovery are similar to the trends for 
predictions of fractional viability.  After culture at 0.5% oxygen, a small amount of viable 
aggregate tissue was lost but significantly more was recovered than for encapsulated islets.  After 
culture at 2% oxygen all viable aggregate tissue was recovered with a significant loss of islet 
tissue.  There were similar amounts of viable islet tissue recovered in both low oxygen 
conditions even though there were predicted differences in fractional viability between the two 
low oxygen conditions.   The predictions for fraction of normal insulin secretion do not exactly 
agree with the results for measurement of glucose stimulated insulin secretion, but the same 
trends were present in the predictions as in the actual experimental results.  After culture in 0.5% 
oxygen the model predicted and the experimental results showed that insulin secretion was 
severely impaired for both tissue types.  After encapsulated islet culture at 2% oxygen, theory 
predicted insulin secretion to be impaired and thus was found experimentally. Insulin secretion 
was predicted to be near normal for encapsulated aggregates cultured at 2% oxygen, and the 
experimental results agreed with the predictions as increased insulin secretion was measured 
after incubation at high glucose: however, insulin secretion was not completely normal as basal 
levels of insulin secretion were high.   
 Aggregate containing microcapsules can successfully reverse diabetes following 
xenogeneic transplantation.  In fact the ability for the aggregate containing capsules to reverse 
diabetes, when a minimal mass of tissue is transplanted, was greater than for islet capsules.  The 
reason for the aggregates’ greater success rate is that tissue in the aggregate containing capsules 
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as a whole is exposed to higher oxygen levels such that less tissue dies after transplantation, and 
remaining viable tissue at the capsule interior is more likely to secrete insulin normally.  Another 
potential reason for improved transplantation success rates is that because there is less tissue 
hypoxia and cell death, there are less pro-inflammatory cytokines and cell debris released from 
the capsules which means a lower risk of initiating a host immune response [107].  
 Limited oxygen transport to microencapsulated tissue is a major obstacle that has limited 
the success of microencapsulated islet transplantation to treat type 1 diabetes.  In this study we 
have been able to show that the use of islet cell aggregates, which are smaller than intact islets, 
can significantly improve the ability of islet tissue to survive and function when cultured in low 
oxygen and to reverse diabetes in mice.  The use of aggregates instead of intact islets has proven 
to be an effective strategy to reduce oxygen transport limitations and improve microencapsulated 
tissue transplants.  This finding has great relevance to the future of insulin replacement therapy 
as a whole.  To date, despite improved outcomes that came with the Edmonton protocol, clinical 
islet transplantation has met with limited success, and is an option only for patients with severe 
manifestations of type one diabetes [112, 113]. Finding a renewable source of beta cells is 
necessary to tackle the mismatch between supply and demand [114, 115]. Furthermore finding a 
means of transplanting those beta cells such that they remain viable and functional for longer, 
and do not require immunosuppressive drugs to evade rejection are key issues which are both 
addressed by the use of islet cell aggregates in microcapsules.  
In conclusion, we found that encapsulated islet cell aggregates  survive and function 
better in low oxygen environments compared to encapsulated whole islets. This has important 
implications for future developments in clinical islet tissue transplantation and beta cell 
replacement therapy as a whole.  
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Contributions:  Islet isolations were performed with the assistance of Jennifer Hollister-Lock, 
Vaja Tchipasvilli, and Vassileios Kostaras from Joslin Diabetes Center.  Histology sections were 
prepared by Chris Cahill (Joslin DERC).  Abdulkadir Omer provided instruction on the 
preparation of microcapsules and assisted with the syngeneic transplantation experiments.  Susan 
Bonner-Weir assisted in the evaluation of the histological sections.  
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Figure 4-1:  Sketches of example model geometries 
 For microcapsules containing one 150-µm islet or 1.2 IE of 50-µm aggregates in culture on 
either an oxygen impermeable bottom (A) or an oxygen permeable silicone rubber bottom 
culture dish (B).   The dashed lines represent the unit cell in which the oxygen profile was 
calculated. 
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Figure 4-2: Predictions of fractional viability for islet (solid) and aggregate (dashed) capsules 
cultured on impermeable bottom dishes (A-C) or silicone rubber bottom dishes (D-F). 
At gas phase oxygen level of 142 mmHg (A,D), 36 mmHg (B,E) or 7 mmHg (C,F). 
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Figure 4-3: Comparison of predictions of fractional viability and insulin secretion for aggregate 
(dashed) and islet (solid) containing capsules cultured on silicon rubber in a gas phase oxygen 
partial pressure of 3.5 or 14 mmHg. 
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Figure 4-4: 1-µm plastic sections of microcapsules stained with toluidene blue after two day 
culture in 2% oxygen.  (A) capsule containing an islet (B) capsule containing aggregates 
 
A B
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Figure 4-5: OCR per ml capsule for islet (black bars) and aggregates (white bars) on the day of 
encapsulation and after two days of culture in 20% or 2% oxygen.   
In all conditions the measured OCR per ml capsule is higher for aggregate containing capsules 
than islet capsules (* = p<0.05 by unpaired student t-test).  Results are presented for one 
representative experiment in which the measurements were made in triplicate (n=3). 
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Figure 4-6: Fractional oxygen recovery of encapsulated islets (black bars) and aggregates (white 
bars) cultured for two days in 20% (n=5), 2% (n=3) or 0.5% (n=2) oxygen.   
n is the number of independent experiments for which the OCR recovery was measured. 
Statistical significance is represented by * which indicated p<0.05 by unpaired student t-test. 
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Figure 4-7: Fractional nuclei recovery of encapsulated islets (black bars) and aggregates (white 
bars) after two days of culture in 20% (n=5), 2% (n=3) or 0.5% (n=2) oxygen.   
n is the number of independent experiments for which the nuclei recovery was measured. 
Statistical significance is represented by * which indicated p<0.05 by unpaired student t-test. 
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Figure 4-8: Ratio of insulin to DNA content in encapsulated islets (black bars) and aggregates 
(white bars) on the day of encapsulation (pre-culture) and after 2 days culture in 20%, 2% or 
0.5% oxygen.   
Pre-culture, 20% O2: n=4, 2% O2 n=1, 0.5% O2 n=2. (n=3 replicates per experiment). *  
p<0.0001, **  p<0.05, ***  p<0.001  (unpaired student t-test). 
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Figure 4-9: Glucose stimulated insulin secretion from encapsulated islets or aggregates (agg) in 
low glucose (2.8 mM, black bars) and high glucose (16.8 mM, white bars) KRBH. 
Measurements were made immediately after encapsulation prior to culture and then after two 
days of culture in 20%, 2%, or 0.5% oxygen. (n=2 experiments for 20% and 2%, 1 experiment 
for 0.5%, 5 replicates per experiment). * p<0.05 (paired student t-test). 
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Figure 4-10: Plastic sections of capsules before and after two week syngeneic transplantation in 
non-diabetic rats.   
(A) islet capsules pre-transplantation, (B) aggregate capsules pre-transplantation, (C) islet 
capsule post-transplantation, and (D) aggregate capsules post-transplantation. 
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Figure 4-11: Blood glucose concentrations in diabetic BALB/c mice following intraperitoneal 
transplantation of encapsulated aggregates (A) or encapsulated islets (B).  
(n=12, 10 respectively). 
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Figure 4-12: Intraperitoneal glucose tolerance test results 
Blood glucose concentrations before (time 0) and after injection of glucose (2mg/g body weight) 
for encapsulated aggregates (○) or encapsulated islets (●), compared to normoglycemic (□) and 
hyperglycemic (■) controls. (n=12 10 3 and 2 respectively). 
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Table 4-1:  Model parameters 
 
 Parameter Symbol Value Units Source 
O2 diffusivity in media Dm 2.78x10-5 cm2/s [23] 
O2 diffusivity in tissue Dt 1.24x10-5 cm2/s [23] 
O2 diffusivity in silicone rubber Dsr 2.17x10-5 cm2/s [116] 
O2 solubility in media αm 1.27x10-9 mol/mmHg/ml [23] 
O2 solubility in tissue αt 1.00x10-9 mol/mmHg/ml [23] 
O2 solubility in silicone rubber αsr 1.21x10-8 mol/mmHg/ml [116] 
O2 permeability in 2% (v/v) alginate αDsr 3.43x10-14 mol/cm/mmHg/s [23] 
Maximum  oxygen consumption rate Vmax 4x10-8, 6x10-8 mol/cm3/s [23], experiment
Michaelis-Menten Constant Km 0.44 mmHg [23] 
Insulin Secretion Model Parameter P* 5.1, 1.1 mmHg [93] 
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 Table 4-2: Composition of islets and islet cell aggregates before and after hypoxic culture 
Tissue type Pre-culture 
β-cells (%) 
20% O2 
β-cells (%) 
2% O2 
β-cells (%) 
Islet 74 ± 4 * 83 ± 0 * 76 ± 8 
Islet cell aggregate 73 ± 1 73 ± 2 # 84 ± 5 # 
 
Data are means +/- SE, n=3, *‡  p<0.05 by paired student t-test, †p<0.02 by unpaired student t-
test. 
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Chapter 5 Evaluation of a perfluorocarbon emulsion within alginate 
capsules 
 
5.1 INTRODUCTION 
Microcapsules can be used to transplant islets to treat type 1 diabetes without the use of 
immunosuppressive drugs.  Microcapsules are small spherical gels that range in size from 
200 µm to 2 mm.  Microcapsules are the most extensively studied encapsulation system and are 
the system that is under study in our lab.  Microcapsules are hydrogels, most commonly made of 
alginate, that contain one to two islets.  The tissue within a microcapsule relies on diffusion of 
nutrients through the hydrogel to the tissue and diffusion of waste products and secreted proteins 
of interest away from the tissue.  The cells are protected from the immune system because the 
hydrogel keeps immune system effector cells, such as T cells and macrophages, from coming in 
contact with the transplanted tissue along with preventing or minimizing access of some large 
immune molecules such as antibodies and complement components. 
Islets within the native pancreas are heavily vascularized, and during islet isolation 
procedures the vascular network of the islet is destroyed, collapses during culture and is never 
allowed to regenerate when the islets are transplanted within an immunoisolating device [89-91].  
Tissue within a microcapsule must rely on delivery of oxygen and other nutrients by diffusion 
from the exterior of the device.  Oxygen diffusion is much more limited than glucose diffusion 
because glucose concentrations in vivo are much higher than oxygen [92].  We will assume that 
the oxygen level is the critical component that determines encapsulated tissue survival and 
function.  For oxygen to reach the encapsulated tissue it must diffuse from the vasculature to the 
device exterior, through the device to the tissue and through the islet while being consumed to 
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reach the cells at the center.  Oxygen delivery is even further hampered when an immune 
reaction to the transplanted cells or immunoisolating material results in cells adhering to the 
outside of the device consuming oxygen before it is able to reach the cell in the device interior 
[23].   
Reduced oxygen levels have been shown to reduce islet insulin secretion below what was 
observed under normoxic conditions [44, 47].  In the work by Dionne et al. [44] islets were 
perfused with media that was equilibrated with air at various oxygen levels, at gas phase PO2 
values below 60 mmHg there was a reduction in insulin secretion.  The ability of an islet to 
effectively secrete insulin following transplantation is essential for transplantation success.  
Thus, since reduced oxygen levels have been shown to decrease islet survival and function, 
effective oxygen delivery is critical for successful transplantation of immunoisolated islets to 
treat type 1 diabetes.  Previous theoretical analysis of oxygen limitations to immunoisolated 
tissue have been studied and have shown that depending on the transplantation conditions these 
problems can be quite serious [23, 93].   
In this study we will evaluate the use of a perfluorocarbon (PFC) emulsion as a 
permeability enhancer within the alginate matrix of a microcapsule to increase oxygen delivery 
to encapsulated islets.  Perfluorocarbons are highly desirable materials for enhancing oxygen 
transport, due to their very high oxygen solubility, approximately 25 times that of water, on a 
volumetric basis.  Enhanced solubility will lead to enhanced permeability because the 
permeability is a product of the solubility and diffusivity.  Perfluorocarbon emulsions have been 
developed to be used as a blood substitute.  There are reports in the literature that including a 
perfluorocarbon emulsion in islet culture enhances function [60].    Perfluorocarbons are also 
used during pancreas storage prior to islet isolation [61].  Culture of islets at the interface of a 
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perfluorocarbon and cell culture media (two layer method) has been studied and was not shown 
to be beneficial in improving islet survival  [62].  There are two potential reasons for the lack of 
improvement (1) the culture system probably did not have any oxygen limitations for the islets 
cultured without PFC and (2) the two layer method is beneficial for short periods of time when 
the PFC can act as a source of oxygen, but as it is not exposed to the air directly it does not have 
an effect after its oxygen store has been depleted.  All of these facts taken together indicate that 
the incorporation of perfluorocarbons into an encapsulating material is likely to be beneficial to 
enhancing islet survival in low oxygen.  In Chapter 3 we determined based on theoretical 
predictions that perfluorocarbons can increase the oxygen levels experienced by encapsulated 
tissue and improve fractional viability and fraction of normal insulin secretion after 
transplantation.  In this study we will expand the theoretical model in order predict encapsulated 
islet survival and function in culture in capsules with and without a perfluorocarbon emulsion.  
The modeling predictions will be used to select oxygen levels at which to carry out experiments.  
In vitro experiments were performed to determine if a PFC emulsion enhances islet survival in 
low oxygen.  In vivo experiments were performed to evaluate the biocompatibility of PFC 
emulsion containing alginate microcapsules.     
5.2 MODELING 
To determine the culture conditions where the benefits of PFC containing microcapsules 
will be observed in terms of enhanced islet survival and function, a theoretical model has been 
developed to predict the local partial pressure of oxygen, which, in turn, is used to assess tissue 
viability and fraction of normal insulin secretion for encapsulated islets in culture.  This model 
was adapted from the model for microcapsules containing islets discussed in Chapter 3 and quite 
similar to the model used in Chapter 4.  For all calculations the microcapsules have a diameter of 
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500 µm, will contain one centrally located 150-µm diameter islet, and the microcapsule material 
will be 2% (v/v) alginate.   
 
5.2.1 Model Geometry 
 Sketches of example geometries that were analyzed are presented in Figure 4-1A for 
microcapsules cultured on polystyrene which can be approximated as having an oxygen 
impermeable bottom and Figure 4-1B for microcapsules cultured in silicone rubber bottom plates 
which are oxygen permeable.  All islet tissue is assumed to be spheres.  An islet equivalent (IE) 
is a volume of tissue equal to that of a 150-µm sphere.  The capsules are arranged in a monolayer 
on the bottom of the culture dish in a cubic array.  For each capsule, with the origin placed at the 
center of the capsule, there are planes of symmetry perpendicular to the bottom of the culture 
dish, thus the model can be solved for only one quarter of the capsule in order to reduce the 
number of degrees of freedom. 
 
5.2.2 Material and Tissue Properties    
The effective permeability in subdomains containing several components was determined 
from theoretical relationships.  The ratio of the effective permeability (αD)eff,i for layer i 
consisting of a dispersed (d) phase and a continuous (c) phase (as occurs in the alginate 
subdomains of the model system) to the permeability of the continuous phase (αD)c was 
calculated from Maxwell’s relationship [75] 
 
( )
( )
eff,i
c
αD 2-2 +ρ(1+2 ) = 
αD 2+ +ρ(1- )
φ φ
φ φ  (5-1) 
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where αD is the effective permeability of the material (mol/cm/mmHg/s), ( ) ( )d cρ= αD αD  is 
the ratio of the permeability of the dispersed phase to the permeability of the continuous phase, 
and φ  is the volume fraction of the dispersed phase.  For the multiple dispersed phases employed 
in our model system, Maxwell’s relationship was used sequentially, starting with the phase with 
the smallest particle size and ending with the phase with the largest particle size.  For particle 
types of the same size, Maxwell’s relationship was used for one particle, then the other (and in 
the reverse order), and the two results were averaged. 
The perfluorocarbon emulsion that was studied consists of 70% (w/v) perfluorodecalin 
and 20% (w/v) Intralipid® (Baxter), a soybean oil emulsion and this emulsion will be what is 
used in all model simulations that contain PFC alginate [71].  In the final PFC alginate composite 
phase, there were perfluorodecalin and soybean oil droplets of approximately the same size; the 
alginate polymer itself was treated as an impermeable dispersed in water.  The effective 
permeability of PFC emulsion was estimated by first using Maxwell’s relationship for PFC 
droplets in water and then for soybean oil droplets in the PFC and water emulsion.   Secondly, 
Maxwell’s relationship was used for soybean oil droplets in water and then for PFC droplets in 
the soybean oil and water emulsion.  The two calculated effective permeabilites were averaged.  
Finally, the effective permeability of PFC alginate was estimated with alginate as the dispersed 
phase and PFC emulsion as the continuous phase.  The parameters used in the model are in Table 
3-1.   
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5.2.3 Model Equations 
The three-dimensional species conservation equation for reaction and diffusion at steady 
state was used to predict the oxygen profile within the different tissue, alginate, cell culture 
media, and silicone rubber subdomains of the culture system: 
 2i i iD C = V∇  (5-2) 
where Di (cm2/s) is the effective diffusivity of oxygen in subdomain i, Ci (mol/cm3) is the 
concentration of oxygen in subdomain i, and Vi (mol/cm3/s) is the local oxygen consumption rate 
per unit volume in subdomain i.  For convenience, since partial pressures are equal across 
interfaces of different materials, we make use of oxygen partial pressure instead of 
concentration, which are related by 
 C = αP  (5-3) 
where α (mol/cm3/mmHg) is the effective Bunsen solubility coefficient in subdomain i and P is 
the partial pressure of oxygen.  Combining  Eq. (1) and Eq. (2) gives   
 ( ) 2i i iαD P = V∇  (5-4) 
The oxygen consumption rate is assumed to follow Michaelis-Menten kinetics for all tissue, 
 max i ii
m i
V ε P
V  = 
K +P
 (5-5) 
where Vmax is the maximum oxygen consumption rate for the tissue, εi is the tissue volume 
fraction in subdomain i, and Km is the Michaelis-Menten constant.  No oxygen is consumed in 
the alginate, cell culture media, or silicone rubber subdomains; therefore Vi is equal to zero in 
those subdomains, and the tissue volume fraction in the islet or aggregate subdomains is equal to 
one. 
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The model was solved by the finite element method using the commercially available 
software package COMSOL Multiphysics in combination with MATLAB and using the model 
parameters in Table 3-1.  (3-4) was solved simultaneously for all subdomains of the culture 
system subject to the following conditions.  There are planes of symmetry on the sides of the unit 
cell where the media or capsule was cut and thus zero flux of oxygen across these boundaries.  
At the boundary between a tissue subdomain and the alginate subdomain or the alginate 
subdomain and culture media the partial pressure of oxygen and the flux of oxygen across the 
boundary are both equal.  For the case of capsules cultured on polystyrene the bottom of the 
culture dish is assumed to be impermeable to oxygen and the flux across that boundary is zero.   
For the silicone rubber bottom culture condition, the oxygen partial pressure and flux of oxygen 
across the boundary are equal at the culture media and silicone rubber boundary.  The bottom 
boundary of the silicone rubber membrane is at the partial pressure of oxygen in the gas phase.  
The external partial pressure of oxygen in the gas phase is specified and it is assumed that the top 
surface of the culture media is at the gas phase partial pressure of oxygen.   
The fractional viability of the encapsulated tissue was estimated by determining the 
volume fraction of tissue where P>PC.  PC is the critical oxygen partial pressure below which 
tissue dies and the value of PC is assumed to be 0.1 mmHg [23].  The fractional viability was 
calculated using the following equation: 
 Viable
Tissue
V
Fractional Viability=
V
 (5-6) 
where VViable is the volume of tissue where P is greater that 0.1 mmHg and VTissue is the total 
encapsulated tissue volume. 
 The relationship used to predict the local fraction (FI) of normal insulin secretion rate as a 
function of local oxygen partial pressure within the islet was developed from data on the effect of 
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hypoxia on islet insulin secretion, estimating the oxygen partial pressure profile within the islet 
in the experimental system, and then determining the simplest model type and parameter(s) that 
best predict the insulin secretion level [44, 93].   
 I
I
PP <  P* mmHg     F  = 
P*
P  P* mmHg     F  =  1.0≥
 (5-7) 
When Vmax equals 6x10-8 mol/cm3/s, P* equals 1.1 mmHg [93].   A value of Vmax of 6x10-8 
mol/cm3/s was used for the predictions of encapsulated tissue viability and function in culture 
because it corresponds to an OCR per cell of 4 fmol/min/cell which is within the range that was 
measured for rat islets used in these experiments.  The fraction of normal insulin secretion 
averaged over all tissue within the microcapsule was determined by evaluating the volume 
integral of FI in all tissue containing subdomains 
 
I
S
Viable
Tissue
FdV
F =
V
∫
 (5-8) 
where FS is the fraction of normal insulin secretion averaged over all of the encapsulate tissue. 
    
5.3 MODELING RESULTS 
Traditional cell culture is carried out in polystyrene dishes which have a bottom that can 
be assumed to be impermeable to oxygen.  We performed calculations to predict the fractional 
viability for islet capsules with and without perfluorocarbon emulsion cultured on polystyrene 
dishes over a range of oxygen levels.  We performed these calculations in order to determine 
what gas phase oxygen level should be used for in vitro culture experiments in order to show that 
islets survive better in PFC containing microcapsules.  The predicted differences in fractional 
viability of islets were not as great between the normal alginate and PFC alginate capsules as we 
 169
would have hoped based on previous theoretical predictions with a specified capsule surface PO2 
(Figure 5-2A-C).  When cultured on polystyrene the prediction fractional viabilities were very 
dependent on tissue surface density.  We also performed calculations in which the capsules were 
cultured in oxygen permeable silicone rubber bottom dishes (Figure 5-2D-F) which have been 
previously used to enhance oxygen transport to islets cultured at PO2 of 142 mmHg and for better 
oxygen control during embryonic stem cell differentiation at low oxygen [109, 110]. 
Calculations predicted greater differences in encapsulated islet survival, tissue could survive at 
lower gas phase oxygen levels for both capsule types, and the predicted viabilities had less of a 
dependence on surface density.  The silicone rubber membranes allow for better oxygen control 
to the encapsulated islets and maximize the predicted differences in tissue survival.  Silicone 
rubber membranes were therefore used for in vitro experiments to demonstrate that islets in PFC 
capsules will survive better than islets in normal alginate in low oxygen.   
Calculations were performed to predict the fraction of normal insulin secretion and 
fractional viability of encapsulated islets with and without PFC emulsion in the microcapsule 
cultured on silicone rubber over at a gas phase oxygen level of 3.5 mmHg or 0.5% oxygen.  
These calculations were used to determine what gas phase oxygen level should be used during in 
vitro experiments to observe that islets in PFC alginate microcapsules function and survive better 
in low oxygen than islets in normal alginate microcapsules.  At a gas phase oxygen level of 
3.5 mmHg (0.5%) islet survival is predicted to be greater in PFC alginate capsules compared to 
normal alginate capsules (34% versus 23%) at low surface densities (Figure 4-3A).  Insulin 
secretion is significantly impaired for both tissue types (<20%) (Figure 4-3B).  We chose to 
culture tissue at a gas phase PO2 of 3.5 mmHg in order to ensure that there would be loss of tissue 
in the normal alginate capsules, but still greater survival rates in the PFC alginate capsules. 
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5.4 MATERIALS AND METHODS 
5.4.1 Animals 
Male Sprague-Dawley rats weighing 200-250 g (Harlan Sprague-Dawley, IN) were used 
as islet donors. Lewis rats were used as recipients of empty capsule transplants. Animals were 
kept in a conventional animal facility with free access to food and water.  All animal experiments 
were approved by the Joslin Animal Care Committee.  
5.4.2 Islet Isolation 
Rat islets were isolated according to standard techniques [70]. Briefly a laparotomy was 
performed under anesthesia with Ketamine/Xylazine. The common bile duct was cannulated and 
8-10 ml of rodent Liberase RI ((Roche) 0.33 mg/ml) in M199 media was injected. The pancreas 
was then removed and incubated in a circulating water bath at 37oC for 24.5 minutes. The 
digested pancreatic tissue was washed with M199 containing 10% newborn calf serum 
(Mediatech) and then strained through 400 μm wire mesh (Thomas Scientific). Islets were 
purified by centrifugation at 1750xg for 17 minutes through a discontinuous Hisotpaque 1077 
gradient (Sigma Aldrich). Islets were handpicked under a dissecting microscope, counted, and 
then cultured overnight at a density of up to 30 islets/cm2 and a media height of 1.3 mm. Islet 
culture media was RPMI 1640 supplemented with 10% fetal bovine serum, penicillin 100 
units/ml and 100 μg/ml streptomycin (Mediatech). 
5.4.3 PFC Emulsion Preparation 
A perfluorocarbon emulsion made from perfluorodecalin (Fluoromed, Round Rock, TX) and 
20% (w/v) Intralipid® (Baxter, Deerfield, IL) (a soybean oil emulsion with composition 20% 
(w/v)  soybean oil, 1.2% (w/v) egg yolk phospholipids, 2.3% (w/v) glycerin with balance water) 
was prepared similarly to a previously developed emulsion to be used a blood substitue 
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(Schweighardt and Kayhart 1990).  40 ml of Intralipid was added to the holding vessel of an 
M110Y Microfluidizer (Microfluidics, Newton, MA) and recirculated for 2 minutes at an 
operating pressure of 14,500 psi.  Upon exit from the interaction chamber, before returning to the 
holding reservoir, the liquid was passed through a cooling coil during all instrument operation.  
11.25 ml of perfluorodecalin was added dropwise over 3 minutes to the holding vessel while the 
emulsion was being recirculated.  The instrument and contents sat without running for 5 minutes 
to cool and for the ice bath to be changed.  The remainder of the perfluorodecalin (11.25 ml) was 
added dropwise to the holding vessel over three minutes while the emulsion was recirculated.  
After all of the emulsion components had been added the emulsion was recirculated for 5 
minutes before being collected.  The final PFC content of the emulsion was 70% (w/v). 
5.4.4 Microencapsulation 
Microcapsules were produced using highly purified sterile alginate.  The exact 
concentrations and type of alginate varied depending on the experiment and if PFC emulsion was 
contained in the capsule.  For normal alginate capsules a concentration of 1.5% (w/v) SLG100 
(FMC Polymer, Norway) was used for in vitro experiments and a concentration of 1.9% (w/v) 
SLM100 (FMC Polymer, Norway) was used for transplant experiments both alginate types were 
dissolved in 0.9% (w/v) NaCl solution. For PFC alginate capsules a concentration of 0.5% (w/v) 
SLG100 was used for in vitro experiments and a concentration of 0.63% (w/v) SLM100 was 
used for transplant experiments both alginate types were dissolved in 70% (w/v) PFC emulsion.  
The final PFC concentration in the microcapsules was 70% (w/v).  Islets were washed with 
calcium free Krebs buffer (135 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 
25 mM HEPES, pH 7.4) and then resuspended in alginate to form a tissue-alginate suspension.  
Microcapsules were produced by extrusion of the alginate-tissue suspension for in vitro 
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experiments or pure alginate solution for in vivo experiments through a needle using an 
electrostatic droplet generator (Pronova Polymer, Norway) into a stirred 20 mM BaCl2 solution. 
Microcapsules ranged in size from 350 μm to 600 μm in diameter with an average for each batch 
between 400 μm and 500 μm. After sequential washes in HEPES buffer (132 mM NaCl, 4.7 mM 
KCl, 1.2mM MgCl2, 25 mM HEPES, pH 7.4) and Krebs buffer (133 mM NaCl, 4.7 mM KCl, 
1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, 2.5 mM CaCl2, pH 7.4) the microcapsules 
were placed into culture.  Some of the capsules used for the transplantation experiments were 
coated by two different methods.  The coating of PFC alginate capsules with poly-L-lysine 
(PLL) and alginate used in the transplantation experiments were prepared as follows.  After the 
wash with HEPES buffer the capsules were placed in a 0.1% PLL solution in calcium free Krebs 
buffer for 10 minutes, washed with calcium free Krebs buffer, placed in 0.19% (w/v) SLM100 
alginate in calcium free Krebs buffer for 6 minutes, washed with calcium free Krebs buffer, and 
then with Krebs buffer.  The second type of coated capsules had a pure alginate coating that was 
prepared after the HEPES buffer wash by placing the capsules in 0.19% (w/v) SLM100 in 
calcium free Krebs buffer for 6 minutes, washing the capsules with calcium free Krebs, 
transferring the capsules into 20 mM BaCl2 for 5 minutes, washing the capsules with HEPES 
buffer, and finally with Krebs buffer. 
5.4.5 Encapsulated Tissue Culture 
Capsules that were cultured in 1% oxygen were placed in 100 cm2 silicone rubber flasks 
(PR-AY-5-0017-5 from Wilson Wolf Manufacturing Inc., New Brighton, MN) in islet culture 
media at a depth of 2.5 mm, at a density of less than 30 IE/cm2 The silicone rubber flasks were 
placed in a sealed humidified chamber within in an incubator at 37oC that was continually 
flushed with 1% O2, 5% CO2, and balance N2. Capsules to be cultured at 0.5% oxygen were 
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placed in 24 well plates that were custom made to contain silicone rubber bottoms (PR-AY-7-
0004, from Wilson Wolf Manufacturing Inc., New Brighton, MN) in islet culture media at a 
depth of 10 mm at a density of 50-200 IE/cm2 and then placed into a humidified incubator 
(Xvivo from Biospherix Ltd., Redfield, NY) where the gas levels were controlled to be at 5% 
CO2, 0.5% O2, and with balance N2.  Capsules were cultured for two days under these conditions 
for the in vitro experiments.  
5.4.6 Oxygen Consumption Rate (OCR) 
The oxygen consumption rate measurements were performed as previously described 
(Chapter 2 and [66]). Islet microcapsules were resuspended in DMEM without phenol red 
containing 4.5 g/l glucose supplemented with 0.6 g/l L-glutamine, 100 units/ml penicillin, 
100 µg/ml streptomycin, 10 mM HEPES (all from Mediatech Inc., Herdon, VA) without serum 
for OCR measurements.  Phenol red free media was required such that the media would be 
colorless as to not interfere with the absorbance measurements associated with the alginate or 
PFC emulsion content assays.  The tissue microcapsule samples were added to a 200 μl stirred 
titanium chamber maintained (Micro Oxygen Uptake System FO/SYSZ-P250, Instech 
Laboratories, Plymouth Meeting, PA) at 37oC [66].  After the samples equilibrated with air at 
37oC the chambers were sealed.  The time dependent PO2 within the chamber was recorded with 
a fluorescence-based oxygen sensor (Ocean Optics, Dunedin, FL), and the data at high PO2 was 
fit to a straight line. The maximal OCR was evaluated from OCR=Vchα(ΔPO2/Δt), where Vch is 
the chamber volume and α is the effective Bunsen solubility coefficient for the contents of the 
OCR chamber and must be adjusted for the presence of PFC and soybean oil in the 
microcapsules. 
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5.4.7 Capsule Dissolution 
Many of the quantitative measures of encapsulated tissue - nuclei counts, DNA content, 
alginate content, or insulin content require that the capsule first be dissolved.  After OCR 
measurements were complete the tissue was collected from the chamber in order to determine the 
tissue and capsule quantity corresponding to each measurement.  Tissue was removed from the 
microcapsules by adding 800 μl of 100 mM tetrasodium EDTA (pH=8) to approximately 300 μl 
of a capsule suspension.  The samples were placed in an incubator at 37oC for 1 and were vortex 
mixed every 30 minutes at which point the capsules had dissolved.  
 
5.4.8 Nuclei Counts 
Nuclei suspensions were prepared and quantified as described in Chapter 2. 200 µl 
aliquot of islet tissue from dissolved capsules (~ 2.5 x 106 cells/ml or 125 IEQ/ml) was 
resuspended in 100 µl of PBS and then incubated in a lysis solution (0.1 M citric acid and 10% 
(v/v) Triton X-100 (Sigma Aldrich)) for 15 min with vortex mixing every 5 minutes.  Next the 
nuclei sample was sheared through a needle to liberate all nuclei.  100 µl of 100mM tetrasodium 
EDTA was added to the nuclei suspension to prevent alginate gelling prior to nuclei counting. 
The liberated nuclei were stained with 0.8 µM LDS 751 and 0.2 µM Sytox Orange (Invitrogen,) 
in D-PBS and counted using a benchtop flow cytometer (Guava Personal Cell Analyzer, Guava 
Technologies, Hayward, CA).  
 
5.4.9 Alginate Content 
The alginate content of samples were assayed by a method adapted from the literature 
using dimethyl methylene blue (DMMB)  (Sigma Aldrich) dye which is a cation that binds to 
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polyanions such as alginate(Chapter 2, [72]).  The ratio of the absorbance of a sample at the 
wavelengths of 520 nm and 650 nm increased linearly with increases in alginate concentration. 
 
5.4.10 PFC Emulsion Content 
The PFC emulsion content of samples were assayed by measuring the absorbance of 
diluted PFC emulsion samples.  The emulsion content could be assessed by absorbance because 
due to the emulsion particle size (400 nm) the emulsion is opaque and thus at dilute 
concentrations the absorbance of a sample at any wavelength increases linearly with increasing 
emulsion content.  We chose to measure the absorbance at 620 nm. 
5.4.11 Histology 
Encapsulated islets or islet cell aggregates were fixed in 2.5% (w/v) glutaraldehyde in 
0.1M phosphate buffer pH 7.4. Plastic 1-μm thick sections were generated and stained with 
toluidene blue (Thermo Fisher Scientific). 
5.4.12 Transplantation of Microcapsules into the Peritoneal Cavity 
Microcapsules were injected into the peritoneal cavity of recipient rats through a central 
midline 5-10 mm incision using a sterile plastic transfer pipette (Fisher Scientific, Chicago, IL). 
The incision was closed using 5/0 silk, the outer layers were stapled. The animals were under 
anesthesia with Ketamine/Xylazine.  Capsules were retrieved 2 weeks after transplantation by 
laparotomy and peritoneal lavage.  Capsules were washed in PBS and prepared for paraffin 
sections. 
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5.4.13 Paraffin Sections 
Capsules were fixed in buffered formalin for 1 hour.  Capsules were embedded in 2% 
(w/v) agar, embedded in paraffin, sectioned, and stained with hematoxylin to label cells on the 
capsule exterior.  Slides were then examined under a microscope and it was determined whether 
or not they elicited an immune reaction.  It was necessary to look at the capsule sections to 
determine the degree of immune reactions because due to the complete opacity of the PFC 
containing capsules the cells on the capsule exterior could only clearly be observed after 
sectioning. 
 
5.4.14 Statistics 
Data are expressed as average ± standard deviation. Statistical significance was 
determined by a two-way Student t-test. 
5.5 RESULTS 
5.5.1 OCR and Tissue Recovery 
Oxygen consumption rate (OCR) measurements of encapsulated islets were performed on 
the day of encapsulation and again after two days of culture under low (0.5% or 1%) oxygen 
conditions.  The OCR is measured for a sample of capsules, and then the capsules are removed 
from the chamber and dissolved.  The dissolved capsule tissue and alginate suspension can be 
analyzed to determine nuclei count, alginate content (normal alginate only), or PFC emulsion 
content of the sample within the OCR chamber.  The alginate content or PFC emulsion content is 
measured in order to normalize the OCR results by the volume of capsules in the chamber.  OCR 
recovery, a measure of the fractional recovery of viability tissue from culture, is calculated from 
the measured values of OCR per ml capsule using the following equation: 
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( )
( )
After 2 Day Culture
After Encapsulation
OCR per ml capsule
Fractional OCR Recovery = 
OCR per ml capsule
 (5-9) 
OCR recovery was assessed for capsules containing islets with or without PFC emulsion cultured 
for two days in 0.5% oxygen in one experiment (Figure 5-4).  The fractional OCR recovery in 
low oxygen for capsules containing islets and PFC was 0.91 indicating reduced oxygen 
limitations compared to an OCR recovery of 0.59 for the capsules containing islets without PFC.  
These results seem to indicate the PFC emulsion in the alginate microcapsule enhances tissue 
survival in low oxygen. 
Prior to the one experiment at 0.5% oxygen many experiments (n=11) were performed in 
which islets were encapsulated in alginate with and without a PFC emulsion and cultured at 1% 
oxygen.  The OCR and tissue recovery were then measured.  Fractional tissue recovery from 
culture based on nuclei counts is calculated by the following equation:   
 
( )
( )
After 2 Day Culture
After Encapsulation
Nuclei per ml capsule
Fractional Tissue Recovery = 
Nuclei per ml capsule
 (5-10) 
The alginate or PFC emulsion content of the sample is measured to normalize the nuclei count by 
the total volume of capsules in the sample due to the high variability of capsule sampling.  The 
results of the experiments at 1% oxygen were highly variable as can be seen by the large error 
bars even though the sample number is quite high and there was no difference in OCR recovery 
for either tissue type, but there was a significantly less tissue recovery in the PFC containing 
capsules compared to the normal alginate capsules (Figure 5-5).  The loss of total tissue but not 
viable tissue indicated that something else was going on with the islets in the PFC emulsion 
containing capsules.  There was a minimal loss of OCR recovery for either capsule type 
indicating that oxygen was not limiting enough to cause tissue death.  Upon further analysis the 
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silicone rubber culture vessels used for 1% oxygen culture have a head space of about half a liter 
and no filter in cap for gas exchange.  Potentially the large volume of air at atmospheric oxygen 
trapped in the flask initially continued to supply oxygen to the tissue throughout the two days of 
culture and thus limited the extent of tissue loss.  The culture vessel was changed for the 0.5% 
experiments in order to not trap large amounts of atmospheric levels of oxygen in the culture 
system with the use of a 24 well plate with silicone rubber bottom wells that allows for gas 
exchange in the head space, a much smaller head space, and delivery of oxygen through the 
silicone rubber membrane at the bottom of the device. 
 From the measurements of OCR and nuclei one can also calculate the oxygen 
consumption rate per cell (Figure 5-6).    The OCR per cell results were unusual for islets in PFC 
containing microcapsules.  There was no change in OCR per cell for islets in normal alginate 
capsules between the two days of the experiment, but there was a significant increase in OCR per 
cell for islets in PFC containing capsules after two days of culture at 1% oxygen.  At either 
experimental time point, pre-culture or after two days of culture at 1% oxygen the measured 
OCR per cell was significantly higher in the PFC containing capsules compared to the islets in 
the normal alginate capsules.  The presence of PFC in the microcapsule appears to favorably 
influence oxygen consumption rates.  
 
5.5.2 Histology 
 Histological sections of islet capsules with and without a perfluorocarbon emulsion 
cultured in 1%  or 20% oxygen for two days were prepared to examine the health of the tissue 
following culture (Figure 5-7).  In Figure 5-7A,D an islet in a normal alginate capsule shows 
signs of central necrosis as there is lighter toluidene blue staining at the center of the islet.  In 
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Figure 5-7B,C,E,F a histological section of an islet in a PFC alginate capsulr the cells at the 
exterior of the islet, indicated by the arrow, are dead.  In Figure 5-7F there appear to be reduced 
signs of central necrosis after culture in 1% oxygen as the capsules at the center are not lightly 
stained.   In all section of islets in PFC capsules it was observed that cells that were in contact 
with the PFC alginate were dying leading us to believe that some component of the PFC 
emulsion is toxic to the islets.   
 In order to investigate further which component of the PFC emulsion was toxic to the 
islets, unencapsulated islets were cultured for two days in standard islet culture media (Figure 
5-8A), at the interface between pure perfluorodecalin and islet culture media (Figure 5-8B), or 
islet culture media that contained Intralipid® (a soybean oil emulsion) (Figure 5-8C).  The islets 
in standard islet culture media appear to be healthy.  The islets cultured on top of 
perfluorodecalin also appear to be healthy with no signs of dead cells at the islet exterior.  The 
islets tended to clump on top of the perfluorodecalin, but this could be due to the hydrophobic 
nature of perfluorodecalin.   Islets cultured in media that contained Intralipid® do not look 
healthy and dead cells are present at the islet exterior.  Based on histological analysis it seems 
that the toxic component of the PFC emulsion is the Intralipid®.   
 
5.5.3 Empty PFC Capsule Transplants 
 Empty alginate capsules of four types: (1) no PFC emulsion 1.9% (w/v) alginate, (2) PFC 
emulsion 0.63% (w/v) alginate, (3) PFC emulsion 0.63% (w/v) alginate coated with pure 
alginate, and (4) PFC emulsion 0.63% (w/v) alginate coated with poly-L-lysine and alginate 
were transplanted into the peritoneal cavity of Lewis rats for 2 weeks.  The PFC emulsion that 
was incorporated into the microcapsules was 70% (w/v) perfluorodecalin.     At two weeks the 
 180
animals were sacrificed and the capsules were recovered from the peritoneal cavity.  Alginate 
capsules that did not contain PFC emulsion caused no immune response in vivo as no cells were 
detected attached to the capsule surface after retrieval (Figure 5-9A).  Capsules containing PFC 
emulsion with no additional coatings or only a pure alginate coating elicited a strong immune 
reaction as can be seen in the histological sections where the capsules are covered with many 
layers of cells (Figure 5-9B and C).  Capsules containing PFC emulsion were biocompatible 
when a poly-L-lysine and pure alginate coatings were applied to the outside as again no cells 
were attached to the outside of the capsules after transplantation (Figure 5-9D).  An effectively 
bound coating of the PFC capsules consisting of poly-L-lysine and alginate was necessary in 
order to make the capsules biocompatible.  
5.6 DISCUSSION 
The PFC emulsion that was incorporated into the alginate microcapsules proved to be 
toxic to encapsulated islets as observed by histology.  Upon further examination by culturing 
naked islets in each of the emulsion components (perfluorodecalin or soybean oil emulsion) the 
component of the PFC emulsion that was toxic to islets was the soybean oil emulsion and not the 
PFC itself.  The fact that we observed that a soybean oil emulsion was toxic to islets is not 
surprising as culture of islets in free fatty acids (the components of soybean oil) can induce 
apoptosis and reduces insulin secretion during long term culture [117-120].  The histology 
samples with islets cultured on top of perfluorodecalin showed that the islets tended to clump 
and in some cases there were no signs of central necrosis with very large tissue sizes.  Potentially 
the presence of the perfluorodecalin in the culture flask was actually enhancing oxygen transport 
to the large tissue aggregates.  This is only a general observation and was not quantified in any 
sort of systemic way, and there was some tissue that showed signs of central necrosis.   
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 The OCR and nuclei recovery results for islets cultured in microcapsules with and 
without PFC emulsion at 1% oxygen were puzzling.   There was no difference in OCR recovery 
for islets in the two capsule types, but there was a loss of tissue in the PFC containing 
microcapsules.  The loss of tissue would be consistent with the fact that we observed cell death 
by histological analysis, but cell death was not detected by OCR recovery a proven method of 
measuring tissue loss due to oxygen transport limitations [110].  One potential explanation for a 
greater loss of tissue as compared to oxygen consumption is that the soybean oil emulsion in the 
microcapsule was stimulating insulin secretion.  It has been reported that treatment of islets with  
free fatty acids, the components of soybean oil, for several hours can induce insulin or glucagon 
secretion [121].  The effect of free fatty acids on islets is complex as they are toxic in the long 
term, but stimulate insulin secretion in the short term.  OCR has also been shown to increase 
with increases in insulin secretion in response to glucose [122].  Potentially the soybean oil 
emulsion is stimulating the islets to secrete insulin and thus increasing their oxygen consumption 
rate on a per cell basis in comparison to the islets in alginate microcapsules without PFC.  The 
OCR recoveries presented at 0.5% oxygen look promising in that there is more tissue survival in 
capsules with PFC containing microcapsules, but all of these results are difficult to interpret as 
the effects of the soybean oil on the islets are complicating the interpretation of the data.   
 The experiment that was performed where encapsulated islets were cultured in 0.5% 
oxygen did show tissue death in the normal alginate capsules.  We were able to actually induce 
death in the normal alginate capsules because a culture system was used that was not trapping 
large amounts of atmospheric oxygen levels in the culture system.  It seems that this culture 
system is much better suited to carry out low oxygen culture experiments.  The loss of tissue in 
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alginate capsules cultured at 0.5% oxygen is at least keeping with the theoretical predictions that 
the fractional viability should only be 20%; however the actual loss of tissue was not as severe. 
 In order to make the PFC emulsion containing microcapsules biocompatible after 
transplantation into the peritoneum of Lewis rats a poly-L-lysine and pure alginate coating 
needed to be applied to the capsules exterior.  It is unknown whether with a new emulsion 
formulation that does not contain soybean oil whether this will be necessary.  Potentially the 
soybean oil was toxic to tissue in the peritoneum and thus this is what caused the immune 
reaction.  When a new formulation is developed the biocompatibility of capsules with and 
without coatings should be tested. 
There is a potential for perfluorocarbons to be used to enhance oxygen transport to islets 
as pure perfluorocarbons do not appear to be toxic.  A different PFC emulsion formulation needs 
to be developed which does not contain soybean oil.  This new emulsion will likely be a suitable 
material to enhance the oxygen permeability of encapsulation materials.  The theoretical 
predictions in Chapter 3 and this chapter have shown that a PFC emulsion can enhance the 
oxygen delivery to encapsulated tissue which in turn increases fractional viability and insulin 
secretion.   Unfortunately due to the toxic side effects of the PFC emulsion we were not able to 
show that a PFC emulsion conclusively enhanced oxygen transport to encapsulated islets, but the 
approach warrants further investigation.  When a non-toxic PFC emulsion is developed the 
experimental approach of culturing the encapsulated islets on silicone rubber and performing 
OCR and nuclei measurements should be performed to evaluate if the PFC emulsion can enhance 
islet survival in low oxygen. 
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Contributions:  Islet isolations were performed with the assistance of Esther O’Sullivan, 
Jennifer Hollister-Lock, Vaja Tchipasvilli, and Vassileios Kostaras from Joslin Diabetes Center.  
Histology sections were prepared by Chris Cahill (Joslin DERC).  Abdulkadir Omer provided 
instruction on the preparation of microcapsules and performed the empty capsule transplants 
with my assistance.  Susan Bonner-Weir assisted in the evaluation of the histological sections.   
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Figure 5-1:  Sketches of example model geometries for microcapsules containing one 150-µm 
islet in culture on either an oxygen impermeable bottom (A) or an oxygen permeable silicone 
rubber bottom culture dish (B).    
The dashed lines represent the unit cell in which the oxygen profile was calculated. 
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Figure 5-2: Comparison of predicted fractional viability for islets cultured in normal alginate 
(solid lines) or PFC alginate (dashed lines) capsules on polystyrene (A-C) or silicone rubber (D-
F).   
Predictions were made for a gas phase oxygen level of 142 (A,D), 36 (B,E), or 7 (C,F) mmHg. 
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Figure 5-3: Comparison of predictions of fractional viability (A) and insulin secretion (B) for 
islets encapsulated in PFC alginate (dashed lines) and normal alginate (solid lines) cultured on 
silicon rubber at a gas phase oxygen partial pressure of 3.5 mmHg (0.5%). 
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Figure 5-4:  Measured fractional OCR recovery for islets in normal alginate or PFC alginate 
capsules cultured for two days at 0.5% oxygen from triplicate measurements in one experiment.  
The results were not statistically different based on a t-test p>0.05.   
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Figure 5-5: Measured fractional recoveries of oxygen consumption and tissue after culture for 
two days in 1% oxygen for islet capsules (black bars) or islet capsules with PFC (grey bars). 
There was no difference in OCR recoveries for either type of capsule (p>0.05 by unpaired 
student t-test), but there was a significant more loss of total tissue in the PFC containing capsules 
(* p<0.05 by unpaired student t-test). 
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Figure 5-6: Measured oxygen consumption rater per cell before and after culture for two days in 
1% oxygen for islet capsules (black bars) or islet capsules with PFC (grey bars).   
There was no difference in OCR per cell for islet capsules between the two days (p>0.05 by 
unpaired student t-test), but there was a significant increase in OCR per cell in the PFC 
containing capsules (* p<0.05 by unpaired student t-test).  Also at each experimental time point, 
prior to culture or after two days of culture at 1% oxygen the OCR per cell was significantly 
higher in the PFC containing capsules. 
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Figure 5-7: Histological sections of islets in microcapsules with and with PFC. 
(A) normal alginate microcapsule after two days of culture 20 % oxygen– there are signs of 
central necrosis in the larger islet (*) as there is only light staining at the islet center. (B,E) 70% 
(w/v) PFC alginate microcapsule with islets on the day of encapsulation, there are already signs 
of toxicity as dead cells are found at the islet exterior. (C) 70% (w/v) PFC alginate microcapsule 
with an islet after two days of culture in 20% oxygen, there are signs of dead cells at the islet 
exterior.  (D) normal alginate microcapsule after two days of culture in 1% oxygen there are 
signs of central necrosis.  (F) 70% (w/v) PFC alginate microcapsule after two days of culture in 
1% oxygen – there appear to be reduced signs of central necrosis as the tissue at the center of the 
islet appears healthy.  The arrows indicate dead cells at the islet exterior due to toxic effects of 
the PFC alginate. 
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Figure 5-8: Histological sections of naked islets cultured under normal oxygen for two days. 
(A) naked islet in islet culture media – tissue appears healthy (B) naked islets cultured in islet 
culture media on top of pure perfluorodecalin – tissue appears healthy, but clumping occurred.  
(C) naked islets cultured in islet culture media containing Intralipid – arrow indicates dead cells 
most likely due to toxicity of Intralipid. 
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Figure 5-9:  Paraffin sections of empty capsules transplanted into the peritoneal cavity of Lewis 
rats for two weeks stained with hematoxylin. 
(A) 1.9% (w/v) Alginate (B) 70% (w/v) PFC 0.63% (w/v) Alginate (C) 70% (w/v) PFC 0.63% 
(w/v) Alginate coated with Alginate (D) 70% (w/v) PFC 0.63% (w/v) Alginate coated with PLL 
and Alginate. 
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Table 5-1:  Model parameters 
 
 Parameter Symbol Value Units Source 
O2 diffusivity in media Dm 2.78x10-5 cm2/s [23] 
O2 diffusivity in tissue Dt 1.24x10-5 cm2/s [23] 
O2 diffusivity in silicone rubber Dsr 2.17x10-5 cm2/s [116] 
O2 solubility in media αm 1.27x10-9 mol/mmHg/ml [23] 
O2 solubility in tissue αt 1.00x10-9 mol/mmHg/ml [23] 
O2 solubility in silicone rubber αsr 1.21x10-8 mol/mmHg/ml [116] 
O2 permeability in 2% (v/v) alginate αDAlg 3.43x10-14 mol/cm/mmHg/s [23] 
O2 permeability in 70% (w/v) PFC 
2% (v/v) alginate αDPFC,Alg 9.63x10
-14 mol/cm/mmHg/s [123] 
Maximum  oxygen consumption rate Vmax 4x10-8, 6x10-8 mol/cm3/s [23], experiment
Michaelis-Menten Constant Km 0.44 mmHg [23] 
Insulin Secretion Model Parameter P* 5.1, 1.1 mmHg [93] 
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Chapter 6 Appendix 
 
6.1 Effective Permeability and Solubility Calculations  
The pure component solubility, diffusivity and permeability were found in the literature for 
each different type of material present in our model (Table 6-1).  The effective solubility of each 
multicomponent phase modeled in the system was calculated by taking a volume average of the 
solubility of each pure component.  The list of the volume fractions of each type of multiphase 
component are listed in Table 6-2 along with the volume averaged effective solubility. 
The effective permeability in subdomains containing several components was determined 
from theoretical relationships.  The ratio of the effective permeability (αD)eff,i for subdomain i 
consisting of a dispersed (d) phase and a continuous (c) phase (as occurs in the alginate 
subdomains of the model system) to the permeability of the continuous phase (αD)c was 
calculated from Maxwell’s relationship [75] 
 
( )
( )
eff,i
c
αD 2-2 +ρ(1+2 ) = 
αD 2+ +ρ(1- )
φ φ
φ φ  (6-1) 
 
where αD is the permeability of the material (mol/cm/mmHg/s), ( ) ( )d cρ= αD αD  is the ratio of 
the permeability of the dispersed phase to the permeability of the continuous phase, and φ  is the 
volume fraction of the dispersed phase.  For the multiple dispersed phases employed in our 
model system, Maxwell’s relationship was used sequentially, starting with the phase with the 
smallest particle size and ending with the phase with the largest particle size.  For particle types 
of the same size, Maxwell’s relationship was used for one particle, then the other (and in the 
reverse order), and the two results were averaged.   
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For the alginate capsules that contained PFC emulsion and cells Maxwell’s relationship 
was used in the following order.  The perfluorocarbon emulsion that we have been studying in 
the lab consists of 70% (w/v) perfluorodecalin and 20% (w/v) Intralipid® (Baxter), a soybean oil 
emulsion, and a PFC emulsion of this composition will be what is used in all model simulations 
that contain PFC alginate [71].  In the final PFC alginate composite phase, there were 
perfluorodecalin and soybean oil droplets of approximately the same size (0.4 µm mean diameter 
based on a volume average as measured by dynamic light scattering with Nanotrac, Microtrac 
Inc. Mongomeryville, PA); the alginate polymer itself was treated as an impermeable phase 
dispersed in water (Figure 6-1).  The effective permeability of PFC emulsion was estimated by 
first using Maxwell’s relationship for soybean oil droplets in water and then for PFC droplets in 
the soybean oil and water emulsion.   Secondly, Maxwell’s relationship was used for PFC 
droplets in water and then for soybean oil droplets in the PFC and water emulsion.  The two 
calculated effective permeabilites were averaged (Figure 6-2).  Finally, the effective permeability 
of PFC alginate was estimated with alginate as the dispersed phase and PFC emulsion as the 
continuous phase.  For the case of single cells in normal alginate, Maxwell’s relationship was 
first used to calculate the effective permeability of a dispersed tissue phase in water and then for 
alginate in the tissue and water emulsion.  For single cells in PFC alginate, first the effective 
permeability of the PFC emulsion was calculated as described above, then the effective 
permeability of a dispersed tissue phase (diameter of a cell ~10 µm is greater than the emulsion 
particles 0.4 µm) in the PFC emulsion, and finally the overall effective permeability is calculated 
for a dispersed alginate phase in the PFC and tissue emulsion.  The detailed description the 
calculations of effective permeability are contained in Table 6-3 through Table 6-6.  The 
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effective diffusivities that were used in Chapter 2 were calculated by dividing the effective 
permeability by the effective solubility. 
The enhancement of PFC emulsion permeability relative to that of water or to the 
Intralipid® emulsion that is used as the starting material is shown in Figure 6-3.   A 70% (w/v) 
PFC emulsion has approximately 2.8 times the permeability of water and 2.1 times the 
permeability of Intralipid®.  There is a smaller relative enhancement in the permeability of the 
emulsion when compared to Intralipid® because Intralipid® contains soybean oil, which has an 
enhanced permeability to oxygen as compared to water.   In comparison, a 90% (w/v) PFC 
Emulsion (maximum PFC loading in our experimental system) has 3.6 times the permeability of 
water, and a 110% (w/v) PFC emulsion (maximum reported loading for a PFC emulsion in the 
literature) has 4.6 times the permeability of water.   
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Figure 6-1: A schematic drawing of the components of PFC alginate which consists of PFC and 
soybean oil droplets suspended in an alginate matrix with a continuous water phase. 
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Figure 6-2: Sequence of calculations performed using Maxwell's relationship to calculate the 
effective permeability of PFC emulsion. 
PFC emulsion consists of three phases: PFC droplets, soybean oil droplets, and water as the 
continuous phase. 
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Figure 6-3: Permeability enhancement of PFC emulsion relative to water (left axis, solid line) or 
Intralipid® (right axis, dashed line) 
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Table 6-1:  Diffusion coefficient (D), Bunsen solubility coefficient (α) or permeability 
coefficient for oxygen in all pure components in microcapsules. 
Parameters are from the literature.  The cell concentration in the microcapsules is 2.4x107 
cells/ml. 
  D (cm2/s) α  (mol/mmHg/ml) 
α D 
(mol/cm/mmHg/s) Source 
Tissue (t) 1.24x10-5 1.00x10-9 1.24x10-14 [23] 
Alginate (a) 0 0 0 [23] 
PFC (pfc) 5.61x10-5 2.54x10-8 1.42x10-12 [76] 
Soybean Oil (soy) 2.13x10-5 6.84x10-9 1.46x10-13 [77, 78] 
Water (w) 2.78x10-5 1.27x10-9 3.53x10-14 [23] 
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Table 6-2: Density of materials, volume fraction (φ) of phases in capsules and calculated 
effective solubilities (αeff) . 
Capsules contained 2% (v/v) alginate, pure PFC emulsion contained 70% (w/v) PFC, capsules 
with cells contained 2.4x107 cells/ml. 
 
n
eff j j
j=1
α = α φ∑  (6-2) 
Where n is the number of components in the system, αj is the solubility of the jth component, and 
φj is the volume fraction of jth component.  The calculations of effective permeability and 
solubility used in Chapter 3 employed a tissue volume fraction of 0.027 which only had effects 
on the parameters in the second decimal place.  The effects of the different parameters would not 
be noticeable in the final calculations and thus the calculations were not updated with the 
parameter set. 
 
   Volume fraction (φ) of phases in capsules 
Component 
Density 
(g/ml) α  (mol/mmHg/ml) Alginate 
PFC 
Emulsion
PFC 
Emulsion 
+ Alginate
Cells + 
Alginate 
Cells + Alginate + 
PFC 
Tissue (t)  1.00x10-9 0 0 0 0.023 0.023 
Alginate (a)  0 0.02 0 0.02 0.02 0.02 
PFC (pfc) 1.93 2.54x10-8  0 0.36 0.36 0 0.36 
Soybean Oil (soy) 0.92 6.84x10-9  0 0.12 0.12 0 0.12 
Water (w) 1 1.27x10-9 0.98 0.52 0.5 0.953 0.473 
αeff (mol/mmHg/ml)   1.24x10-9 1.06x10-8 1.06x10-8 1.23x10-9 1.06x10-8 
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Table 6-3: Calculation sequence for effective permeability of 70% (w/v) PFC emulsion and 70% 
(w/v) PFC emulsion in 2% (v/v) alginate (αD)PFC_alg. 
Where soy is soybean oil, w is water, pfc is pure perfluorodecalin, a is alginate and the subscript 
numbers correspond to the effective permeability that was calculated in that step number.  (αD)5 
is the effective permeability of the PFC emulsion, and(αD)6 is the effective permeability of the 
PFC emulsion in alginate (αD)PFC_alg. 
Maxwell 
Step 
Number φ ρ (αD)eff 
1 0.12 (αD)soy/(αD)w = 4.13 4.21x10-14 
2 0.36 (αD)pfc/(αD)1 = 33.85 1.04x10-13 
3 0.36 (αD)pfc/(αD)w = 40.34 8.85x10-14 
4 0.12 (αD)soy/(αD)3 = 1.65 9.42x10-14 
5 average of (αD)2 and (αD)4 9.92x10-14 
6 0.02 (αD)a/(αD)5 = 0 9.63x10-14 
 
Table 6-4: Calculation sequence for effective permeability of 70% (w/v) PFC emulsion in 2% 
(v/v) alginate with 2.4x107 cells/ml (αD)cell_PFC_alg 
Where soy is soybean oil, w is water, pfc is pure perfluorodecalin, t is tissue, a is pure alginate 
and any subscript numbers correspond to the effective permeability that was calculated in that 
step number.  (αD)7 is the effective permeability of the PFC emulsion and cells in alginate 
(αD)cell_PFC_alg.  Steps 1-5 are the same as in Table 6-3. 
 
Maxwell 
Step 
Number φ ρ (αD)eff 
1 0.12 (αD)soy/(αD)w = 4.13 4.21x10-14 
2 0.36 (αD)pfc/(αD)1 = 33.85 1.04x10-13 
3 0.36 (αD)pfc/(αD)w = 40.34 8.85x10-14 
4 0.12 (αD)soy/(αD)3 = 1.65 9.42x10-14 
5 average of (αD)2 and (αD)4 9.92x10-14 
6 0.023 (αD)t/(αD)5 = 0.125 9.63x10-14 
7 0.02 (αD)a/(αD)6 = 0 9.36x10-14 
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Table 6-5: Calculation sequence for effective permeability of 2% (v/v) alginate (αD)alg 
Where a is pure alginate and any subscript numbers correspond to the effective permeability that 
was calculated in that step number.  (αD)1 is the effective permeability of alginate (αD)alg. 
Maxwell 
Step 
Number φ ρ (αD)eff 
1 0.02 (αD)a/(αD)w = 0 3.43x10-14 
 
 
Table 6-6: Calculation sequence for effective permeability 2% (v/v) alginate with 2.4x107 
cells/ml (αD)cell_alg 
Where t is tissue, a is pure alginate and any subscript numbers correspond to the effective 
permeability that was calculated in that step number.  (αD)2 is the effective permeability of the 
PFC emulsion and cells in alginate (αD)cell_alg. 
 
 
Maxwell 
Step 
Number φ ρ (αD)eff 
1 0.023 (αD)t/(αD)w = 0.35 3.46x10-14 
2 0.02 (αD)a/(αD)1 = 0 3.36x10-14 
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6.2 Model Equations 
 
Equations ((3-4)) for the theoretical models solved in Chapter 3 are written out in detail for 
each subdomain type in this section.  For the model geometries that contain discrete tissue 
subdomains for the islet and aggregate cases.  The model equation in the tissue subdomain is: 
 ( ) 2 max ttt
m t
V P
αD P
K +P
=∇  (6-3) 
Where (αD)t is the permeability of tissue, Vmax is the maximum oxygen consumption rate of 
solid islet tissue, Pt is the partial pressure of oxygen within the tissue subdomain, and Km is the 
Michaelis-Menten constant.  The model equation in the alginate subdomain is given by: 
 ( ) 2 algalgαD P 0=∇  (6-4) 
Where (αD)alg is the effective permeability of 2% (v/v) alginate that was calculated using 
Maxwell’s relationship described above taking into account that there is water and a dispersed 
alginate phase in the alginate capsules.  The model equation in the alginate subdomains that 
contain PFC emulsion is given by: 
 ( ) 2 PFC_algPFC_algαD P 0=∇  (6-5) 
Where (αD)PFC_alg is the effective permeability of PFC alginate that was calculated using 
Maxwell’s relationship sequentially as described above taking into account that there is water 
with dispersed alginate, PFC and soybean oil phases in the PFC alginate capsules. 
There is only one subdomain in the cell containing capsules where the cells are considered to 
be a homogenous phase distributed throughout the entire capsule.  The model equation for the 
cell containing alginate capsules is: 
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 ( ) 2 max t cell_algcell_algcell_alg
m cell_alg
V P
αD P
K +P
=
φ∇  (6-6) 
Where (αD)cell_alg is the effective permeability of alginate capsules containing cells that was 
calculated using Maxwell’s relationship described above taking into account that there is water 
with a dispersed alginate and cell phase and φt is the volume fraction of tissue homogenously 
distributed throughout the capsule.  The volume fraction (φt) of tissue for a 500-µm capsule 
containing one 150-µm is (150/500)3=0.027 and also would correspond to a cell concentration of 
2.4x107 cells/ml assuming 1560 cells per IE distributed throughout the capsule volume.  This cell 
concentration and tissue volume fraction were used for calculations of capsules cells that contain 
one IE in a 500-µm capsule.  The model equation for the cell and PFC emulsion containing 
alginate capsules is:     
 ( ) 2 max t cell_PFC_algcell_PFC_algcell_PFC_alg
m cell_PFC_alg
V P
αD P
K +P
=
φ∇  (6-7) 
 
Where (αD)cell_PFC_alg is the effective permeability of PFC alginate capsules containing cells that 
was calculated using Maxwell’s relationship described above taking into account that there is 
water with dispersed alginate, cells, PFC and soybean oil phases. 
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6.3 Predictions of Actual Oxygen Level in 1% Experiments 
 
For the experiments carried out in Chapter 5 at 1% oxygen they were not really at 1% 
oxygen as about a half liter of air at atmospheric oxygen was trapped within the head space of 
the culture vessel since the cap did not contain a filter.  An order of magnitude estimate for the 
amount of time for the oxygen in the culture vessel head space to diffuse through the media and 
out of the device was on the order of 20 days over a surface area of 100 cm2 and a media 
thickness of 2.5mm.  Thus verifying that the experiments were not really carried out at 1% 
oxygen as the air at atmospheric oxygen was maintained within the vessel throughout the 2 day 
experiment.  A reasonable assumption to model what conditions were experienced during culture 
would be to modify the models that were used in Chapter 5 and have the bottom of the silicone 
rubber at 1% oxygen or PO2 7mmHg and the top of the media at atmospheric oxygen.  The steady 
state oxygen profile was calculated at a surface density of 25 IE/cm2 in normal alginate and PFC 
alginate capsules.  The partial pressure of oxygen at the bottom of the islet in normal alginate 
was 4 mmHg and the top of the islet was at 10 mmHg for an average of 7 mmHg at the islet 
exterior.  The partial pressure of oxygen at the bottom of the islet in PFC alginate was 9 mmHg 
and top was 15 mmHg for an average of 12 mmHg at the islet exterior.  Similar oxygen levels at 
the islet exterior for normal alginate (7 mmHg) and PFC alginate (12 mmHg) are observed for 
culture on silicone rubber when the bottom of the silicone rubber and the top of the media are 
both at atmospheric oxygen for a gas phase oxygen level of 21 mmHg or about 3% oxygen.  
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6.4 Additional Figures from Calculations Performed in Chapter 3 
 
 
Figure 6-4: Predicted fractional viability as a function of capsule surface PO2 for a 500-µm  
capsule that contains one islet equivalent – homogeneously distributed throughout the capsule, as 
64 37.5-µm aggregates, 27 50-µm aggregates, 8 75-µm aggregates, or 1 150-µm islet. 
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Figure 6-5:  Predicted fractional viability for single cells, an islet, and 50-µm aggregates at 
various loadings in a 500-µm capsule. 
(A) Alginate capsules (B) 50-µm aggregates at various loadings in a capsule containing 70% 
(w/v) PFC emulsion. IE=islet equivalent 
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Figure 6-6: Predictions of fractional viability for one centrally located islet in a 250, 500, 1000, 
or 2000-µm capsule with (dashed lines) and without (solid lines) 70% (w/v) PFC emulsion. 
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Figure 6-7: Predictions of fractional viability for 50-µm aggregates in either a 500-µm or 
1000-µm diameter capsule.   
(A) Normal alginate capsule (B) normal alginate (solid curves) and 70% (w/v) PFC alginate 
(dashed curves). 
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Figure 6-8: Predictions of fractional viability and fraction of normal insulin secretion for 
37.5-µm aggregates in a 500-µm planar device.   
The device surface oxygen level is 40 mmHg and the tissue within the device is arranged in 3-13 
layers. The solid lines are for the predictions in normal alginate devices and the dashed lines are 
the predictions for 70% (w/v) PFC alginate devices. 
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Figure 6-9:  Predictions of fractional viability for 50-µm aggregates in a 500-µm planar device.   
The device surface oxygen level is 40 mmHg and the tissue within the device is arranged in 3-10 
layers. The solid lines are for the predictions in normal alginate devices and the dashed lines are 
the predictions for 70% (w/v) PFC alginate devices. 
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Figure 6-10: Predictions of fractional viability for 75-µm aggregates in a 500-µm planar device.   
The device surface oxygen level is 40 mmHg and the tissue within the device is arranged in 3-6 
layers. The solid lines are for the predictions in normal alginate devices and the dashed lines are 
the predictions for 70% (w/v) PFC alginate devices. 
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Figure 6-11: Predictions of fractional viability and fraction of normal insulin secretion for 
100-µm aggregates in a 500-µm planar device.   
The device surface oxygen level is 40 mmHg and the tissue within the device is arranged in 1, 3, 
4, or 5 layers. The solid lines are for the predictions in normal alginate devices and the dashed 
lines are the predictions for 70% (w/v) PFC alginate devices. 
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Figure 6-12: Predictions of fractional viability and fraction of normal insulin secretion for 
125-µm aggregates in a 500-µm planar device.   
The device surface oxygen level is 40 mmHg and the tissue within the device is arranged in 1,3 
or 4 layers. The solid lines are for the predictions in normal alginate devices and the dashed lines 
are the predictions for 70% (w/v) PFC alginate devices. 
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Figure 6-13: Predictions of fractional viability for 150-µm islets in a 500-µm planar device.   
The device surface oxygen level is 40 mmHg and the tissue within the device is arranged in 1 or 
3 layers. The solid lines are for the predictions in normal alginate devices and the dashed lines 
are the predictions for 70% (w/v) PFC alginate devices. 
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Figure 6-14: Fractional viability as a function of tissue surface density for tissue of a variety of 
sizes with tissue arranged in multiple layers throughout the device thickness the number of which 
being the maximum number that will fit for a particular size.   
The device thickness is 500-µm. Device surface PO2 equals 40 mmHg.  The solid lines are the 
predictions for normal alginate the dashed lines are the predictions for 70% (w/v) PFC alginate. 
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Figure 6-15: Predictions of fractional viability over a range of device surface PO2 for tissue of a 
variety of sizes arranged in multiple layers within a 500-µm planar diffusion chamber.  
The number of layers used is the maximum that would fit for a particular tissue size – 
37.5-µm 13 layers, 50-µm 10 layers, 75-µm 6 layers, 100-µm 5 layers, 125-µm 4 layers, and 
150-µm 3 layers.   The device is 500-µm thick and made of normal alginate. The tissue device 
surface density was equal to (A) 150 IE/cm2, (B) 1000 IE/cm2, (C) 2000 IE/cm2, and (D) 7272 
IE/cm2. 
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Figure 6-16: Predictions of fractional viability over a range of device surface PO2 for tissue of a 
variety of sizes arranged in multiple layers within a 500-µm planar diffusion chamber.  
The number of layers used is the maximum that would fit for a particular tissue size – 
37.5-µm 13 layers, 75-µm 6 layers, and 150-µm 3 layers.   The device is 500-µm thick and made 
of normal alginate (solid curves) and 70% (w/v) PFC alginate (dashed curves). The tissue device 
surface density was equal to (A) 150 IE/cm2, (B) 1000 IE/cm2, (C) 2000 IE/cm2, and (D) 7272 
IE/cm2.   
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Figure 6-17: Effects of increasing device thickness on predictions of fractional viability for 
50-µm aggregates arranged in multiple layers. 
250-µm device 5 layers, 500-µm device 10 layers, and 1000-µm device 20 layers made from 
normal alginate (solid curves) or 70% (w/v) PFC alginate (dashed curves).  (A) The effects of 
varying surface density for a device surface PO2 of 40mmHg were investigates and (B) the effects 
of reducing the device surface PO2 at a tissue loading of 1000 IE/cm2.  
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Figure 6-18: Predictions of fraction of normal insulin secretion for a 150-µm islet in a 500- µm 
capsule with and without PFC emulsion where the capsule is located at the center of the capsule 
or touching the surface of the capsule.   
There are not large effects of the exact location of the islet for either microcapsule type. 
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Figure 6-19: Volume averaged results for predicts of fraction of normal insulin secretion for 
150-µm islets that are located through out the diameter of the 500-µm capsule.   
The results are averaged either assuming an equal distribution of tissue throughout the capsule 
diameter or a normal distribution.  The averaged results for the different distributions are all 
nearly identical to the results for an islet at the center.  Thus in all calculations the results for a 
centrally located islet are only reported for the cases where a microcapsule contains one islet. 
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Calculations were also performed for encapsulated tissue in culture where a value of Vmax = 
4x10-8 nmol/cm3/s was used for tissue oxygen consumption.  The value of P* used in the insulin 
secretion model was 5.09 mmHg.  The results are presented at 4 different oxygen levels in the 
following four figures.  The data points represent the surface coverage at which the calculations 
were performed. 
 
 
Figure 6-20: Predictions of viability and fraction of normal insulin secretion for tissue cultured in 
500-µm capsules on silicone rubber at a gas phase PO2 of 3.5 mmHg. 
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Figure 6-21: Predictions of viability and fraction of normal insulin secretion for tissue cultured in 
500-µm capsules on silicone rubber at a gas phase PO2 of 7 mmHg. 
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Figure 6-22: Predictions of viability and fraction of normal insulin secretion for tissue cultured in 
500-µm capsules on silicone rubber at a gas phase PO2 of 14 mmHg. 
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Figure 6-23: Predictions of viability and fraction of normal insulin secretion for tissue cultured in 
500-µm capsules on silicone rubber at a gas phase PO2 of 36 mmHg. 
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